Use and formulations of camptothecin (CPT)-containing nanoparticles
By conjugating camptothecin with mucinic acid polymer to form the nanoparticle preparation DAN-222, the problem of restricted application of topoisomerase I inhibitors in the treatment of breast cancer and other cancers is solved, and more efficient tumor suppression is achieved and reduce side effects.
Patent Information
- Application Number
- CN202380032765.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-14
- Filing Date
- 2023-02-13
- Publication Date
- 2024-11-22
AI Technical Summary
Existing topoisomerase I inhibitors such as camptothecin (CPT) have poor water solubility, low plasma stability and dose-limiting toxicity, making it difficult to effectively cross the blood-brain barrier and hematologic barrier, resulting in their treatment of breast cancer and other Applications in cancer are limited.
By conjugating camptothecin with mucinic acid polymer, the nanoparticle preparation DAN-222 is formed, and the enhanced permeability and retention effects accumulate in the tumor, increasing the concentration and stability of topoisase I inhibitors, and enhancing the tumor. Cell killing effect.
DAN-222 showed greater efficacy and sustained tumor suppression in tumors, reducing unnecessary risks and side effects associated with free CPT, improving the cytotoxicity of chemotherapy drugs, and enhancing the sensitivity to defective HR repair cells.
Smart Images

Figure CN119013047A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 309,810, filed on February 14, 2022, under 35 U.S.C. §119(e)(1); the disclosure of which (including all drawings and text) is incorporated herein by reference in its entirety. Technical Field
[0003] The present invention generally relates to the formulation and use of nanoparticles comprising camptothecin conjugated to mucinic acid polymers. Background Art
[0004] Breast cancer is the second most common cancer among women in the United States. Despite advances in screening and treatment, breast cancer remains the second leading cause of cancer death in women. In addition, the efficacy of various treatments varies across breast cancer subtypes at different stages of progression. This creates a complex picture for pathologists and oncologists in diagnosing, treating, and predicting recurrence in breast cancer patients.
[0005] Genomic DNA is constantly challenged by endogenous and exogenous DNA damaging agents, which can result in different types of DNA lesions. These lesions can block DNA replication and transcription and, if not repaired or repaired improperly, can generate mutations that threaten the survival of individual cells or even entire organisms. The inability to accurately repair complex DNA lesions and resolve DNA replication stress leads to genomic instability and contributes to cancer etiology, but also makes cancer cells more vulnerable to DNA damaging therapeutic agents.
[0006] Homologous recombination (HR) repair is one of several DNA repair pathways that involve a series of interconnected pathways for the repair of DNA double-strand breaks and interstrand crosslinks. Defects in HR repair have been observed in various cancers. It has long been known that the breast cancer genes type 1 (BRCA1) and BRCA type 2 (BRCA2) encode proteins that play a key role in HR repair, and mutations in one or both of these genes put patients at greater risk for breast, ovarian, prostate, melanoma, and pancreatic cancer. Tumor cells with defective HR repair have increased sensitivity to chemotherapeutic agents, suggesting that if HR repair can be therapeutically inactivated, HR-proficient tumor cells may be sensitive to chemotherapeutic drugs.
[0007] Topoisomerase inhibitors damage DNA by binding to topoisomerase I, which prevents DNA unwinding required for replication. This leads to replication fork stalling, which can be repaired by poly (ADP-ribose) polymerase (PARP). PARP inhibitors block the PARP enzyme DNA repair activity and have been shown to induce apoptosis in tumor cells. In addition to directly killing tumors, PARP inhibition increases the cytotoxicity of chemotherapeutic drugs and increases the cytotoxicity of DNA damaging agents such as topoisomerase inhibitors, camptothecin (CPT) and its derivatives.
[0008] Unfortunately, although CPT is well known for its antitumor activity (including on a wide range of human cancers), it has poor water solubility, low plasma stability, and dose-limiting toxicity. Summary of the invention
[0009] The present invention provides methods, compositions and uses of camptothecin (CPT) conjugated nanoparticles. Specifically, the present invention relates to compositions, formulations and methods of use of formulations comprising nanoparticles, which include 20(S)-camptothecin (MAP-Gly-CPT) covalently linked to a mucic acid-based polymer carrier via a glycyl bond, which includes formula (I):
[0010]
[0011] wherein n is the number of ethylene glycol repeating units, which is in the range of 20 to 200 units, and m is the number of repeating units of MAP-Gly-CPT, which is in the range of 5 to 200.
[0012] In a preferred aspect, the MAP-Gly-CPT compound is DAN-222, which has a structure of Formula I, wherein the average number of repeating ethylene glycol repeating units (n) is in the range of about 75 to 85. In a preferred aspect, in the formulations and compositions of the invention, n averages about 79. In certain aspects, the number of repeating units (m) of MAP-Gly-CPT averages 16±4.
[0013] Camptothecin (CPT), the active ingredient in DAN-222, is a naturally occurring pentacyclic quinolone alkaloid isolated from the bark of Camptotheca acuminata. CPT is a topoisomerase I inhibitor that acts during replication and transcription in tumor cells by forming a ternary complex with topoisomerase I and DNA, thereby blocking the religation of DNA, resulting in torsional tension downstream of the transcription fork or replication fork, thereby causing DNA strand breaks.
[0014] Unfortunately, although CPT is well known for its antitumor activity (including on a wide range of human cancers), it has poor water solubility, low plasma stability, and dose-limiting toxicity.
[0015] However, as discovered by the present inventors, DAN-222 is more potent than other topoisomerase I inhibitors (including free CPT) because it accumulates in tumors via the enhanced permeability and retention (EPR) effect, resulting in greater and longer topoisomerase I inhibition.
[0016] In certain aspects, the present invention provides aqueous formulations comprising nanoparticles made from a mucic acid polymer (MAP) camptothecin (CPT) conjugate compound of formula (I):
[0017]
[0018] wherein n is a number in the range of 20 to 200; and
[0019] Wherein m is a number in the range of 5 to 200.
[0020] In certain aspects, n is a number in the range of about 75 to 85. In certain formulations, m is a number in the range of about 12 to 20.
[0021] In some preparations of the present invention, the molecular weight of the compound of formula (I) is about 75,000Da. In a preferred aspect, the nanoparticles of the preparation include two chains including the compound of formula (I) on average, and have an average molecular weight of about 150,000Da. The average particle size of these nanoparticles of the preparation can be about 20nm to 80nm. Preferably, the average particle size of the nanoparticles is about 30 to 40nm. In some aspects, the nanoparticle concentration of the preparation is about 17-23mg / mL.
[0022] The formulations of the present invention include formulations having a total CPT concentration between 1.7 and 3.6 mg / mL. In a preferred aspect, the total CPT concentration of the formulation is about 2.6 mg / mL. In certain aspects, the formulation includes a compound of formula (I) at a concentration of about 20 mg / mL.
[0023] In certain aspects, the pH of the formulation is between pH 4 and pH 5. In certain aspects, the pH of the formulation is between pH 4 and pH 4.6. In preferred aspects, the pH of the formulation is about pH 4.3.
[0024] The formulation of the present invention may further comprise at least one buffer selected from the group consisting of, for example, sodium succinate, sodium citrate, sodium acetate, phosphoric acid, histidine-HCl, and sodium phosphate. In a preferred aspect, the buffer is a sodium acetate buffer. The formulation may further comprise at least one tension regulator selected from the group consisting of, for example, KCl, NaCl, proline, arginine-HCl, sucrose, and glycine. Preferably, the at least one tension regulator is NaCl.
[0025] In a preferred aspect, the formulation comprises about 20 mg / mL of the compound of formula (I), about 20 mM sodium acetate, about 200 mM NaCl, and has a pH of 4.3 ± 0.3.
[0026] The present invention also provides a method for producing a formulation comprising the compound of formula (I). In certain embodiments, the method for producing a formulation of the compound of formula (I) comprises: (i) derivatizing camptothecin (CPT) to obtain Gly-CPT in the form of a trifluoroacetic acid (TFA) salt; (ii) synthesizing a parent mucin acid polymer (MAP); (iii) covalently linking the Gly-CPT to the parent MAP to obtain a solid amorphous MAP-Gly-CPT; and (iv) using the amorphous MAP-Gly-CPT to prepare an aqueous formulation, thereby producing an aqueous formulation of nanoparticles comprising the compound of formula (I).
[0027] In certain aspects, step (i) of the method comprises dissolving CPT, N-(tert-butyloxycarbonyl)-Gly-OH (Boc-Gly) and 4-dimethylaminopyridine (DMAP) in dichloromethane (DCM) to form a reaction mixture; and adding diisopropylcarbodiimide (DIC) to the reaction mixture to produce a solution comprising a Boc-Gly-CPT intermediate. In certain embodiments, the reaction is carried out at 25-30° C. for about six hours.
[0028] In certain methods of the invention, step (i) further comprises removing 90% to 99% of the DCM from the solution comprising the Boc-Gly-CPT intermediate. In preferred methods, the DCM is removed by vacuum distillation. Step (i) may further comprise precipitating the Boc-Gly-CPT intermediate using methanol. Such methods may also comprise washing the precipitated Boc-Gly-CPT intermediate using isopropyl alcohol (IPA).
[0029] In certain aspects, step (i) further comprises treating the Boc-Gly-CPT intermediate with TFA in DCM to obtain the TFA salt of Gly-CPT. In certain embodiments, the treatment with TFA is performed at 25-30° C. for about two hours.
[0030] In a preferred method for producing the formulation, step (ii) comprises: charging a reactor with (succinimidyl propionate) 2-PEG 3500 (diSPA-PEG 3500 ) and a neutral substance of mucin acid monomer (MAM) of formula (II):
[0031]
[0032] Dimethyl sulfoxide (DMSO) is added to the reactor; the reaction is initiated by adding TFA to the reactor; and DIPEA is added to the reaction to obtain the parent MAP. In certain embodiments, the reaction is carried out at 21-23° C. for about three hours.
[0033] In certain aspects, the comonomer ratio of DIPEA:MAM used in step (ii) is at least about 2.5. Preferably, the comonomer ratio is at least 2.6.
[0034] In certain aspects, step (ii) further comprises precipitating the parent MAP from the DMSO by adding at least one antisolvent. An exemplary antisolvent is isopropanol (IPA). In preferred embodiments, the precipitation step comprises a filtration step under an inert atmosphere (e.g., nitrogen or argon).
[0035] In certain methods of the invention, step (iii) comprises: adding the parent MAP and DMSO to a reaction vessel; adding the Gly-CPT (TFA salt) and (7-azabenzotriazol-1-yloxy)tripyrrolidinephosphonium hexafluorophosphate (PyAOP) to the reaction vessel; and adding DIPEA to the reaction vessel, thereby producing a solution comprising MAP-Gly-CPT. In certain embodiments, the reaction is carried out at 19-25° C. for 16-22 hours.
[0036] Step (iii) may further comprise purifying amorphous MAP-Gly-CPT from the solution using tangential flow filtration (TFF). Preferably, the solution is diluted with water at pH 3 prior to the tangential flow filtration, and the tangential flow filtration uses a polyethersulfone (PESU) TFF filter. In a further embodiment, a membrane made of regenerated cellulose is used for TFF.
[0037] In certain methods of the invention, step (iv) comprises: adding water at a pH of about pH 4 to the amorphous MAP-Gly-CPT to produce a nanoparticle (NP) solution; and adding a formulation buffer to the NP solution.
[0038] In certain aspects, the formulation buffer comprises sodium acetate. Preferably, the formulation buffer further comprises NaCl and has a pH of about pH 4.16.
[0039] In certain methods, the NP solution is filtered after the step of adding water at a pH of about pH 4. In certain embodiments, after the step of adding the formulation buffer to the NP solution, the NP solution is concentrated by ultrafiltration.
[0040] The present disclosure also provides methods for treating cancer in a subject using the DAN-222 formulations described herein. An exemplary method comprises providing to a subject having cancer at least one dose of a composition comprising a compound of formula (I):
[0041]
[0042] wherein n is a number in the range of 20 to 200; and wherein m is a number in the range of 5 to 200. In preferred methods: n is a number in the range of about 75 to 85; m is a number in the range of about 12 to 20; and the pH of the composition is between pH 4 and pH 4.6.
[0043] Preferably, the composition is provided in the form of a solution for infusion.
[0044] In a preferred method, the composition comprises 2 mg / mL to 3 mg / mL of camptothecin (CPT). In certain embodiments, the dosage of the composition comprises 2 mg / mL to 3 mg / mL of camptothecin (CPT). 2 Up to 16 mg / m 2 The compound of formula (I). Exemplary dosages of the composition include about 2 mg / m 2 , about 4mg / m 2 , about 6mg / m 2 , about 8mg / m 2 , about 10mg / m 2 , about 12mg / m 2 , about 14mg / m 2 or about 20 mg / m 2 The compound of formula (I).
[0045] In certain methods, multiple doses are provided to the subject during a treatment cycle. Preferably, these doses are provided in weekly doses, i.e., one dose is provided every seven days.
[0046] The exemplary treatment method further comprises providing the subject with at least one dose of a poly (ADP-ribose) polymerase (PARP) inhibitor. The PARP inhibitor may comprise, for example, one of olaparib, rucaparib, niraparib, and tarazzoparib. Preferably, the PARP inhibitor is niraparib. Preferably, the subject receives a dose of niraparib every day during the treatment cycle. In the exemplary method, each dose of niraparib is a 100 mg dose.
[0047] In an exemplary method of the invention, the cancer is one or more of breast cancer, ovarian cancer, brain cancer, lung cancer, testicular cancer, head cancer, neck cancer, esophageal cancer, lymphoma cancer, central nervous system cancer, peripheral nervous system cancer, bladder cancer, stomach cancer, pancreatic cancer, liver cancer, oral mucosal cancer, colorectal cancer, anal cancer, kidney cancer, bladder cancer, urothelial cancer, prostate cancer, endometrial cancer, fallopian tube cancer, mesothelioma, melanoma, myeloma, leukemia and Kaposi's sarcoma.
[0048] In a preferred method, the cancer is breast cancer. The breast cancer may include, for example, a breast cancer that is a homologous recombination repair deficiency (HRD) positive or HRD negative breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 The formation of DAN-222 engineered nanoparticles is shown.
[0050] Figure 2 The calculated median tumor volume (MTV) over time presented by the different treatment groups in HRD-positive (ER-positive, PR-positive, HER2-positive) breast ductal carcinoma (BT-474 model) is provided. The treatment groups are:
[0051] Vehicle control (circle, top line)
[0052] Camptothecin (3 mg / kg) IV once a week for 3 weeks (diamonds, lowermost line)
[0053] Irinotecan (100 mg / kg) intravenously once a week for 3 weeks (triangle, lowermost line)
[0054] • DAN-222 (3 mg / kg) intravenously once a week for 3 weeks (squares, lowest line).
[0055] Figure 3 Provided Figure 2 Kaplan-Meier plots of time to endpoint (TTE) for animals in each treatment group as described. The endpoint was a tumor volume of 2,000 mm 3 The treatment groups were:
[0056] Vehicle control (circles, first line down from 100%)
[0057] Camptothecin (3 mg / kg) IV once a week for 3 weeks (diamonds, second line down from 100%)
[0058] Irinotecan (100 mg / kg) IV once a week for 3 weeks (triangle, third line down from 100%)
[0059] - DAN-222 (3 mg / kg) iv once a week for 3 weeks (squares, line not decreasing from 100%).
[0060] Figure 4 Shown are median tumor volume measurements over time for different treatment groups in the HRD-positive, triple-negative (ER-negative, PR-negative, HER2-negative) breast adenocarcinoma (MDA-MB-436) model. The treatment groups are listed from top to bottom according to the position of the rightmost data point:
[0061] Medium (dark circle)
[0062] 25 mg / kg of niraparib orally once daily for 28 days (light circles)
[0063] 0.3 mg / kg intravenous DAN-222 once a week for four weeks (light squares)
[0064] 1 mg / kg intravenous DAN-222 once a week for four weeks (dark squares)
[0065] 0.3 mg / kg IV DAN-222 once a week for four weeks plus 25 mg / kg oral niraparib once a day for 28 days (light triangles)
[0066] 1 mg / kg IV DAN-222 once a week for four weeks plus 25 mg / kg oral niraparib once a day for 28 days (light triangles)
[0067] 3 mg / kg intravenous DAN-222 once a week for four weeks (dark squares)
[0068] 3 mg / kg IV DAN-222 once a week for four weeks plus 25 mg / kg oral niraparib once a day for 28 days (dark triangles).
[0069] Figure 5Shown are median tumor volume measurements over time following DAN-222 administration in HRD-positive (ER-negative, PR-negative, HER2-negative [triple-negative]) breast adenocarcinoma (MDA-MB-436 model). Treatment groups are, from top to bottom, by the position of the rightmost data point:
[0070] Medium (dark circle)
[0071] 40 mg / kg of niraparib orally once daily for 28 days (light circles)
[0072] 0.3 mg / kg intravenous DAN-222 once a week for four weeks (light squares)
[0073] 1 mg / kg intravenous DAN-222 once a week for four weeks (dark squares)
[0074] 0.3 mg / kg intravenous DAN-222 once a week for four weeks plus 40 mg / kg oral niraparib once a day for 28 days (light triangles)
[0075] 3 mg / kg intravenous DAN-222 once a week for four weeks (dark squares)
[0076] 1 mg / kg IV DAN-222 once a week for four weeks plus 40 mg / kg oral niraparib once a day for 28 days (dark triangles).
[0077] Figure 6 Median tumor volume over time in the OVCAR3 human ovarian cancer xenograft model using DAN-222 and high-dose niraparib is shown. Treatment groups are listed from top to bottom by the position of the rightmost data point:
[0078] Medium (dark circle)
[0079] 50 mg / kg of niraparib orally once daily for 28 days (light circles)
[0080] 1 mg / kg IV DAN-222 once a week for four weeks (squares)
[0081] 1 mg / kg IV DAN-222 once a week for four weeks plus 50 mg / kg oral niraparib once a day for 28 days (triangle)
[0082] 3 mg / kg IV DAN-222 once a week for four weeks (squares)
[0083] Figure 7Shown are the concentrations of CPT in the plasma of male rats after intravenous administration of DAN-222 on days 1 and 22.
[0084] Figure 7 A (left side of the figure) shows plasma free CPT levels after intravenous administration of three different doses of DAN-222: 1.1 mg / kg (triangle), 3.2 mg / kg (square), and 9.6 mg / kg (circle). The upper panel shows the free CPT level on day 1 after dosing. The lower panel shows the free CPT level after repeated dosing on day 22.
[0085] Figure 7 B (right side of the figure) shows the plasma total CPT levels after intravenous administration of three different doses of DAN-222: 1.1 mg / kg (triangle), 3.2 mg / kg (square) and 9.6 mg / kg (circle). The upper panel shows the total CPT levels on day 1 after dosing. The lower panel shows the total CPT levels after repeated dosing on day 22.
[0086] Figure 8 The stability of DAN-222 in rat, dog and human plasma at physiological pH over time is shown. The three curves show the results for dog, rat and human, respectively, in order of the position of the rightmost data point.
[0087] Fig. 9A The biodistribution of DAN-222 in different tissues of JIMT-1 xenograft mice is shown. The darker bars show the results for total CPT; the lighter bars show the results for free CPT.
[0088] Fig. 9B The biodistribution of DAN-222 in JIMT-1 xenograft mice over time is shown. The leftmost group of six bars shows the amount of total CPT in plasma; the center group of six bars shows the amount of total CPT in skeletal muscle; and the rightmost group of six bars shows the amount of total CPT in tumor tissue.
[0089] Fig.10 A summary of the DAN-222 biodistribution studies performed is provided.
[0090] Fig.11 Stability data for DAN-222 formulations over 14 days at 2-8°C are presented as free CPT % and mean particle size trends.
[0091] Fig.12 Stability data for DAN-222 formulations over 14 days at 20-25°C are presented as free CPT % and mean particle size trends.
[0092] Fig.13 The stability data of DAN-222 formulations over 14 days at 40°C are presented as free CPT % and mean particle size trends.
[0093] Fig.14 Stability data for the DAN-222 formulations over a 24 hour stirring period are presented as % free CPT and average particle size.
[0094] Fig.15 Stability data for DAN-222 formulations over six freeze / thaw (F / T) cycles are presented as free CPT % and mean particle size trends.
[0095] Fig.16 The stability data of DAN-222 formulations under 0.02% H2O2 stress over 24 hours are presented as free CPT% and mean particle size trends.
[0096] Fig.17 The stability data of DAN-222 formulations during 24 hours of 0.05% H2O2 stress are presented as free CPT% and mean particle size trends.
[0097] Fig.18A Stability data for DAN-222 formulations in acetate buffer at 2-8°C over one month are presented as free CPT % and mean particle size trends.
[0098] Fig.18B Stability data for DAN-222 formulations in histidine buffer over a period of one month at 2-8°C are presented as free CPT % and mean particle size trends.
[0099] Fig.19 Stability data for DAN-222 formulations at 2-8°C over 4 months are presented as free CPT % and mean particle size trends.
[0100] Fig. 20A Stability data for DAN-222 formulations in acetate buffer at 20-25°C over one month are presented as free CPT % and mean particle size trends.
[0101] Fig. 20B Stability data for DAN-222 formulations in histidine buffer over a period of one month at 20-25°C are presented as free CPT % and mean particle size trends.
[0102] Fig.21A Stability data for DAN-222 formulations in acetate buffer at 40°C over 7 days are presented as free CPT % and mean particle size trends.
[0103] Fig. 21BStability data for DAN-222 formulations in histidine buffer over 7 days at 40°C are presented as free CPT % and mean particle size trends.
[0104] Fig. 22 Stability data for DAN-222 formulations at -20°C over 4 months are presented as free CPT % and mean particle size trends.
[0105] Fig.23 Stability data for DAN-222 formulations at -80°C over 4 months are presented as free CPT % and mean particle size trends.
[0106] Fig.24A Stability data for DAN-222 formulations in acetate buffer over a 24 hour stirring period are presented as % free CPT and average particle size.
[0107] Fig. 24B Stability data for DAN-222 formulations in histidine buffer over a 24 hour stirring period are presented as % free CPT and average particle size.
[0108] Fig.25A Stability data for DAN-222 formulations in acetate buffer over six freeze / thaw (f / T) cycles are presented as free CPT % and mean particle size trends.
[0109] Fig.25B Stability data for DAN-222 formulations in histidine buffer over six freeze / thaw (F / T) cycles are presented as free CPT % and mean particle size trends.
[0110] Fig.26A The stability data of DAN-222 formulations in acetate buffer during 24 hours of 0.05% H2O2 stress are presented as free CPT% and mean particle size trends.
[0111] Fig.26B The stability data of DAN-222 formulations in histidine buffer during 24 hours of 0.05% H2O2 stress are presented as free CPT% and average particle size trends.
[0112] Fig. 27 Stability data for DAN-222 formulations at 2-8°C over a one month period are presented as free CPT % and mean particle size trends.
[0113] Fig.28 Stability data for DAN-222 formulations at 2-8°C over 3 months are presented as free CPT % and mean particle size trends.
[0114] Fig.29The stability data of DAN-222 formulations at 20-25°C over one month are presented as free CPT % and mean particle size trends.
[0115] Fig.30 Stability data for DAN-222 formulations at 40°C over 7 days are presented as free CPT % and mean particle size trends.
[0116] Fig.31 The stability data of DAN-222 formulations at -20°C over 3 months are presented as free CPT % and mean particle size trends.
[0117] Fig.32 Stability data for DAN-222 formulations at -80°C over 3 months are presented as free CPT % and mean particle size trends.
[0118] Fig.33 The stability data of the DAN-222 formulations during stirring at 450 rpm for 24 hours are presented as free CPT % and average particle size trends.
[0119] Fig.34 Stability data for DAN-222 formulations over six freeze / thaw (F / T) cycles are presented as free CPT % and mean particle size trends.
[0120] Fig.35 A schematic diagram of a method of producing a DAN-222 formulation of the invention is provided.
[0121] Fig.36 A protocol for producing Gly-CPT is provided.
[0122] Fig.37A The first part of a workflow for producing the DAN-222 formulations of the invention is provided.
[0123] Fig.37B A second part of a workflow for producing the DAN-222 formulations of the invention is provided.
[0124] Fig.38 A synthetic scheme for the preparation of mucin acid polymers (MAP) is shown.
[0125] Fig.39 A workflow for producing the DAN-222 formulations of the invention is provided.
[0126] Fig.40 A synthetic protocol for the preparation of amorphous MAP-Gly-CPT is provided.
[0127] Fig.41AThe first part of a schematic flow chart of the synthetic method of MAP-Gly-CPT amorphous form is provided, including control points.
[0128] Fig.41B The second part of the schematic flow chart of the synthetic method of MAP-Gly-CPT amorphous form is provided, including the control points.
[0129] Fig.42 A protocol for preparing DAN-222 solutions / formulations is provided.
[0130] Fig.43A The first part of a high-level flow chart of the DAN-222FBDS method is provided, including the control points.
[0131] Fig.43B The second part of the high-level flow chart of the DAN-222FBDS method is provided, including the control points.
[0132] Fig.44 Results showing the effect of the MAM:diSPA-PEG comonomer ratio on MAP molecular weight (MW) are provided. Circles represent a ratio of 1.01:1; squares represent a ratio of 1.03:1; and triangles represent a ratio of 1.10:1.
[0133] Fig.45 Shown are the chemical structures of the mucic acid monomer (MAM) diTFA salt and the neutral species of MAM.
[0134] Fig.46 Results of an initial set of experiments (Screen 1) are provided that were designed to investigate the combined effects of different comonomer ratios and TFA and DIPEA equivalents on the kinetics of polymerization of mucic acid monomers (MAMs) to mucic acid polymers (MAPs). The results are shown as polymer molecular weight versus time. The reaction conditions are shown in the table below the figure. Circles represent results obtained using the reaction conditions shown in column 1-A of the table. Squares represent results obtained using the reaction conditions shown in column 1-B of the table. Triangles represent results obtained using the reaction conditions shown in column 1-C of the table. Diamonds represent results obtained using the reaction conditions shown in column 1-D of the table.
[0135] Fig.47 Results of a second set of experiments using different conditions to prepare mucin acid polymers (MAP) are provided. The results are shown as changes in polymer molecular weight over time. The reaction conditions are shown in the table below the figure. Circles represent results obtained using the reaction conditions shown in column 2-A of the table. Squares represent results obtained using the reaction conditions shown in column 2-B of the table. Triangles represent results obtained using the reaction conditions shown in column 2-C of the table. Diamonds represent results obtained using the reaction conditions shown in column 2-D of the table.
[0136] Fig.48 Shown is the change in MAP molecular weight over time for the scaled-up MAP synthesis reaction.Three reactions were performed at 5 g scale (triangles, squares, and upper set of circles), and one reaction was performed at 50 g scale (lower set of circles).
[0137] Fig.49 The drug loading percentage and grafting efficiency of MAP-gly-CPT conjugates synthesized using PyAOP as coupling reagent are shown as a function of CPT equivalents. The letters in the circles refer to the columns in Table 9.
[0138] Fig.50 A summary of manufacturing variations between batches of DAN-222 formulations made using the methods disclosed herein is provided.
[0139] Fig.51 Compatibility results for IV bag administration of DAN-222 in a low dose (0.022 mg / mL) formulation are presented.
[0140] Fig.52 Compatibility results for IV bag administration of DAN-222 in a high dose (0.400 mg / mL) formulation are presented.
[0141] Fig.53 A protocol is provided for a dose escalation study of the safety and pharmacology of DAN-222 in subjects with metastatic breast cancer. DETAILED DESCRIPTION
[0142] The present invention provides methods, compositions and uses of camptothecin (CPT) conjugated nanoparticles. Specifically, the present invention relates to compositions, formulations and methods of use of compositions comprising DAN-222, which is a polymer small molecule conjugate, formulated and assembled into engineered nanoparticles (NPs). The polymer is a linear modified mucic acid-polyethylene glycol (PEG) copolymer. The small molecule active pharmaceutical ingredient is camptothecin (CPT), which is a topoisomerase I inhibitor. CPT is conjugated to the polymer via a glycyl bond. As a polymer construct, DAN-222 consists of multiple copies of a main repeat unit constructed as a linear polymer. The repeat unit of the polymer consists of modified mucic acid combined with a nominal 3,500 Da linear PEG derivative. The chemical structure of the DAN-222MAP-Gly-CPT polymer-drug conjugate repeat unit is provided in formula (I):
[0143]
[0144] Where n is the number of ethylene glycol repeating units (average n=79 for 3,500 Da PEG), and m is the number of repeating units of the MAP-Gly-CPT polymer-drug conjugate (average m=16±4 for the MAP parent polymer).
[0145] Formula (I) represents the polymer-drug conjugate (MAP-Gly-CPT) of DAN-222. The polymer repeating unit consists of a modified mucic acid moiety bonded to a dipropionyl PEG unit. The nominal molecular weight of each PEG unit is 3,500 Da ((C2H4O) 79 ). On average, each polymer chain consists of 16 repeats of this PEG-MAP unit, each of which can be conjugated to up to two Gly-CPT molecules. When Gly-CPT is conjugated to MAP, the reaction is performed so that about 90% of the available sites react.
[0146] The average molecular weight of the MAP parent polymer consisting of 16 repeating units is approximately 65,000 Da. The target molecular weight range for this material is 50,000-80,000 Da. At 90% CPT loading, the molecular weight of the 65,000 Da MAP polymer is approximately 75,000 Da.
[0147] like Figure 1 As shown, when formulated in aqueous media, DAN-222 self-assembles into NPs. When formulated into NPs, each NP is expected to consist of approximately two MAP-Gly-CPT chains. Therefore, the molecular weight of the average DAN-222 NP is about 150,000 Da.
[0148] The inability to accurately repair complex DNA damage and resolve DNA replication stress leads to genomic instability and contributes to cancer etiology. For example, defects in homologous recombination (HR) repair have been observed in various cancers. It has long been known that the breast cancer gene type 1 (BRCA1) and breast cancer gene type 2 (BRCA2) encode proteins that play key roles in HR repair, and mutations in one or both of these genes put patients at greater risk for breast, ovarian, prostate, melanoma, and pancreatic cancer.
[0149] At the same time, this loss of repair ability also makes cancer cells more vulnerable to therapeutic agents that damage DNA. For example, tumor cells with defective HR repair have increased sensitivity to chemotherapeutic agents, suggesting that if HR repair can be therapeutically inactivated, HR-proficient tumor cells may be sensitive to chemotherapeutic drugs. Topoisomerase inhibitors such as CPT damage DNA by binding to topoisomerase I, thereby preventing DNA unwinding required for replication, leading to replication fork stalling. This prevents cancer cells from replicating and proliferating in the subject.
[0150] Camptothecin (CPT), the active ingredient in DAN-222, is a naturally occurring pentacyclic quinolone alkaloid isolated from the bark of Camptotheca acuminata. CPT is a topoisomerase I inhibitor that acts by forming a ternary complex with topoisomerase I and DNA during replication and transcription in tumor cells, thereby blocking DNA religation, resulting in torsional tension downstream of RNA polymerase to induce DNA strand breaks.
[0151] Treatment of many brain disorders (such as brain cancer and metastasis to the brain) requires delivery of therapeutic molecules to the brain. Direct delivery of therapeutic drugs to the brain poses serious risks to the subject (e.g., damage to the skull) and cannot be carried out continuously as required by most chemotherapy. However, due to the presence of the blood-brain barrier (BBB) (the tightly bound endothelial cell layer lining the cerebral blood vessels), systemic delivery (e.g., through the blood) will not be able to efficiently deliver molecules to the brain. A similar permeability barrier exists in some solid tumors, called the blood-tumor barrier (BTB).
[0152] Breast cancer often metastasizes to the brain, and these brain metastases could be treated with chemotherapeutic molecules used to treat breast cancer if the therapeutic agent could be delivered to the brain (across the BBB) or tumor (across the BTB) in sufficient concentration. One such chemotherapeutic drug is CPT.
[0153] Unfortunately, although CPT is well known for its antitumor activity against a variety of human cancers, it has poor water solubility, low plasma stability, and dose-limiting toxicity. In addition, as mentioned above, the BBB and / or BTB may inhibit the ability of cells to take up CPT.
[0154] However, as discovered by the present inventors, DAN-222 is more effective than other topoisomerase I inhibitors (including free CPT) because it accumulates in tumors through the enhanced permeability and retention (EPR) effect, resulting in greater and longer inhibition of topoisomerase I. The EPR effect relies on the differences in vasculature between healthy tissue and tumor. DAN-222 nanoparticles encapsulate CPT and are able to pass through the leaky walls of tumor neovasculature without passing through the tighter walls of healthy blood vessels. In addition, encapsulation in DAN-222 nanoparticles protects CPT from conversion of its active lactone form to the inactive carboxylate form in serum, thereby preventing rapid blood clearance of NP-encapsulated CPT.
[0155] For example, as described herein, the anti-tumor activity of DAN-222 was evaluated in several tumor xenograft studies containing cell lines from breast (BT474, MDA-MB-23, MBA-MB-436) and ovarian (OVCAR3) tumors. In all tumor xenograft models studied, DAN-222 had significantly greater efficacy and sustained tumor inhibition compared to other topoisomerase I inhibitors including free CPT and irinotecan (FDA-approved topoisomerase I inhibitor for cancer treatment). The biodistribution of DAN-222 compared to irinotecan was evaluated in wild-type mice, indicating that the exposure of DAN-222 in the bone marrow was significantly lower than that of irinotecan.
[0156] Furthermore, DAN-222 not only demonstrates efficacy, but is also designed to reduce or eliminate the unnecessary risks and side effects associated with free CPT. The DAN-222 construct is designed to limit the acute toxicity of CPT by attaching it to the nanoparticle polymer, thereby controlling the release of the active CPT portion. The release of free CPT is caused by hydrolysis, the release of which can be controlled in part by the nanoparticle construct and can also be controlled by using the DAN-222 formulation described herein.
[0157] The present invention also includes compositions and methods for combining DAN-222 with poly (ADP-ribose) polymerase (PARP) inhibitors (such as niraparib). Recently, PARP has become a new target for cancer treatment. PARP inhibitors take advantage of genomic instability and defects in DNA repair pathways. Currently, the U.S. Food and Drug Administration (FDA) has approved four PARP inhibitors, namely Olaparib, Rucaparib, Niraparib and Tarazoparib. Among them, Olaparib and Tarazoparib are approved for HER2-negative locally advanced or mBC with germline BRCA1 / 2 mutations. Currently, PARP inhibitors are considered to be the most important therapeutic drugs for BRCA mutations in TNBC and BRCA-mutated estrogen receptor-positive breast cancer.
[0158] As explained, topoisomerase inhibitors (such as CPT) damage DNA by binding to topoisomerase I and preventing DNA unwinding required for replication. This leads to replication fork stalling, which can be repaired by poly (ADP-ribose) polymerase (PARP). PARP inhibitors block the PARP enzyme DNA repair activity and have been shown to induce apoptosis in tumor cells. Therefore, in addition to directly killing tumors, inhibiting PARP will increase the cytotoxicity of chemotherapeutic drugs and DNA damaging agents (such as topoisomerase inhibitors, such as CPT).
[0159] In some aspects, the present invention includes preparations that can be used to treat cancer, cancer metastasis and / or the illness of brain and central nervous system. In some aspects, cancer is selected from breast cancer, lung cancer, colon cancer, ovarian cancer, melanoma, bladder cancer, kidney cancer, liver cancer, salivary gland cancer, gastric cancer, glioma, thyroid cancer, thymic cancer, epithelial cancer, head and neck cancer, gastric cancer and pancreatic cancer. In preferred aspects, cancer is breast cancer or ovarian cancer. In some aspects, cancer is HER2 negative metastatic breast cancer (mBC). In some aspects, HER2 negative mBC is homologous recombination defect (HRD) positive or negative HER2 negative mBC. In other aspects, cancer is the brain metastasis of breast tumor.
[0160] Abbreviations and definitions
[0161] Reference to an alcohol, aldehyde, amine, carboxylic acid, ketone or other similar reactive functional group also encompasses protected analogs thereof. For example, reference to hydroxy or alcohol also includes those substituents in which the hydroxy is protected by acetyl (Ac), benzoyl (Bz), benzyl (Bn, Bnl), b-methoxyethoxymethyl ether (MEM), dimethoxytrityl, [bis-(4-methoxyphenyl)benzyl] (DMT), methoxymethyl ether (MOM), methoxytrityl [(4-methoxyphenyl)diphenylmethyl (MMT), p-methoxybenzyl ether (PMB), methylthiomethyl ether, pivaloyl (Piv), tetrahydropyranyl (THP), tetrahydrofuran (THF), trityl (triphenylmethyl, Tr), silyl ether (the most common silyl ethers include trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), triisopropylsiloxymethyl (TOM) and triisopropylsilyl (TIPS) ether), ethoxyethyl ether (EE). References to amines also include those substituents in which the amine is protected by BOC glycine, carbobenzyloxy (Cbz), p-methoxybenzylcarbonyl (Moz or MeOZ), tert-butoxycarbonyl (BOC), 9-fluorenylmethoxycarbonyl (FMOC), acetyl (Ac), benzoyl (Bz), benzyl (Bn), carbamate, p-formylbenzyl (PMB), 3,4-dimethoxybenzyl (DMPM), p-methoxyphenyl (PMP), tosyl (Ts) groups or sulfonamide (Nosyl and Nps) groups. References to substituents containing a carbonyl group also include those substituents in which the carbonyl group is protected by an acetal or ketal, an acyl or dialkyl group. Reference to substituents containing a carboxylic acid or carboxylate group also includes those substituents in which the carboxylic acid or carboxylate group is protected by: its methyl ester, benzyl ester, tert-butyl ester, ester of a 2,6-disubstituted phenol (e.g., 2,6-dimethylphenol, 2,6-isopropylphenol, 2,6-di-tert-butylphenol), silyl ester, orthoester, or oxazoline.
[0162] abbreviation:
[0163] ASCO American Society of Clinical Oncology
[0164] AUC0 - Area under the curve from time 0 to the last measurable concentration
[0165] BOR Best Overall Response
[0166] BRCA Breast Cancer Gene
[0167] BRCA1 Breast cancer gene type 1
[0168] BRCA2 Breast cancer gene type 2
[0169] CAP College of American Pathologists
[0170] CBR Clinical benefit rate
[0171] CI confidence interval
[0172] CL clearance
[0173] Clearance of CL / F after oral administration
[0174] Cmax Maximum observed plasma concentration
[0175] Cmin minimum observed plasma concentration
[0176] CPT Camptothecin
[0177] CR Complete Response
[0178] CRA Clinical Research Assistant
[0179] CT Computerized tomography
[0180] CTC circulating tumor count
[0181] CYP3A4 Cytochrome P450 3A4
[0182] DAN-222 Mucin-containing polymer nanoparticles containing 20(S)-camptothecin
[0183] DAS Dose-limiting toxicity assessable analysis set
[0184] DCR disease control rate
[0185] DLT Dose-limiting toxicity
[0186] DOR Response Duration
[0187] EAS Evaluable Analysis Set
[0188] ECG Electrocardiogram
[0189] ECOG Eastern Cooperative Oncology Group
[0190] eCRF Electronic Case Report Form
[0191] EDC Electronic Data Capture
[0192] EOT End of treatment
[0193] EPR Enhanced Permeability and Retention
[0194] FAS Full Analysis Set
[0195] FDA U.S. Food and Drug Administration
[0196] GCP Good Clinical Practice
[0197] G-CSF Granulocyte colony stimulating factor
[0198] HER2 Human epidermal growth factor receptor 2
[0199] HNSTD Highest non-severely toxic dose level
[0200] HR Homologous recombination
[0201] HRD Homologous recombination repair deficiency
[0202] ICF Informed Consent Form
[0203] ICH International Committee for Harmonization
[0204] ILD interstitial lung disease
[0205] IRB / IEC Institutional Review Board / Independent Ethics Committee
[0206] IV
[0207] MAD maximum administered dose
[0208] mBC metastatic breast cancer
[0209] MDS / AML Myelodysplastic syndrome / acute myeloid leukemia
[0210] MedDRA Medical Dictionary for Regulatory Activities
[0211] MRI Magnetic Resonance Imaging
[0212] MTD maximum tolerated dose
[0213] NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
[0214] NP Nanoparticles
[0215] ORR objective response rate
[0216] PARP Poly(ADP-ribose) polymerase
[0217] PD Pharmacodynamics
[0218] PEG Polyethylene glycol
[0219] PFS Progression-free survival
[0220] PK Pharmacokinetics
[0221] PPAS Protocol Analysis Set
[0222] PR Partial Response
[0223] PRES Posterior reversible encephalopathy syndrome
[0224] QD Daily
[0225] QW Weekly
[0226] RECIST v1.1 Response Evaluation Criteria in Solid Tumors Version 1.1
[0227] RP2D Recommended Phase 2 Dose
[0228] SAE Serious Adverse Event
[0229] SAS Security Analytics Suite
[0230] SAP Statistical Analysis Program
[0231] SD Stable disease
[0232] SRT Safety Review Team
[0233] t1 / 2 terminal elimination half-life
[0234] TEAE Treatment-emergent adverse events
[0235] TNBC Triple-negative breast cancer
[0236] ULN Upper limit of normal
[0237] V Volume of distribution
[0238] Vz / F Volume of distribution after oral administration
[0239] When a value is expressed as an approximate value by using the descriptor "about", it should be understood that the particular value forms another embodiment. In general, the term "about" is used to represent approximate values, which may vary depending on the desired properties sought to be obtained by the disclosed subject matter, and should be interpreted based on its function in the specific context in which it is used. Those skilled in the art will be able to interpret this as a routine matter. In some cases, the number of significant figures for a particular value can be a non-limiting method for determining the degree of the word "about". In other cases, the classification used in a series of values can be used to determine the established range of the term "about" that can be used for each value. If present, all ranges are inclusive and combinable. That is, reference to the value stated in a range is included in each value within the range.
[0240] It should be understood that certain features of the present disclosure described in the context of a separate embodiment for the purpose of clarity may also be provided in combination in a single embodiment. That is, unless clearly incompatible or excluded, each separate embodiment is considered to be combinable with any other embodiment, and such combination is considered to be another embodiment. Conversely, for the sake of brevity, the various features of the present disclosure described in the context of a single specific embodiment may also be provided individually or in any sub-combination. Finally, although an embodiment may be described as part of a series of steps or part of a more general structure, each of the steps itself may also be considered to be an independent embodiment that may be combined with other steps.
[0241] As used herein, a "pure isomer" compound or an "isomerically pure" compound is substantially free of other isomers of the compound. The term "pure isomer" compound or "isomerically pure" means that the compound includes at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% by weight of a compound having a particular structure. In certain embodiments, the weight is based on the total weight of all isomers of the compound.
[0242] As used herein, a "stereoisomerically pure" compound or a "stereoisomerically pure" compound is substantially free of other stereoisomers of the compound. Thus, the composition is substantially free of isomers that differ at any chiral center. If the compound has multiple chiral centers, most compositions contain compounds with the same stereochemistry at all chiral centers. The term "stereoisomerically pure" compound or "stereoisomerically pure" means that the compound includes at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% by weight of a compound with a specific stereochemistry. In certain embodiments, the weight is by the total weight of all stereoisomers of the compound.
[0243] As used herein, a pure enantiomer compound is substantially free of other enantiomers or stereoisomers of the compound (i.e., enantiomeric excess). In other words, the "S" form of the compound is substantially free of the "R" form of the compound, and is therefore in enantiomeric excess relative to the "R" form. The term "enantiomerically pure" or "pure enantiomer" means that the compound includes at least 95% by weight, at least 96% by weight, at least 97% by weight, at least 98% by weight, at least 99% by weight, at least 99.5% by weight, at least 99.6% by weight, at least 99.7% by weight, at least 99.8% by weight, or at least 99.9% by weight of the enantiomer. In certain embodiments, the weight is based on the total weight of all enantiomers or stereoisomers of the compound.
[0244] The compounds described herein may also include one or more isotopic substitutions. For example, H may be in any isotopic form, including 1 H. 2 H (D or deuterium) and 3 H (T or tritium); C can be in any isotopic form, including 12 C. 13 C and 14 C; N can be in any isotopic form, including 14 N and 15 N; O can be in any isotopic form, including 16 O and 18 O; etc.
[0245] The articles "a" and "an" as used herein may refer to one or more than one (ie, at least one) of the grammatical object of the article. By way of example, "an analogue" means one analogue or more than one analogue.
[0246] "Pharmaceutically acceptable" means approved or approvable by a regulatory agency of the Federal or a state government or its equivalent in countries outside the United States, or listed in the US Pharmacopoeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
[0247] "Pharmaceutically acceptable salt" refers to a salt of a compound of the present invention that is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound. Specifically, such salts are non-toxic and may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts formed from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or formed from organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethylsulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, dodecylsulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, etc.; or (2) salts formed when the acidic proton present in the parent compound is replaced by a metal ion (e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion) or coordinated with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, etc. By way of example only, salts further include sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc.; and when the compound contains a basic functional group, salts of non-toxic organic or inorganic acids such as hydrochloride, hydrobromide, tartrate, methanesulfonate, acetate, maleate, oxalate, etc. The term "pharmaceutically acceptable cation" refers to an acceptable cationic counterion for an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, etc. See, e.g., Berge et al., J. Pharm. Sci. (1977) 66(1): 1-79.
[0248] "Solvate" refers to a form of a compound that is associated with a solvent or water (also referred to as a "hydrate"), usually by a solvolysis reaction. This physical association includes hydrogen bonding. Conventional solvents include water, ethanol, acetic acid, and the like. The compounds of the invention can be prepared, for example, in crystalline form and can be solvated or hydrated. Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and further include both stoichiometric solvates and non-stoichiometric solvates. In certain cases the solvate will be capable of separation, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid. "Solvate" encompasses both liquid phases and separable solvates.
[0249] The procedures described herein contain standard solvents and catalysts known in the art. Although specific compounds (eg, acids, bases, coupling agents) are recited in this disclosure, it will be apparent to those skilled in the art that different reagents may be used.
[0250] Exemplary solvents include, but are not limited to, chlorinated solvents (e.g., dichloromethane, chloroform, 1,2-dichloroethane), ethers (e.g., diethyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, diglyme, 1,4-dioxane, 2-methyltetrahydrofuran), alcohols (e.g., methanol, ethanol, isopropanol, tert-butanol), alkanes (e.g., pentane, hexane, heptane), glycols (e.g., ethylene glycol, polyethylene glycol), polar aprotic solvents (e.g., dimethylacetamide, acetonitrile, dimethyl sulfoxide, dimethylformamide, acetone, N-methyl-2-pyrrolidone), and polar protic solvents (e.g., water, ethanol, acetic acid, propionic acid).
[0251] Exemplary acids include, but are not limited to, inorganic acids (e.g., hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid) and organic acids (e.g., acetic acid, malonic acid, methanesulfonic acid, propionic acid, thioacetic acid, p-toluenesulfonic acid, tribromoacetic acid, trichloroacetic acid, trifluoroacetic acid).
[0252] Exemplary bases include, but are not limited to, amide bases (e.g., 1,4-diazabicyclo[2.2.2]octane, diethylamine, triethylamine, N,N-diisopropylethylamine, lithium amide, lithium bis(trimethylsilyl)amide, morpholine, piperidine), alkoxides (e.g., barium tert-butoxide, lithium tert-butoxide, sodium methoxide), hydroxides (e.g., tetrabutylammonium hydroxide, sodium hydroxide, potassium hydroxide), organometallic bases (e.g., n-butyllithium, tert-butyllithium, butylmagnesium chloride), pyridines (e.g., 4-dimethylaminopyridine, 2,6-lutidine, pyridine), carbonates (e.g., lithium carbonate, sodium carbonate, magnesium carbonate, potassium carbonate), and hydrides (e.g., sodium hydride, calcium hydride, potassium hydride).
[0253] Exemplary coupling agents include, but are not limited to, carbodiimide reagents (e.g., N,N'-diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N'-dicyclopentylcarbodiimide), additives to carbodiimide reagents (e.g., 1-hydroxy-7-azabenzotriazole, 6-chloro-1-hydroxybenzotriazole, N-hydroxysuccinimide, 1-hydroxy-2-pyridone, 6-chloro-N-hydroxy-2-phenylbenzimidazole, 2-cyano-2 -(hydroxyimino)ethyl acetate), anhydride groups or forming reagents (e.g., di-tert-butyl carbonate, acetic anhydride, 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, ethyl chloroformate), acyl azoles (e.g., carbonyl diimidazole), acyl halide generating reagents (e.g., thionyl chloride, phosgene, cyanuric chloride, benzyltriphenyltrifluoride dihydrogen phosphine), phosphine ion salt coupling reagents (e.g., benzotriazol-1-yloxytris(dimethylamino)phosphine hexafluorophosphate), tetramethyl ammonium reagents (e.g., 2-(2-oxo-1(2H)-pyridinyl-1,1,3,3-tetrafluoroborate tetramethyluronium), ammonium reagents (e.g., 2-chloro-1,3-dimethylimidazolidine hexafluorophosphate), uranium oxide salts (e.g., 1-((1-cyano-2-ethoxy-2-oxoethylideneaminooxy)(morpholino)methylene)pyrrolidine hexafluorophosphate), uranium antimonate salts (e.g., benzotriazol-1-yloxy-N,N-dimethyl-methylamine hexachloroantimonate ), organophosphorus reagents (e.g., diethyl cyanophosphonate, 1-oxo-phospholane, 2-propanephosphonic anhydride), triazine-based reagents (e.g., 2-chloro-4,6-dimethoxy-1,3,5-triazine), organosulfur reagents (e.g., pentafluorophenyl-4-nitrobenzenesulfonate), pyridinium cation reagents (e.g., 2-chloro-1-methylpyridinium iodide), polymer-bound reagents (e.g., polymer-supported N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline).
[0254] As used herein, the term "isotopic variant" refers to a compound that contains unnatural proportions of isotopes at one or more of the atoms that constitute such a compound. For example, an "isotopic variant" of a compound may contain one or more non-radioactive isotopes, such as deuterium ( 2 H or D), carbon-13 ( 13 C), nitrogen-15 ( 15 It is understood that in compounds subject to such isotopic substitution, if any, the following atoms may vary so that, for example, any hydrogen may be 2 H / D, any carbon can be 13 C or any nitrogen can be 15N, and allows the presence and placement of such atoms to be determined within the skill of the art. Likewise, the invention may encompass the preparation of isotopic variants having radioactive isotopes, in which case, for example, the resulting compounds may be useful in drug and / or substrate tissue distribution studies. The radioactive isotope tritium (i.e. 3 H) and the radioactive isotope carbon-14 (i.e. 14 C) is particularly useful for this purpose due to its ease of incorporation and readily available detection methods. 11 C. 18 F. 15 O and 13 Compounds substituted with positron emitting isotopes such as N may be useful in positron emission tomography (PET) studies for examining substrate receptor occupancy. All isotopic variations of the compounds provided herein, whether radioactive or non-radioactive, are intended to be encompassed within the scope of the present invention.
[0255] “Stereoisomers”: It will also be understood that compounds having the same molecular formula but differing in the nature or sequence of bonding of the atoms or the arrangement of the atoms in space are termed “isomers”. Isomers that differ in the spatial arrangement of the atoms are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereomers”, while stereoisomers that are non-superimposable mirror images of one another are termed “enantiomers”. For example, when a compound has an asymmetric center, and the atoms such as carbon atoms are bonded to four different groups, a pair of enantiomers may exist. Enantiomers may be characterized by the absolute configuration of their asymmetric center and described by the R- and S-sequencing rules of Cahn and Prelog, or by the way in which the molecule rotates the plane of polarized light and is designated as right-handed or left-handed (i.e., (+) or (-)-isomers, respectively). A chiral compound may exist as an individual enantiomer or as a mixture of two enantiomers. A mixture containing equal proportions of enantiomers is termed a “racemic mixture”.
[0256] "Tautomers" refer to compounds that are interchangeable forms of a particular compound structure and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures can reach equilibrium through the movement of n electrons and one atom (usually H). For example, enols and ketones are tautomers because they can interconvert rapidly by treatment with acid or base. Another example of tautomerism is the acidic and nitro forms of phenylnitromethane, which are also formed by treatment with acid or base. Tautomeric forms can be relevant to achieving optimal chemical reactivity and biological activity of the compound of interest.
[0257] The "subject" contemplated for administration includes, but is not limited to, humans (i.e., males or females of any age group, such as pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young, middle-aged, or elderly)) and / or non-human animals, such as mammals, such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal.
[0258] Disease, disorder and condition are used interchangeably herein.
[0259] As used herein, and unless otherwise indicated, the terms "treat," "treating," and "treatment" refer to actions taken while a subject has a particular disease, disorder, or condition to reduce the severity of the disease, disorder, or condition, or to delay or slow the progression of the disease, disorder, or condition ("therapeutic treatment"), and also refer to actions taken before a subject begins to have a particular disease, disorder, or condition ("prophylactic treatment").
[0260] In general, an "effective amount" of a compound means an amount sufficient to elicit a desired biological response (e.g., to treat cancer). As will be appreciated by those of ordinary skill in the art, the effective amount of a compound, composition, or formulation of the invention may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, weight, health, and condition of the subject. An effective amount encompasses both therapeutic and prophylactic treatments.
[0261] As used herein, unless otherwise indicated, a "therapeutically effective amount" of a compound is an amount sufficient to provide a therapeutic benefit for treating a disease, disorder or condition or to delay or minimize one or more symptoms associated with the disease, disorder or condition. A therapeutically effective amount of a compound refers to the amount of a therapeutic agent alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of a disease, disorder or condition. The term "therapeutically effective amount" can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of another therapeutic agent (i.e., reduces the amount and / or severity of symptoms associated with the condition). For example, in the case of cancer metastasis to the brain, administration of a therapeutically effective amount of nanoparticles or nanoparticle formulations as described herein reduces and / or reverses metastatic symptoms; for example, regression of metastatic tumors. The therapeutically effective amount for treating brain metastases varies depending on the type and extent of brain damage, and may also vary depending on the overall condition of the subject.
[0262] As used herein, unless otherwise indicated, a "prophylactic effective amount" of a compound is an amount sufficient to prevent a disease, disorder or condition, or one or more symptoms associated with a disease, disorder or condition, or to prevent its recurrence. A prophylactic effective amount of a compound means the amount of a therapeutic agent that provides a prophylactic benefit of preventing a disease, disorder / disorder or condition, either alone or in combination with other agents. The term "effective amount" may encompass an amount that improves overall prevention or enhances the prophylactic efficacy of another prophylactic agent.
[0263] Aqueous suspensions can contain a mixture of these compounds and excipients suitable for making aqueous suspensions. Such excipients can be suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinyl pyrrolidone, tragacanth and gum arabic; dispersants or wetting agents, such as naturally occurring phospholipids (e.g., lecithin), or condensation products of olefin oxides and fatty acids (e.g., polyoxyethylene stearate), or condensation products of ethylene oxide and long-chain fatty alcohols (e.g., heptadecaethyleneoxycetanol), or condensation products of ethylene oxide and partial esters derived from fatty acids and hexitol (e.g., polyoxyethylene sorbitol monooleate with partial lipids derived from fatty acids and hexitol anhydrides). Aqueous suspensions can also contain: one or more preservatives, such as ethyl p-hydroxybenzoate or n-propyl p-hydroxybenzoate; one or more coloring agents; one or more flavoring agents; and one or more sweeteners, such as sucrose or saccharin.
[0264] DAN-222 formulation
[0265] The chemical structure of the repeating unit of the DAN-222MAP-Gly-CPT polymer-drug conjugate is provided in formula (I):
[0266]
[0267] Formula (I) represents a polymer-drug conjugate of DAN-222 (MAP-Gly-CPT). The polymer repeating unit consists of a modified mucic acid moiety bonded to a dipropionyl PEG unit. Figure 1 As shown, when formulated in aqueous media, DAN-222 self-assembles into nanoparticles (NPs). When formulated into NPs, each NP is expected to consist of approximately two MAP-Gly-CPT chains.
[0268] In formula (I), (n) is the number of ethylene glycol repeating units. In certain aspects, in exemplary formulations of the invention, (n) is a number in the range of 5 to 200. Preferably, in formulations of the invention, the average (n) of MAP-Gly-CPT molecules of formula (I) in the formulation is about 79.
[0269] In formula (I), (m) is the number of repeating units of MAP-Gly-CPT in the chain of the polymer-drug conjugate. In certain aspects, (m) is a number from 20 to 200. In preferred formulations of the invention, on average, each polymer chain consists of 16±4 repeats of the PEG-MAP unit, each unit of which can be conjugated to up to two Gly-CPT molecules.
[0270] When Gly-CPT is conjugated to MAP, the reaction is performed so that conjugation occurs at about 75% to 100% of the sites on the MAP available for reaction with Gly-CPT. In certain aspects, about 75%, 80%, 85%, 90%, 95%, 98%, 99% or 100% of the available sites are reacted and conjugated with CPT. In preferred aspects, at least about 90% of the available sites are reacted and conjugated with CPT.
[0271] As explained, DAN-222 self-assembles into nanoparticles (NPs) when formulated in an aqueous formulation.
[0272] In certain aspects, in the preparation of the present invention, the diameter size range of nanoparticles is about 20 to about 80nm. Exemplary nanoparticle diameter is about: 15nm, 16nm, 17nm, 18nm, 19nm, 20nm, 21nm, 22nm, 23nm, 24nm, 25nm, 26nm, 27nm, 28nm, 29nm, 30nm, 31nm, 32nm, 33nm, 34nm, 35nm, 36nm, 37nm, 38nm, 39nm, 40nm, 45nm, 50nm, 55nm, 60nm, 65nm, 70nm, 75nm or 80nm. In preferred aspects, the diameter size range of nanoparticles is about 30nm to about 40nm.
[0273] In certain aspects, the values of (m) and (n) are selected such that after the DAN-222 chains are assembled into nanoparticles, the size of the nanoparticles is in the range of 10 to 900 nm or any integer value therebetween, such as 20 nm to 80 nm.
[0274] In certain aspects, the formulations of the invention comprise a DAN-222 nanoparticle concentration of 5 mg / mL to 40 mg / mL, 10 mg / mL to 30 mg / mL, or 15 mg / mL to 25 mg / mL. In preferred aspects, the nanoparticle concentration is between 17 mg / mL and 23 mg / mL.
[0275] In certain aspects, the formulations of the invention comprise DAN-222 nanoparticles having a polydispersity index (PDI) less than or equal to 0.9. In certain aspects, the nanoparticles have a PDI less than or equal to 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, or 0.1.
[0276] In certain aspects, the formulations of the invention comprise a total CPT concentration of 0.5 mg / ml to 10 mg / ml, 1 mg / ml to 9 mg / ml, 2 mg / ml to 8 mg / ml, 3 mg / ml to 7 mg / ml, 4 mg / ml to 6 mg / ml, 1 mg / ml to 4 mg / ml, 1.5 mg / ml to 3.8 mg / ml, 2 mg / ml to 3 mg / ml, 2.5 mg / ml to 3.0 mg / ml, or 1.7 mg / ml to 3.6 mg / ml. In a preferred aspect, the formulations of the invention comprise a total CPT concentration of about 2.6 mg / ml.
[0277] In certain aspects, the formulation comprises a concentration of the compound of Formula (I) of 5 mg / ml to 100 mg / ml, 4 mg / ml to 77 mg / ml, 10 mg / ml to 90 mg / ml, 10 mg / ml to 80 mg / ml, 15 mg / ml to 50 mg / ml, 15 mg / ml to 40 mg / ml, 15 mg / ml to 30 mg / ml, 15 mg / ml to 25 mg / ml, 13 mg / ml to 28 mg / ml or about 20 mg / ml.
[0278] In certain aspects, exemplary formulations of the invention have a pH between 3 and 6. In further embodiments, the pH of the formulation is between pH 3.5 and pH 5.5, or between pH 4 and pH 5. In certain aspects, the pH of the formulation is between pH 4 and pH 4.6. In preferred aspects, the pH of the formulation is about pH 4.3. The inventors have found that formulations with a lower pH (e.g., a pH between pH 3 and pH 5) show less CPT loss during storage, wherein CPT stability increases with decreasing pH of the formulation. However, formulations with a pH below pH 4 may cause discomfort to patients.
[0279] The formulation of the present invention may further comprise at least one buffer selected from the group consisting of sodium succinate, sodium citrate, sodium acetate, phosphoric acid, histidine-HCL and sodium phosphate. In a preferred aspect, the buffer is a sodium acetate buffer. The formulation may further comprise at least one tension regulator selected from the group consisting of KCl, NaCl, proline, arginine-HCl, sucrose and glycine. Preferably, the at least one tension regulator is NaCl.
[0280] In a preferred aspect, the formulation comprises about 20 mg / mL of the compound of formula (I), about 20 mM sodium acetate, about 200 mM NaCl, and has a pH of 4.3 ± 0.3.
[0281] The zeta potential is a measure of surface charge. In certain DAN-222 formulations of the invention, the zeta potential is between -5 mV and +5 mV. In preferred aspects, the DAN-222 formulations of the invention exhibit a zeta potential that is close to neutral.
[0282] In certain aspects, the osmotic pressure of the DAN-222 formulations of the present invention is between 300 mOsm / kg and 600 mOsm / kg. In preferred aspects, the osmotic pressure of the DAN-222 formulations is between about 336 and about 504 mOsm / kg. In certain aspects, this range represents the osmotic pressure of the formulation buffer, as the DAN-222 molecule has little effect on the osmotic pressure results.
[0283] The molecular weight of the DAN-222 nanoparticles in the aqueous formulations described herein can be determined by gel permeation chromatography (GPC) using PEO standards with nominal molecular weights of 100 kDa and 200 kDa. The molecular weight of the DAN-222 conjugate is calculated from the molecular weight of the polymer (i.e., MAP) used in the conjugate synthesis adjusted for drug (CPT) loading as follows:
[0284] MW conjugate =MW polymer / (1-T),
[0285] MW polymer is the molecular weight of MAP used to synthesize the DAN-222 conjugate, and T is the fractional loading of the therapeutic agent (CPT), expressed as a decimal fraction.
[0286] In a preferred formulation of the invention, the average molecular weight of the MAP parent polymer, which is composed of an average of 16 repeating units, is about 65,000 Da. The target molecular weight range for this material is 50,000-80,000 Da. At 90% CPT loading, the molecular weight of a 65,000 Da MAP polymer is about 75,000 Da. In certain embodiments, the molecular weight of the MAP-Gly-CPT molecule is between 30 kDa and 100 kDa, between 40 kDa and 90 kDa, between 50 kDa and 80 kDa, or between 60 kDa and 70 kDa. In a preferred aspect, the nanoparticles of the formulation include an average of two chains comprising the compound of formula (I) and have an average molecular weight of about 150,000 Da. In other embodiments, the nanoparticles include 1, 2, 3, 4, 5 or 6 chains of the compound of formula (I).
[0287] As used herein, chains per particle (SpP) is the number of mucic acid polymer ("MAP") therapeutic (CPT) conjugate molecules present in a particle or nanoparticle. For the purpose of determining SpP, a particle or nanoparticle is an entity having at least one MAP-Gly-CPT chain / molecule that behaves as a single unit in any aqueous solution (e.g., water at neutral pH), PBS at pH 7.4, or any formulation that will be administered to a patient at a concentration suitable for administration to a human. For the purpose of calculating chains per particle, a MAP-Gly-CPT molecule is a single MAP-Gly-CPT conjugate chain. In a preferred formulation of the invention, the DAN-222 nanoparticles contain an average of two MAP-Gly-CPT conjugate chains.
[0288] The methods disclosed herein provide methods for evaluating nanoparticles, wherein the particles include one or more MAP-Gly-CPT molecules. Typically, the method requires providing a sample including a plurality of said particles and determining an average value of the number of MAP-Gly-CPT molecules per particle in the sample to evaluate the preparation of the particles. The value for the particle sample will be a function of the values obtained for the plurality of particles.
[0289] As mentioned above, SpP is defined as the number of MAP-Gly-CPT molecules that self-assemble into particles or nanoparticles, so SpP = [MAP-Gly-CPT molecules] / P (or NP),
[0290] where [MAP-Gly-CPT molecules] is the number of MAP-Gly-CPT chains / molecule and P (or NP) is a single particle (or nanoparticle).
[0291] In certain embodiments, the method further comprises comparing the determined value to a reference value. The comparison can be performed in a variety of ways. For example, in response to the comparison or determination in the method, a decision or step is made, such as changing a production parameter in the process of manufacturing the particles; sorting, selecting, accepting or discarding, releasing or withholding the sample; processing into a drug product; transporting, moving to a different location; formulating, such as formulating with another substance (e.g., an excipient); labeling; packaging; placing on the market; or selling or offering for sale. For example, based on the results of the assay or comparison with a reference standard, the sampled batch can be processed, such as described above.
[0292] To calculate the number of MAP-Gly-CPT chains per particle, the size of the particles is determined by light scattering of the self-assembled particles (e.g., by molecular weight), and the size of the individual polymers is determined by light scattering of the individual polymers (e.g., by molecular weight), and the loading of CPT is determined, for example, by mass %. From these values, SpP can be calculated as follows:
[0293] SpP=MW particle / (MW conjugate ),
[0294] MW particle is the molecular weight of the particle, and MW conjugate is the molecular weight of the MAP-Gly-CPT molecule, which is calculated as follows:
[0295] MW conjugate =MW polymer / (1-T%),
[0296] MW polymer is the molecular weight of MAP and T% is the loading percentage of the therapeutic agent (CPT) expressed as a decimal, e.g., 10% loading results in T% = 0.1.
[0297] Polymer molecular weight distribution and particle dispersibility: MAP is synthesized so that it has a range of molecular weights. Molecules of different molecular weights provide different contributions to particle diameter and number of chains per particle.
[0298] Particle shape: The particle shape was assumed to be approximately spherical. Self-assembly is believed to be driven by the hydrophobic regions generated by the therapeutic agent of the MAP-Gly-CPT molecule.
[0299] Methods for producing DAN-222 formulations
[0300] The present invention provides methods for producing DAN-222 formulations as described herein. The drug substance DAN-222 consists of 20(S)-camptothecin (CPT) covalently bound to a mucic acid-based polymer carrier via a glycyl bond (MAP-Gly-CPT). During manufacturing, MAP-Gly-CPT is isolated as an amorphous solid. In aqueous solution, the MAP-Gly-CPT polymer-drug conjugate self-assembles into nanoparticles (NPs).
[0301] In certain aspects, an exemplary method for making a DAN-222 formulation comprises four main steps: (i) derivatization of camptothecin (CPT) to obtain Gly-CPT (trifluoroacetic acid (TFA) salt); (ii) synthesis of a parent mucic acid polymer (MAP); (iii) covalent attachment of the derivatized camptothecin to the parent polymer to obtain a solid amorphous MAP-Gly-CPT polymer-drug conjugate; and (iv) aqueous formulation of MAP-Gly-CPT to form nanoparticles (NPs).
[0302] Examples 5-8 provide details and data related to exemplary methods for making DAN-222 and DAN-222 formulations of the present invention.
[0303] Fig.35 A scheme of an exemplary method of manufacturing DAN-222 is provided. Starting materials are indicated in black boxes, and manufacturing steps performed under GMP conditions for Phase 1 clinical trial drug substance are indicated in text or surrounded by boxes 3401.
[0304] Briefly, in an exemplary method, in step (i), the production of derivatized CPT is a two-step process in which the hydroxyl group of CPT is esterified with a tert-butyloxycarbonyl-protected glycine linker (Boc-Gly), followed by removal of the Boc protecting group and isolation to obtain glycine-linked CPT (Gly-CPT) in the form of a trifluoroacetic acid (TFA) salt.
[0305] As described in Example 7, the inventors discovered several improvements to the method for producing Gly-CPT in the form of a trifluoroacetic acid (TFA) salt.
[0306] For the Boc-Gly-CPT synthesis step, it was found that the reaction proceeded more smoothly when carried out under more dilute conditions and at higher reaction temperatures compared to existing methods. Further, a new water extraction step was added to improve the removal of process impurities. In early syntheses, DCM was removed to obtain a crude solid. In contrast, the inventors used vacuum distillation to remove only 95% of the DCM volume and added a significantly lower proportion of methanol at a higher temperature for the final precipitation. Additional washing with isopropyl alcohol (IPA) was found to improve separation performance.
[0307] For the deprotection and isolation of Gly-CPT, significantly lower volumes of methyl tert-butyl ether (MTBE) were used in the subsequent precipitation step, followed by washing the filter cake with a MTBE:DCM mixture having a lower MTBE:DCM ratio.
[0308] In an exemplary method for producing a DAN-222 formulation, in step (ii), the parent polymer (i.e., mucic acid polymer (MAP)) is produced by step-growth polymerization of two comonomers, MAM and diSPA-PEG (a linear PEG molecule with a succinimide-activated propionyl ester at each end). The comonomers are dissolved in dimethyl sulfoxide (DMSO), and the reaction is initiated by adding N,N-diisopropylethylamine (DIPEA), thereby initiating the amidation of the free amines at each end of the MAM monomer. When the MAP molecular weight (MW) is expected to reach or approach the target value, the reaction is quenched with water, and the MAP is separated from the DMSO and water by dialysis and then lyophilized.
[0309] As described in Example 7, the inventors discovered several improvements to the process for producing MAP required for making DAN-222.
[0310] The process of step (ii) is intended to control the reaction kinetics and achieve near-stationary growth of polymer MW over time. While conditions for producing MAP can be determined to produce approximately linear growth of MW over time, this strategy requires precise in-process monitoring of MW and reaction quenching. Alternatively, given that polymerization has been shown to follow a known model of stepwise growth of polymers, a strategy to stall the reaction over time has been developed based on polymerization theory (modified Carothers equation and Flory-Shulz distribution). This strategy achieves growth stationarity by exploiting the stoichiometric imbalance of the comonomers and slows the reaction as the MAP approaches the target MW. Fig.44 and 46 -48 shows an example polymerization where the MW of MAP at a late time point is controlled by the stoichiometric ratio of MAM to diSPA-PEG in the reaction mixture.
[0311] The present inventors have found that an increase in the ratio of MAM:diSPA-PEG results in the production of lower MW polymers. Therefore, it is desirable that the preparation of the monomer starting material has a high degree of functionalization as specified herein, and that the reaction is carried out under anhydrous conditions to maintain the stability of the activated SPA groups on the diSPA-PEG in order to prevent early termination of the amidation reaction, thereby allowing the stoichiometric ratio of the comonomers to be well controlled at or near the target.
[0312] During the development of step (ii), several modifications were made to the process to make it more robust, scalable, safe, and / or reduce impurity levels. These modifications included: (i) using MAM as the diTFA salt instead of the neutral species; (ii) the stoichiometric ratio of MAM, diSPA-PEG, TFA, and DIPEA; and (iii) the use of dialysis and precipitation for purification.
[0313] To reduce potential variability, it was decided to isolate the MAM as a neutral species (lacking the TFA counterion) and allow for more precise addition of TFA as a subsequent reaction step prior to polymerization.
[0314] The development of MAM modification is the result of reactions using isolated MAMs as diTFA salts or neutral species (only trace amounts of TFA were isolated) to study the effect of the presence or absence of TFA in the monomer starting material on the reaction behavior. Although the TFA group does not participate in the actual polymerization reaction, it was found that it significantly affects the solubility of the MAM in DMSO and therefore affects the reaction kinetics. Unlike diTFA salts, which are generally soluble in DMSO, the neutral species was found to have the lowest solubility in DMSO. Despite its poor solubility, studies on the polymerization of neutral species with diSPA-PEG showed that the reaction proceeded without the addition of TFA, although the reaction generally showed linear kinetics regardless of the comonomer ratio. In contrast, the polymerization of neutral species with diSPA-PEG was approximately 1-2 eq. Adding TFA to the reaction before initiation with DIPEA resulted in the expected restoration of smooth behavior.
[0315] Based on the results obtained from preliminary experiments, it was decided to develop reaction conditions with isolated MAM as the neutral species and subsequently add TFA to level out the polymer MW at or near the target.
[0316] Further, the inventors conducted a series of experiments to investigate the combined effects of different comonomer ratios and TFA and DIPEA equivalents on the kinetics of the reaction in step (ii). The results showed that a reduction in the amount of DIPEA (~2.5 equivalents) resulted in a decrease in the reaction kinetics, while a decrease in the MAM:diSPA-PEG ratio to 1:1 resulted in an increase in the MW of the MAP product. An increase in TFA concentration produced an improved logarithmic plateau of the MW values; rather than a linear plateau. The combined results of the preliminary screening indicated that the comonomer ratios, TFA and DIPEA equivalents, and reaction time were sufficient to achieve the targeted degree of MAP polymerization.
[0317] Conditions were determined for polymerization to level out the MW and provide a MW in the target range of 50,000-80,000 Da over a wide time window for MAP as described in Example 7. DIPEA was slightly increased in the scaled-up reaction (2.6 vs. 2.5 equiv.) compared to the kinetics observed in the small-scale experiments and provided similar kinetics.
[0318] To address aspects of scale-up of MAP production, step (ii) may include a step of precipitating MAP from DMSO using IPA under an inert atmosphere such as argon or nitrogen. As described in Example 7, the use of this procedure to isolate MAP affords a product having low levels of impurities as a dry or substantially dry solid that is readily recoverable.
[0319] Other exemplary methods for generating MAP include the methods provided in U.S. Patent Publication No. US2021 / 0170049A1, which is hereby incorporated by reference.
[0320] In an exemplary method for producing a DAN-222 formulation, in step (iii), the synthesis of a MAP-Gly-CPT amorphous polymer-drug conjugate comprises the use of EDC / NHS coupling chemistry. However, as described in Example 7 herein, in order to reduce the excess of starting materials and reagents in the reaction, especially the excess of Gly-CPT, it is preferred to use a more active (7-azabenzotriazol-1-yloxy)tripyrrolidinephosphonium hexafluorophosphate (PyAOP) coupling reagent to prepare MAP-Gly-CPT.
[0321] In order to minimize the process risk of forming high molecular weight substances (HMWS), high drug loading levels are used to minimize the number of unreacted carboxylic acid groups on the MAM. In addition, reacting under increased dilution significantly reduces the possibility of polymer chain end groups participating in the reaction. As described in Example 7, development reactions were performed with 1.0, 1.1 and 1.2 equivalents of Gly-CPT at 2.5 and 4 g scales at increased dilution. Under improved reaction conditions, all reactions proceeded well and there was no evidence of HMWS formation.
[0322] In an exemplary method for producing a DAN-222 formulation, in step (iv), the preparation of MAP-Gly-CPT NPs requires dissolving the amorphous polymer drug conjugate in an aqueous medium, whereby the hydrophobicity of CPT promotes the self-assembly of the conjugate into NPs. The process initially developed involves dissolving the MAP-Gly-CPT amorphous material in water at pH 4.0, adding concentrated saline (9% NaCl, pH 4.0), concentrating using a centrifugal ultrafiltration device, and sterile filtering at 0.22 microns.
[0323] During the development of step (iv), several modifications were made to the process to make it more robust, scalable, safe, and / or reduce impurity levels, including: (i) concentrated formulation buffer exchange; (ii) use of centrifugal ultrafiltration versus TFF concentration; and (iii) adjustment of the filtration step.
[0324] Although MAP-Gly-CPT Np exhibits good stability in unbuffered saline solution (0.9% NaCl, pH 4.0), nanoparticles are sensitive to pH; and a robust drug formulation requires a buffer system to prevent pH drift and degradation. Therefore, in a preferred aspect, the addition of a concentrated formulation buffer (e.g., 200 mM sodium acetate, 2 M NaCl, pH 4.16) is used instead of adding concentrated saline. An exemplary resulting formulation using this buffer comprises 20 mM sodium acetate, 200 mM NaCl, pH 4.3 ± 0.3. As described in Example 7, when this buffer was used to produce a DAN-222 formulation, no effect on particle properties (e.g., size, zeta potential, filterability) was observed, and the product showed sufficient stability.
[0325] In some aspects, step (iv) comprises a concentration step. The concentration process may comprise centrifugal ultrafiltration. In preferred aspects, the concentration process comprises TFF ultrafiltration. Compared with TFF ultrafiltration, the scaled-up version of centrifugal ultrafiltration requires longer processing time and is generally not able to be carried out on a large scale.
[0326] In certain aspects, step (iv) comprises a single final filtration step. In preferred aspects, step (iv) comprises an intermediate conditioning filtration step, which can allow for a seamless and risk-free final sterile filtration. During the development and production of the DAN-222 formulation of the present invention, it was observed that the final sterile filtration process is often difficult and often requires multiple sterile filters to complete the filtration.
[0327] To reduce this process risk, the MAP-Gly-CPT amorphous material can be dissolved in water at pH 4.0 and filtered to condition the material and remove some product-related particles. After the subsequent addition of concentrated formulation buffer and a TFF step to formulate and concentrate the FBDS, a final 0.22 micron sterile filtration can be performed without the risk of extended filtration time.
[0328] Methods of treatment, formulations, kits and routes of administration
[0329] Also provided are therapeutic compositions and formulations comprising DAN-222 disclosed herein. Such formulations generally include nanoparticles and a pharmaceutically acceptable carrier. Supplementary active compounds may also be incorporated into such formulations.
[0330] In some aspects, the invention comprises preparations that can be used to treat cancer, cancer metastasis and / or disorders of the brain and central nervous system. In some aspects, the cancer is selected from breast cancer, lung cancer, colon cancer, ovarian cancer, melanoma, bladder cancer, kidney cancer, liver cancer, salivary gland cancer, gastric cancer, glioma, thyroid cancer, thymic cancer, epithelial cancer, head and neck cancer, gastric cancer and pancreatic cancer.
[0331] In preferred aspects, cancer is breast cancer or ovarian cancer. In some aspects, cancer is HER2 negative metastatic breast cancer (mBC). In some aspects, HER2 negative mBC is homologous recombination defect (HRD) positive or negative HER2 negative mBC.
[0332] The inability to accurately repair complex DNA damage and resolve DNA replication stress leads to genomic instability and contributes to cancer etiology. For example, defects in homologous recombination (HR) repair have been observed in various cancers. It has long been known that the breast cancer gene type 1 (BRCA1) and breast cancer gene type 2 (BRCA2) encode proteins that play key roles in HR repair, and mutations in one or both of these genes put patients at greater risk for breast, ovarian, prostate, melanoma, and pancreatic cancer.
[0333] At the same time, this loss of repair ability also makes cancer cells more vulnerable to therapeutic agents that damage DNA. For example, tumor cells with defective HR repair have increased sensitivity to chemotherapeutic agents, suggesting that if HR repair can be therapeutically inactivated, HR-proficient tumor cells may be sensitive to chemotherapeutic drugs. Topoisomerase inhibitors such as CPT damage DNA by binding to topoisomerase I, thereby preventing DNA unwinding required for replication, leading to replication fork stalling. This prevents cancer cells from replicating and proliferating in the subject.
[0334] Camptothecin (CPT), the active ingredient in DAN-222, is a naturally occurring pentacyclic quinolone alkaloid isolated from the bark of Camptotheca acuminata. CPT is a topoisomerase I inhibitor that acts by forming a ternary complex with topoisomerase I and DNA during replication and transcription in tumor cells, thereby blocking DNA religation, resulting in torsional tension downstream of RNA polymerase to induce DNA strand breaks.
[0335] Treatment of many brain disorders (such as brain cancer and metastasis to the brain) requires delivery of therapeutic molecules to the brain. Direct delivery of therapeutic drugs to the brain poses serious risks to the subject (e.g., damage to the skull) and cannot be carried out continuously as required by most chemotherapy. However, due to the presence of the blood-brain barrier (BBB) (the tightly bound endothelial cell layer lining the cerebral blood vessels), systemic delivery (e.g., through the blood) will not be able to efficiently deliver molecules to the brain. A similar permeability barrier exists in some solid tumors, called the blood-tumor barrier (BTB).
[0336] Breast cancer often metastasizes to the brain, and these brain metastases could be treated with chemotherapeutic molecules used to treat breast cancer if the therapeutic agent could be delivered to the brain (via the BBB) or tumor (via the BTB) in sufficient concentrations. One such chemotherapeutic drug is CPT.
[0337] Unfortunately, although CPT is well known for its antitumor activity (including on a wide range of human cancers), it has poor water solubility, low plasma stability, and dose-limiting toxicity. In addition, as mentioned above, the BBB and / or BTB may inhibit the ability of cells to take up CPT.
[0338] However, as discovered by the present inventors, DAN-222 is more effective than other topoisomerase I inhibitors (including free CPT) because it accumulates in tumors through the enhanced permeability and retention (EPR) effect, resulting in greater and longer inhibition of topoisomerase I. The EPR effect relies on the different vasculature of healthy tissues compared to tumors. The DAN-222 nanoparticles encapsulate CPT and are able to pass through the leaky walls of tumor neovasculature, but not through the tighter walls of healthy blood vessels. In addition, encapsulation in the DAN-222 nanoparticles provides protection for CPT, preventing CPT from converting from the active lactone form to the inactive carboxyl form in serum, thereby preventing rapid blood clearance and toxicity to non-malignant tissues.
[0339] In certain aspects, exemplary methods of the invention for treating cancer in a subject comprise providing to a subject having cancer at least one dose of a composition comprising a compound of formula (I):
[0340]
[0341] wherein n is a number in the range of 20 to 200; and
[0342] Wherein m is a number in the range of 5 to 200.
[0343] In an exemplary method, n is a number in the range of about 75 to 85; m is a number in the range of about 12 to 20; and the pH of the composition is between pH 4 and pH 4.6.
[0344] In a preferred method, the composition comprises 2 mg / mL to 3 mg / mL of camptothecin (CPT). In a preferred method, the dosage of the composition comprises 2 mg / mL 2 Up to 16 mg / m 2 For example, the dosage of the composition may contain about 2 mg / m 2 , about 4mg / m 2 , about 6mg / m 2 , about 8mg / m 2 , about 10mg / m 2 , about 12mg / m 2 , about 14mg / m 2 or about 20 mg / m 2In some aspects, the composition comprises about 2.6 mg / m 2 A compound of formula (I).
[0345] The DAN-222 formulations and compositions described herein can be administered to a subject by any suitable route, including but not limited to inhalation, topical, nasal, oral, parenteral (e.g., intravenous, intraperitoneal, intravesical or intrathecal), or rectal; in a vehicle comprising one or more pharmaceutically acceptable carriers, the proportions of which are determined by the solubility and chemical properties of the compound, the chosen route of administration, and standard practice. Administration of DAN-222 as described herein can be performed using any method known in the art. For example, administration can be transdermal, parenteral, intravenous, intraarterial, subcutaneous, intramuscular, intracranial, intraorbital, ocular, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intracerebroventricular, intrathecal, intranasal, aerosol, by suppository, or oral. The pharmaceutical compositions of DAN-222 described herein can be used for administration by injection, or for oral, pulmonary, nasal, transdermal, or ocular administration.
[0346] In a preferred aspect, the composition comprising a compound of Formula (I) is provided to the subject as a sterile solution for infusion.
[0347] Exemplary formulations may include, but are not limited to, formulations suitable for parenteral administration, such as intrapulmonary, intravenous, intraarterial, intraocular, intracranial, submeningeal or subcutaneous administration, formulations encapsulated in micelles, liposomes or drug release capsules (active agents incorporated into biocompatible coatings designed for sustained release); ingestible formulations; formulations for topical use, such as eye drops, creams, ointments and gels; and other formulations, such as inhalants, aerosols and sprays. The dosage of the compositions of the present disclosure will vary depending on the degree and severity of the treatment needs, the activity of the composition administered, the general health of the subject, and other considerations well known to those skilled in the art.
[0348] In further embodiments, the DAN-222 compositions described herein are delivered at or near the site of injury or metastasis. Such local delivery allows for the delivery of non-systemic compositions, thereby reducing the physical burden of the composition compared to systemic delivery. For example, local delivery can be achieved by injection or use of various medical implant devices including but not limited to stents and catheters, or can be achieved by inhalation, phlebotomy, or surgery. Methods for coating, implanting, embedding, and otherwise attaching desired agents to medical devices such as stents and catheters are established in the art and are contemplated herein.
[0349] The composition can be provided under any suitable dosage regimen. For example, the composition can be provided in a single dose or multiple doses. The provision of multiple doses can be separated by intervals, such as 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks or longer. Multiple doses can be provided over a period of time. For example, multiple doses can be provided in 1 day, 2 days, 3 days, 4 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks or longer time periods. These compositions can be repeatedly provided within a specified duration. For example, but not limited to, these compositions can provide and continue 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, 3 months, 4 months, 5 months, 6 months, 8 months, 10 months, 12 months or longer.
[0350] In a preferred aspect, the composition comprising a compound of formula (I) is provided to the subject as a sterile solution for infusion at a dose once a week. In a preferred aspect, the composition comprising a compound of formula (I) is provided to the subject as a sterile solution for infusion at a dose once a week within a four-week treatment cycle.
[0351] Exemplary methods of the invention comprise providing one or more doses of a composition comprising a compound of Formula (I) concurrently with providing at least one dose of a poly (ADP-ribose) polymerase (PARP) inhibitor.
[0352] Exemplary PARP inhibitors used in the methods of the present invention include, for example, olaparib, rucaparib, niraparib, and talazoparib. Preferably, the PARP inhibitor is niraparib.
[0353] In preferred aspects, a dose of niraparib is provided to the subject every day during the treatment cycle. In certain aspects, multiple doses of niraparib may be provided at intervals of 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks or longer. Multiple doses may be provided over a period of time. For example, multiple doses may be provided over 1 day, 2 days, 3 days, 4 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks or longer time periods. Niraparib may be provided repeatedly over a specified duration. For example, but not limited to, niraparib may be provided for 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, 3 months, 4 months, 5 months, 6 months, 8 months, 10 months, 12 months or longer.
[0354] In a preferred aspect, the method of the present invention comprises providing each dose of niraparib at a dose between 25 mg and 200 mg. In a preferred aspect, the dose is a dose between about 50 mg and 100 mg. In a preferred aspect, the dose is a 100 mg dose.
[0355] In certain methods, the subject is provided with a weekly dose of a composition comprising a compound of Formula (I) and a daily dose of niraparib during a treatment cycle.
[0356] In some methods, the cancer is one or more of breast cancer, ovarian cancer, brain cancer, lung cancer, testicular cancer, head cancer, neck cancer, esophageal cancer, lymphoma cancer, central nervous system cancer, peripheral nervous system cancer, bladder cancer, stomach cancer, pancreatic cancer, liver cancer, oral mucosal cancer, colorectal cancer, anal cancer, kidney cancer, bladder cancer, urothelial cancer, prostate cancer, endometrial cancer, fallopian tube cancer, mesothelioma, melanoma, myeloma, leukemia and Kaposi's sarcoma.
[0357] In preferred aspects, the cancer is breast cancer.In certain aspects, the breast cancer is homologous recombination repair deficiency (HRD) positive or HRD negative breast cancer.
[0358] The therapeutic compositions disclosed herein are particularly useful for treating cancer, cancer metastasis, and disorders of the brain and central nervous system. Thus, a "therapeutically effective amount" of a composition comprising DAN-222 is any amount that reduces symptoms or, for example, stimulates tumor regression. For example, the dose of DAN-222 can vary from about 0.1-1.0 mg / kg body weight or from about 0.5 to 2.0 mg / kg body weight or from about 1-5 mg / kg body weight or from about 1 mg / kg body weight to about 10 mg / kg body weight or more (or any integer value therebetween).
[0359] The subject may be provided with a dosage at a frequency of, for example, hourly, twice daily, once daily, twice weekly, once weekly, twice monthly, once monthly, depending on, for example, body weight, route of administration, severity of disease, etc. Thus, a therapeutically effective amount may include multiple administrations of the same or different amounts of DAN-222. In certain embodiments, a single administration of DAN-222 is a therapeutically effective amount.
[0360] In certain embodiments, the DAN-222 formulation is administered at a dose of 1-20 mg DAN-222 per square meter of subject body surface area (or any integer or decimal value therebetween), which is typical of chemotherapeutic drug dosing.
[0361] Based on the present disclosure, various pharmaceutical compositions and techniques for their preparation and use are known to those skilled in the art. For a detailed list of suitable pharmacological compositions and their administration techniques, reference may be made to texts such as Remington's Pharmaceutical Sciences, 17th edition, 1985; Brunton et al., "Goodman and Gilman's The Pharmacological Basis of Therapeutics", McGraw-Hill, 2005; University of the Sciences in Philadelphia (ed.), "Remington: The Science and Practice of Pharmacy", Lippincott Williams & Wilkins, 2005; and University of the Sciences in Philadelphia (ed.), "Remington: The Principles of Pharmacy Practice", Lippincott Williams & Wilkins, 2008.
[0362] The DAN-222 nanoparticles and DAN-222 nanoparticle formulations described herein can be suspended in a physiologically compatible carrier for administration. As used herein, the term "physiologically compatible carrier" refers to a carrier that is compatible with DAN-222 and any other components of the formulation and is harmless to its receptor. Those skilled in the art are familiar with physiologically compatible carriers. Examples of suitable carriers include water (e.g., water at pH 4), phosphate buffered saline, Hank's balanced salt solution + / - glucose (HBSS), and various electrolyte solutions, such as Plasma-Lyte TM A (Baxter).
[0363] The volume of the DAN-222 suspension administered to the subject will vary depending on the site of administration, the therapeutic target, and the number concentration of DAN-222 in the solution. Typically, the amount of nanoparticles administered will be a therapeutically effective amount. As used herein, a "therapeutically effective amount" or "effective amount" refers to the amount of DAN-222 and / or another drug (such as a PARP inhibitor) required to treat a particular condition; that is, the amount and / or reduction in severity of symptoms associated with the disease. For example, in the case of cancer metastasis, administration of a therapeutically effective amount of a DAN-222 formulation described herein results in a reduction and / or reversal of metastatic symptoms; for example, regression of metastatic tumors. The therapeutically effective amount varies depending on the type and extent of damage caused by the cancer, and may also vary depending on the overall condition of the subject.
[0364] The disclosed therapeutic compositions and formulations may also contain pharmaceutically acceptable materials, compositions or vehicles, such as liquid or solid fillers, diluents, excipients, solvents or encapsulating materials, i.e., carriers. For example, these carriers can stabilize the DAN-222 nanoparticles and / or promote the retention of the DAN-222 nanoparticles in vivo. Each carrier is "acceptable" in the sense that it is compatible with the other ingredients of the formulation and is not harmful to the subject. Some examples of materials that can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol and polyethylene glycol; polyols, such as glycerol, sorbitol, and mannitol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffered saline; and other nontoxic, compatible substances employed in pharmaceutical formulations. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
[0365] Another aspect of the present disclosure relates to a kit for performing administration of a DAN-222 formulation described herein, optionally in combination with another therapeutic agent (e.g., a PARP inhibitor such as niraparib), to a subject. In one embodiment, the kit includes a DAN-222 composition formulated in a pharmaceutical carrier suitable for administration, for example, by injection or infusion.
[0366] The composition can be formulated into a single daily dose. The composition can be formulated into multiple daily doses, such as two, three, four, five, six or more daily doses.
[0367] The composition can be provided to the subject according to any dosing regimen. The composition can be provided once a day. The composition can be provided multiple times a day.
[0368] The method of treating a subject comprises providing a composition of the invention as described above to the subject. Providing may comprise administering the composition to the subject. The composition may be administered by any suitable route or means, such as orally, intravenously, enterally, parenterally, dermally, buccally, topically (including transdermally), by injection, by infusion, intranasally, pulmonary, and with or on an implantable medical device (e.g., a stent or drug eluting stent or balloon equivalent).
[0369] The composition may be provided as a single unit dose.The composition may be provided in divided doses.
[0370] The composition can be provided under any suitable dosing regimen. For example, the composition can be provided in a single dose or multiple doses. Multiple doses can be provided at intervals, such as 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks or longer. Multiple doses can be provided over a period of time. For example, multiple doses can be provided in 1 day, 2 days, 3 days, 4 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks or longer time periods. These compositions can be repeatedly provided within a specified duration. For example, but not limited to, the composition can provide 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, 3 months, 4 months, 5 months, 6 months, 8 months, 10 months, 12 months or longer.
[0371] Examples
[0372] Aspects of the invention are demonstrated in the examples provided below.
[0373] Example 1 - In vivo antitumor activity of DAN-222
[0374] The antitumor activity of DAN-222 was evaluated in several tumor xenograft studies and included HRD-positive and HRD-negative cell lines from breast (BT-474, MDA-MB-231, MBA-MB-436) and ovarian (OVCAR3) tumors.
[0375] Camptothecin (the active ingredient in DAN-222) is a topoisomerase I inhibitor that works by forming a ternary complex with topoisomerase I and DNA during replication and transcription in tumor cells, thereby blocking religation of DNA, resulting in torsional tension downstream of the replication fork or RNA polymerase transcription complex to induce DNA strand breaks. Results from tumor xenograft studies suggest that DAN-222 may be more effective than other topoisomerase I inhibitors as a cancer treatment because its tumor accumulation, achieved through the enhanced permeability and retention (EPR) effect, results in greater and longer-lasting topoisomerase I inhibition.
[0376] As described below, the antitumor activity of DAN-222 was evaluated in several tumor xenograft studies and included HRD-positive and HRD-negative cell lines from breast (BT-474, MDA-MB-231, MBA-MB-436) and ovarian (OVCAR3) tumors. DAN-222 provided significantly higher efficacy with sustained tumor suppression compared to free CPT and the CPT derivative irinotecan alone.
[0377] Further, the effect of DAN-222 treatment in combination with orally administered niraparib tosylate (niraparib) was evaluated in HRD-positive MDA MB-436 and HRD-negative OVCAR3 xenograft models, respectively. The combination of DAN-222 and the PARP inhibitor showed significantly enhanced tumor inhibition compared to either agent alone.
[0378] Efficacy data from these studies demonstrated enhanced anti-tumor responses compared to vehicle control or either agent alone, providing evidence of the complementary effectiveness of DAN 222 as an anti-tumor agent in vivo, as well as information on effective doses and dosing schedules.
[0379] Study ER2019-09-1B: HRD-positive (ER-positive, PR-positive, HER2-positive) breast ductal carcinoma (BT-474 model type)
[0380] In Study ER2019-09-1B, DAN-222 was evaluated as a single agent in the BT-474 murine xenograft model of human breast cancer.
[0381] Figure 2 Calculated median tumor volume (MTV) over time by treatment group is presented. Figure 3 Provides the time to reach the end point (TTE, 2,000mm 3 ) data, which shows the percentage of animals in each group remaining on study over time. Figure 2 and 3As described, animals in the studies were administered DAN-222, unconjugated (free) CPT, or the CPT derivative irinotecan.
[0382] Figure 2 and 3 The results of the study presented in demonstrated that IV dosing of DAN-222 (3 mg / kg) once weekly for three weeks produced sustained tumor growth inhibition throughout the treatment and post-treatment time periods in BT-474 model animals treated with DAN-222, compared to vehicle control, unconjugated CPT, or irinotecan.
[0383] Study ER2020-07-1: HRD-positive (ER-negative, PR-negative, HER2-negative [triple-negative]) breast adenocarcinoma (MDA- MB-436 model)
[0384] In study ER2020-07-1, the antitumor activity of a series of doses of DAN-222 (0.3-3 mg / kg) given weekly for four weeks as a single agent and in combination with low-dose niraparib (25 mg / kg / day) was studied in the HRD-positive (MDA-MB-436) xenograft model. The antitumor activity of a series of doses of DAN-222 (0.3-3 mg / kg) given weekly for four weeks in combination with higher doses of niraparib (50 / 40 mg / kg / day) was also studied in the HRD-positive (MD-MB-436) xenograft model.
[0385] Figure 4 and 5 Median tumor volume measurements over time for Study ER2020-07-1 presented by treatment group are provided.
[0386] like Figure 4 As shown, DAN-222 showed significant single-agent activity in the MDA-MB-436 study, with weekly treatment of up to 3 mg / kg of DAN-222 for 4 weeks, resulting in inhibition of tumor growth or tumor regression. Specifically, DAN-222 (0.3, 1 and 3 mg / kg) induced 11 partial regressions (0.3 mg / kg, n=1; 1 mg / kg, n=6; 3 mg / kg, n=4) and four complete regressions (3 mg / kg, n=4), with three tumor-free survivors observed at the 3 mg / kg dose level.
[0387] like Figure 4 and 5 As shown, the combination of DAN-222 with low-dose (25 mg / kg) or high-dose (50 / 40 mg / kg) niraparib produced a more potent anti-tumor response than either agent alone. DAN-222 was still dose-responsive for complete regression when combined with high-dose or low-dose niraparib.
[0388] Study ER2020-07-01 also revealed that the combination of DAN-222 (3 mg / kg) and high-dose niraparib (50 / 40 mg / kg) was considered intolerable based on limited safety endpoints (ie, mortality and body weight). Efficacy was not measured.
[0389] Study ER2020-07-2: HRD-negative (ER-positive, PR-positive) ovarian adenocarcinoma cell line (OVCAR3 model)
[0390] In study ER2020-07-2, the effect of DAN-222 treatment in combination with orally administered niraparib tosylate (niraparib) was evaluated in the HRD-negative OVCAR3 xenograft model.
[0391] A combination treatment regimen consisting of weekly injections of up to 3 mg / kg of DAN-222 and daily administration of high-dose niraparib (50 mg / kg) was evaluated and Figure 6 Results were presented for low-dose niraparib. Figure 6 As shown, the OVCAR3 study showed that the efficacy of the combination of DAN-222 and niraparib was independent of HRD status. Further, DAN-222 administered as a single agent at 3 mg / kg had a significant effect in all seven animals, with complete responses, all of which were tumor-free survivors. In addition, the combination treatment of 1 mg / kg DAN 222 with high-dose (50 mg / kg) niraparib produced one partial response and six complete responses, including four tumor-free survivors.
[0392] Example 2 – Safety Pharmacology Study
[0393] In studies as part of the toxicology program, camptothecin exposure and toxicokinetic (TK) parameters were evaluated in rats and dogs after single or repeated doses of DAN-222. Rats and dogs were selected as pharmacologically relevant rodent and non-rodent species for evaluating the toxicology of DAN-222 and selecting a safe starting dose for preliminary human studies. Since DAN 222 is a conjugated product, the toxicokinetic (TK) assessment includes the evaluation of total (conjugated and unconjugated) and free (unconjugated) CPT.
[0394] To evaluate the nonclinical safety profile of DAN-222 to support a clinical IV dosing regimen of one dose per week and to determine a safe clinical starting dose for Phase I trials, the studies in the toxicology program consisted of dose-range finding and repeated-dose rat and beagle dog toxicity studies. With the exception of the dose-range finding studies in rats and beagle dogs, all studies were conducted in accordance with the U.S. Food and Drug Administration's Good Laboratory Practice (GLP) regulations for nonclinical laboratory studies (21 CFR, §58).
[0395] The effects of DAN-222 on vital organ function (e.g., cardiovascular, respiratory, and central nervous system) were evaluated as end-point repeated-dose general toxicology studies in rats and dogs.
[0396] Rat studies
[0397] In study NC2020-08-1, acute single-dose IV administration established a maximum tolerated dose (MTD) of 9 mg / kg treatment, and doses above the MTD (18 mg / kg) resulted in death. In each case, a decrease in hematopoietic cell counts in the bone marrow was considered the cause of death or asthenia. At doses up to the MTD, dose-dependent effects on body weight were noted at 3 mg / kg and above, and effects on food consumption associated with mean body weight loss were observed at doses of at least 9 mg / kg.
[0398] In study NC2020-08-3, a GLP 4-week IV repeat-dose toxicology study conducted in Sprague Dawley rats treated with 1 to 9.6 mg / kg DAN-222, there were no test article-related effects on activity, autonomic, excitability, neuromuscular, physiological, or sensorimotor observations in male animals tested in a functional observational test battery on days 1, 8, and 22. At 9.6 mg / kg, adverse treatment-related results were observed in both males and females, including weight loss corresponding to reduced food consumption, and bone marrow cytological changes associated with microscopic findings of bone marrow cell reduction. Hematological results associated with DAN-222 treatment included decreased red blood cell mass and decreased white blood cell counts at doses of 3.2 mg / kg and above. A decrease in lymphocyte count was also observed at 9.6 mg / kg. In males, testicular degeneration was observed at doses of at least 3.2 mg / kg and was associated with lower mean testicular and epididymal weights.
[0399] Based on the findings, the NOAEL was considered to be 3.2 mg / kg CPT for females and 1.1 mg / kg for males.
[0400] Based on the nature and reversibility of the findings and the lack of mortality associated with DAN-222, it is not possible to determine a severe toxicity dose (STD) for 10% of animals. 10 ). Therefore, STD 10 Assumed to be >9.6 mg / kg.
[0401] Dog Research
[0402] In study NC2020-08-2, acute single-dose IV administration determined the MTD for dogs to be 1.5 mg / kg. Treatment with DAN-222 at a dose higher than the MTD (2.6 mg / kg) resulted in early euthanasia of animals due to decreased physical condition caused by gastrointestinal degeneration and atrophy. Clinical observations recorded before early euthanasia included decreased activity, suspected dehydration, hunched posture, and cold to the touch, and both animals experienced weight loss during the first few days after dosing. In animals treated with up to the MTD, clinical observations related to gastrointestinal stress were recorded, which was associated with reduced food consumption and weight loss; however, the increase in these endpoints during the study indicated a trend toward recovery.
[0403] In Study NC2020-08-4, a GLP 4-week repeat-dose IV toxicology study conducted in beagle dogs treated with 0.32 to 0.96 mg / kg DAN-222, all electrocardiogram (ECG) assessments were qualitatively and quantitatively normal at all dose levels tested. No abnormalities in rhythm or waveform morphology were observed based on comparisons of pre- and post-treatment ECG recordings. No treatment-related effects on heart rate, QRS duration, QT, or QTc intervals were observed based on comparisons of Days 1 and 22 (pre- and 2 hours post-dose) and at the end of the recovery period.
[0404] Adverse findings associated with treatment included decreased mean body weight, decreased body weight gain, decreased food consumption, and clinical observations of decreased activity and hunched posture seen in the high dose (0.96 mg / kg) male group.
[0405] In the high dose (0.96 mg / kg) male and female groups, a decrease in thymic cortical cell number associated with a decrease in thymic weight was noted.
[0406] In the 0.64 mg / kg female group and the 0.96 mg / kg male group, a dose-dependent decrease was observed in all leukocyte parameters, red cell mass parameters, platelets and reticulocytes, which was associated with a decrease in bone marrow cellularity and microscopic findings of an increase in the myeloid: erythroid (M:E) ratio and lymphocyte percentage in the bone marrow. At 0.96 mg / kg, perivascular mixed cellular infiltration was detected in the liver of both males and females at the end of recovery and was considered unfavorable.
[0407] The NOAEL was considered to be 0.32 mg / kg for females and 0.64 mg / kg for males. Due to the generally observed recovery of bone marrow cellularity and associated effects on hematology and bone marrow cytology, the HNSTD was considered to be 0.64 mg / kg in both sexes, which is equivalent to 12.8 mg / m 2 .
[0408] Genetic Toxicology
[0409] A single GLP in vitro genotoxicity study was conducted to evaluate the potential mutagenic activity of DAN-222 in a bacterial reverse mutation assay (Study T2020-08). No evidence of mutagenicity was observed at any dose level tested in this study (1.0, 5.0, 10, 50, 100, 500, 1000, or 5000 μg / plate).
[0410] Local tolerance
[0411] As part of toxicology studies in rats and dogs, the tolerability of IV administration of formulations intended for use in clinical studies was evaluated.
[0412] Nonclinical safety summary of DAN-222
[0413] The above studies are part of a comprehensive pharmacology and toxicology program designed to evaluate the potential effectiveness and toxicity of DAN-222 in relevant models when administered using clinical routes of administration and dosing regimens that mimic the expected clinical scenarios. These completed studies provide information that characterizes the toxicological properties of DAN-222 in a manner sufficient to understand the severity and reversibility of toxicities associated with its use and to provide information for the selection of a safe clinical starting dose. In addition, these toxicology studies provide information that allows monitoring of potential safety signals in a clinical setting.
[0414] In acute dose-range-finding toxicology studies, a maximum tolerated dose (MTD) was defined (9 mg / kg DAN-222 in rats; 1.5 mg / kg DAN-222 in dogs), and doses above the MTD resulted in death due to myelotoxicity and decreased hematopoietic cell counts in rats or early euthanasia due to gastrointestinal degeneration and atrophy in dogs.
[0415] In a Good Laboratory Practice (GLP) repeated dose toxicology study, animals were treated once weekly for 4 weeks, thereby simulating one dosing cycle of DAN-222 to support weekly administration in clinical studies. In rats, adverse reactions observed in males under treatment were decreased food consumption and body weight, bone marrow toxicity, and testicular degeneration, resulting in a no observed adverse effect level (NOAEL) of 3.2 mg / kg in females and 1.1 mg / kg in males (equivalent to 19.2 and 6.6 mg / m, respectively). 2In dogs, adverse effects observed under treatment were weight loss and decreased food consumption, hematological changes, and bone marrow toxicity, resulting in a NOAEL of 0.32 mg / kg in females and 0.64 mg / kg in males (6.4 and 12.8 mg / m 2 ), and the highest non-serious toxic dose (HNSTD) for both sexes was 0.64 mg / kg (12.8 mg / m 2 ).
[0416] The proposed first-in-human (FIH) dose of DAN-222, determined by the maximum recommended starting dose (MRSD), is based on the HNSTD determined in dogs, which is considered the most relevant animal species for testing. In a 4-week toxicology study in dogs, the HNSTD was 0.64 mg / kg. The 0.64 mg / kg dose in dogs is equivalent to 12.8 mg / m 2 Therefore, based on the 6-fold safety factor applied to the HNSTD, the MRSD is approximately 2 mg / m 2 .
[0417] Example 3 - PK parameters of DAN-222
[0418] Exposure and other PK parameters of CPT have been evaluated in animal species used for toxicology studies (i.e., rats and dogs). The distribution of CPT in naive mouse and murine tumor models following administration of DAN-222 was also evaluated. Since DAN 222 is a conjugated product, the PK evaluation includes the evaluation of total (conjugated and unconjugated) and free (unconjugated) CPT. In addition, the stability of DAN-222 was tested in human, dog, and rat plasma using in vitro methods.
[0419] After weekly IV injections of DAN-222 in rats, free and total CPT exposure (area under the plasma concentration-time curve [AUC] from time zero to the last observation time) was observed on days 1 and 22. tlast ]) As dose levels increased from 1.1 mg / kg to 9.6 mg / kg DAN-222. Free CPT exposure was low (approximately 0.1% to 0.2% of total CPT exposure). The terminal half-life of total CPT was approximately 15 to 21 hours. The clearance and distribution volume ranged from 14.9 to 24.2 mL / hour / kg and 404 to 647 mL, respectively. The data suggest that clearance is low relative to hepatic blood flow (0.4%) and that the distribution volume suggests minimal distribution in tissues.
[0420] In a similar manner, the PK of DAN-222 was characterized in beagle dogs following repeated weekly dosing of DAN-222 at dose levels of 0.32, 0.64, and 0.96 mg / kg. Total and free CPT exposure (measured as AUC tlast The total CPT exposure increased in a dose-proportional manner with increasing dose levels (expressed as ). The clearance and volume of distribution ranged from 16.4 to 18.7 mL / hour / kg and 563 to 649 mL / kg on Day 1 and Day 22, respectively. The terminal half-life of total CPT was approximately 23.2 to 26 hours. Total CPT exposure increased in a dose-proportional manner. There was no accumulation of total or free CPT.
[0421] The calculated mean concentrations of free and total CPT in plasma were similar in male and female rats. Figure 7 A and 7B provide representative graphs of mean concentrations of free and total plasma CPT in male rats following IV administration of DAN-222 on days 1 and 22.
[0422] The stability of DAN-222 in rat, dog, and human plasma was assessed using an in vitro approach based on the half-life of conjugated CPT in each matrix. Figure 8 Results from these studies are presented, showing the stability of DAN-222 in rat, dog, and human plasma as a percentage of conjugated CPT over time.
[0423] like Figure 8 As shown, the half-lives of DAN-222 in rat and dog plasma were 35.3 and 45.5 hours, respectively. Compared with the calculated stability of DAN-222 in human plasma of 35.7 hours, these results indicate that DAN-222 is sufficiently stable in rat and dog plasma and that the performance of the compound in animals is expected to be similar to that in humans, supporting the relevance of the selected species as models in toxicology studies.
[0424] In single-dose studies conducted in rats or dogs, systemic exposure of free and total CPT in both males and females increased with increasing dose level, and exposure to free CPT accounted for only a small fraction (i.e., <1%) of total CPT exposure. In pivotal toxicology studies conducted in rats and dogs, animals received four weekly IV injections of DAN-222 (1.1 to 9.6 mg / kg in rats and 0.32 to 0.96 mg / kg in dogs) after the first and fourth doses, and TK assessments were performed. On the evaluation days, the terminal half-lives of total CPT and free CPT ranged from 15 to 21 hours and 14 to 26 hours in rats, respectively, and from 23 to 26 hours and 24 to 42 hours in dogs, respectively. In general, increases in systemic exposure to total and free CPT occurred in an approximately dose-proportional manner with increasing dose level. Similarly, systemic exposure to free CPT accounted for only a small fraction of total CPT exposure; in terms of AUC tlast For rats or dogs, free CPT exposure was approximately 0.1% to 0.2%, or <0.1%, of total CPT exposure, respectively. Additionally, exposures were similar between males and females in both species, and no significant accumulation of total or free CPT was observed following repeated dosing with DAN-222 in any of the dosing groups evaluated.
[0425] The biodistribution of CPT in organs of interest was evaluated following a single dose of DAN-222 in female mice, including one study in naive CD-1 mice and two studies in immunodeficient mice bearing human breast cancer xenografts. Figures 9A-9B The results of these studies are presented and show the biodistribution of free and total CPT in the liver, spleen, kidney, heart, and bone marrow of tumor-bearing mice over a period of 2 to 48 hours ( Fig. 9A ), and total CPT levels in plasma, skeletal muscle, and tumor tissue of tumor-bearing mice ( Fig. 9B ).
[0426] Fig.10 A table summarizing the mouse biodistribution studies and their results is provided.
[0427] These biodistribution studies in naive and tumor-bearing mice showed limited exposure to free CPT in healthy tissues (e.g., liver, heart, spleen, and kidneys); and only low levels of total CPT (contained in NPs but not released as free CPT) were quantifiable in the bone marrow. In both naive and tumor-bearing mice, the biodistribution of CPT after DAN-222 administration showed reduced exposure in the bone marrow compared to irinotecan. In tumor-bearing mice, increased accumulation of CPT in tumors was observed 2 to 48 hours after a single dose of DAN-222, while levels in plasma, liver, spleen, heart, and skeletal muscle of the contralateral flank decreased over the same time period.
[0428] Overall, free and total CPT were detected in most organs tested (e.g., liver, heart, spleen, and kidney); however, DAN-222 administration significantly reduced biodistribution in the bone marrow compared with irinotecan. The free CPT level per gram of tissue in the tested organs was less than 1% of the injected dose. In tumor-bearing mice, accumulation of CPT was observed in tumor tissues but not in normal tissues, indicating an EPR effect.
[0429] Overall, data from studies characterizing the PK parameters and CPT profile following administration of DAN-222 support the proposed clinical dosing regimen.
[0430] Example 4 - Development of a Preferred Formulation
[0431] As part of the preliminary formulation development screening, three iterative experimental steps were performed to determine the preferred clinical formulation of DAN-222. The screening was designed to determine the initial indications of material stability and key quality attributes associated with DAN-222. In the three formulation development steps described below, many key quality attributes (CQA) were evaluated to determine the preferred formulation of DAN-222. After each step, the formulation with the highest performance was selected for evaluation in subsequent steps. In this way, the preferred formulation of DAN-222 was determined.
[0432] The study was divided into three steps performed under accelerated stability conditions: (1) univariate buffer and pH selection; (2) addition of key excipients to the first two buffers of step 1; and (3) top buffers / excipients from step 2 over a range of pH values.
[0433] As explained, DAN-222 is a nanoparticle that includes chains of MAP-Gly-CPT (i.e., camptothecin conjugated to a hydrophilic copolymer). MAP-Gly-CPT consists of a 50-80 kDa mucic acid-polyethylene glycol (PEG) copolymer (MAP) conjugated to multiple CPT molecules via a glycine linker. When dissolved in an aqueous medium, the MAP-Gly-CPT polymer chains spontaneously assemble into nanoparticles that have a hydrophobic CPT in a core surrounded by a hydrophilic MAP. On average, the nanoparticles have a mass of approximately 180 kDa and a diameter of 40-60 nm (see Figure 1 The target CPT loading of the formulated nanoparticles was 10-12 wt %, with an average of two MAP-Gly-CPT chains per nanoparticle.
[0434] The physicochemical properties of the DAN-222 drug substance require that it be delivered in the form of a parenteral solution. Therefore, drug development focused on creating a drug product formulation for intravenous infusion. The formulation must meet several criteria: sterility; acceptable stability during drug substance and drug product manufacturing; acceptable stability for long-term storage; and acceptable stability during handling and administration. Since aqueous solutions are required to form DAN-222 nanoparticles, formulation design focuses on identifying excipients that provide both isotonicity and stability within the desired pH range (e.g., buffered pH). Intentionally, no unusual or novel excipients were evaluated. All excipients are available at pharmacopoeial grade and are listed in the FDA Inactive Ingredient Database.
[0435] The main stability issue for DAN-222 formulated bulk drug substance (FBDS) and DAN-222 sterile solution for infusion is the release of free CPT from the nanoparticles. This measurement (percentage of free CPT to total CPT) constitutes the key purity assay for DAN-222 and is the clearest indicator of product stability. The DAN-222 construct is designed to limit the acute toxicity of CPT by attaching it to the nanoparticle polymer, thereby controlling the release of this active moiety. The release of free CPT is caused by hydrolysis and can be controlled by optimized formulations, thereby avoiding temperature increases during manufacturing and filling / finishing processes and keeping the drug substance and drug product frozen during long-term storage. As shown in the results of these studies, the release of free CPT in DAN-222 was controlled by optimizing the formulation, thereby minimizing temperature increases during manufacturing and filling / finishing processes and keeping the drug substance (DS) and drug product (DP) frozen or evaluating the feasibility of lyophilization.
[0436] Nanoparticle size and polydispersity (PDI) is another pathway that can affect the pharmacokinetics and in vivo activity of a product. In addition, solution properties, including pH, viscosity, solubility, and particle formation, are critical to control to ensure a safe and effective product that can be manufactured and administered. As part of three studies, nanoparticle size, polydispersity, and solution properties of a number of different formulations exposed to different conditions were evaluated.
[0437] Screening methods and materials
[0438] DAN-222 Active Pharmaceutical Ingredient
[0439] The active pharmaceutical ingredient (API) examined in these studies was DAN-222 manufactured under development conditions by Abzena, Bristol, PA. The material used for Step 1 and Step 3 of the screening was lot ABZ-2583 / SKT-757-010-LYO / 45 kDa. The material used for Step 2 was lot SKT-757-009-Lyo / 53 kDa / 11.79% CPT.
[0440] Preparation parameters
[0441] In each stability study, the formulation had fixed parameters of buffer concentration of 20 mM, fill volume of 0.5 mL, and API concentration of 10 mg / mL.
[0442] Tables 1-3 provide the various formulations investigated in steps 1-3 of the initial formulation development screen. The formulation codes are used when discussing the results obtained from the three steps of the screen.
[0443]
[0444]
[0445] During all three phases of initial formulation development studies, each of the above formulations was subjected to various stress conditions: temperature; agitation; freeze-thaw; and forced oxidation. These conditions were designed to evaluate key manufacturing process risk factors as well as various temperature risk factors that could affect product stability of DAN-222's critical quality attributes.
[0446] Solution properties, including pH and visible particle formation, are also critical to the product. Through these formulation studies, it was found that pH is the most critical formulation property for nanoparticle purity. At approximately neutral pH and above, the release rate of CPT from the nanoparticles increases. At lower pH (e.g., pH 4-5), a significant decrease in the CPT loss rate of the nanoparticles was observed. At a pH below 4 (i.e., pH 3), the release rate of CPT is slower than that at pH 4. However, below pH 4, there is a problem of pain during infusion. A pH of 4.3 was selected to provide a low release rate of CPT at freezing and refrigeration (2-8°C) temperatures and to reduce the risk of patient discomfort during infusion of this moderately acidic solution. In addition, it has been determined that when the amount of free CPT reaches a critical level (approximately 30% of the total CPT) under stress conditions, visible particle formation occurs in the solution.
[0447] Nanoparticle size and polydispersity index (PDI) are other product quality attributes that may affect the product’s behavior in vivo. Particle size and polydispersity can also demonstrate aggregation, which can lead to poor product performance and potential safety issues for patients.
[0448] Accelerated stability studies
[0449] The solid MAP-Gly-CPT conjugate (amorphous DAN-222DS) was reconstituted in bulk with Milli-Q (MQ) water adjusted to pH 4 with phosphoric acid and stirred vigorously at ambient temperature for approximately 12 hours without bubble formation.
[0450] Steps 1 and 3 used conjugated material from batch SKT-757-010-LYO, and step 2 used conjugated material from batch SKT-757009-Lyo. For step 3, after reconstitution, an aliquot of bulk MAP-Gly-CPT in pH 4MQ water was extracted by SOP-0001-CPTRP for concentration measurement by absorbance (pre-0.45 μm filtration measurement). After reconstitution, the solution was filtered using a 0.45 μm vacuum filter to clarify. After filtration, the bulk formulated MAP-Gly-CPT in pH 4 water was divided into appropriate portions according to Tables 1, 2 and 3. Under gentle stirring, a concentrated (10X) stock solution of either buffer alone (step 1 / 3) or a combination of buffer / excipient / surfactant (step 2 / 3) was slowly added to the pH 4 aqueous solution at a ratio of 1 / 10 to obtain a target formulation of approximately 10 mg / mL. For step 3, after filtration and 10x buffer / excipient spiking, an aliquot of each formulated MAP-Gly-CPT fraction was extracted by SOP-0001-CPTRP for concentration measurement by absorbance (post 0.45 μm filtration / spiking measurement). All concentration measurements by absorbance were performed together with a time zero measurement. No adjustments were made to sample concentrations after measurement.
[0451] After all formulations were prepared, they were sterile filtered using a 0.22 μm syringe barrel filter in a sterile biological safety cabinet (BSC) and filled into final container caps at a fill volume of 0.5 mL. A 100 μL aliquot (step 2) and a 1 mL aliquot (step 3) of each formulation were taken and lyophilized overnight for concentration analysis by solid weight. After filling, the containers were sealed and then removed from the BSC, capped / crimped and labeled. Samples were stored at specified temperatures or exposed to acute stress conditions such as stirring, freeze / thaw, and forced oxidation. Time zero analysis was performed.
[0452] The samples in the stirring study were stirred on an orbital shaker at 450 rpm for 6 hours and 24 hours. An identical set of samples was also incubated at room temperature without stirring for comparison (step 1). The one-day 25°C samples were used as static controls for steps 2 and 3. According to Table 4, the forced oxidation samples were exposed to different concentrations of H2O2 and analyzed immediately after 1 hour, 5 hours and 24 hours (steps 1 and 2). The frozen / thawed samples were exposed to continuous uncontrolled freezing and thawing cycles from -80°C to ambient temperature and sampled at 3x F / T and 6x F / T (step 1) or 6x F / T (steps 2 / 3).
[0453] The accelerated stability study involved incubating the formulation candidates at frozen (-80°C and -20°C), refrigerated (2-8°C), stressed (20-25°C), and accelerated (40°C) storage temperatures. The storage temperature portion of the study was conducted over a 1-week period. Additional extended time points were added after the initial screening pending availability of additional sample volumes. Any additional time points were taken from the original vials and were not sterile.
[0454] Table 4 summarizes the acute stress conditions used for formulation stability evaluation.
[0455]
[0456] Table 5 summarizes the analytical methods used in the screening.
[0457]
[0458] Visual inspection under white light source against black and white backgrounds. Using Orion 2 pH analysis was performed with a pH meter calibrated with three pH standard solutions (pH 4, 7, and 10) with calibration slopes of 95% or greater. The samples were not temperature regulated and allowed to equilibrate to ambient temperature prior to measurement. Osmotic pressure was measured using a 2020 ice point osmometer (Advanced Instruments).
[0459] For the RP-HPLC assay, the free CPT sample was treated with HCl to convert the carboxylate CPT form to the lactone form. If the CPT is not converted to the lactone form, it will elute early (about 2 to 4 minutes) along with the polymer-bound CPT. As more CPT is lost from the polymer due to hydrolysis, the area of the free CPT peak between 5.6 and 7.0 minutes increases. The total CPT sample was first treated with NaOH to release CPT from the parent polymer, and then the carboxylate CPT form was converted to the lactone form with HCl. The amount of these species was measured by monitoring the peak absorbance at 370 nm.
[0460] Dynamic light scattering (DLS) is used to characterize particle size based on the scattering of visible light caused by the difference in refractive index between the dispersed colloid and the dispersion medium. DLS measures the fluctuations over time of light scattered by vibrating particles suspended in a liquid. The Brownian motion caused by collisions with the solvent molecules of the liquid results in the vibrations.
[0461] Step 1 Results
[0462] In the accelerated stability study step 1, the effects of specific buffers and pH on the performance of DAN-222 were evaluated. Historical development data indicated that DAN-222 exhibited enhanced stability at lower pH, so low pH buffer systems including succinate, citrate, acetate, and histidine were evaluated. Mildly alkaline (pH 7.4) phosphate buffer was included in the evaluation as a control (P7.4 in Tables 1 and 2).
[0463] Visual inspection results
[0464] All formulations (listed in Table 1) were free of visible particles (FFVP) at time zero and up to 7 days at 2-8°C and 20-25°C. After 3 days at 40°C, the control (P7.4) had visible particles (PP). After 7 days at 40°C, both formulations W4 and the control (P7.4) had visible particles, formulation H5 had almost no visible particles (PFP), and all other formulations had no visible particles. After 3 months at -20°C and -80°C, all formulations had no visible particles.
[0465] After stirring at 450 rpm for 24 hours, all formulations had no visible particles (FFVP). After 6 consecutive rounds of uncontrolled freezing and thawing from -80°C to ambient temperature, all formulations had no visible particles, but the control (P7.4) did form a gel-like matrix that did not return to a liquid state until it reached room temperature. After exposure to 0.02% or 0.05% peroxide for 24 hours, all formulations except the control (P7.4) had no visible particles. The control (P7.4) had visible particles (PP).
[0466] pH and osmotic pressure results
[0467] At time zero, the pH and osmolality of all formulations (listed in Table 1) were within the target range, except for formulation W4. 25mm w / 0.2μm After filtration through a syringe filter (PALL catalog number 4612), the pH of W4 increased by 1.4 units. All osmotic pressure values were within the target range of theoretical values. After 7 days at 2-8°C, all formulations showed pH and osmotic pressure values similar to those observed at time zero. After 7 days at 20-25°C, all formulations showed pH and osmotic pressure values comparable to those observed at time zero. After 7 days at 40°C, all formulations except H5 showed pH and osmotic pressure values similar to those observed at time zero. After 7 days at 40°C, H5 showed a decrease in pH of -1.1 pH units. After 3 months at -20°C and -80°C, all formulations except W4 showed pH values similar to those observed at time zero. W4 showed a 1.0 unit increase in pH at both temperatures, which emphasizes the importance of adding buffer to maintain pH. All formulations showed osmotic pressure values similar to those observed at time zero.
[0468] After 24 hours of agitation at 450 rpm, all formulations showed pH and osmolality values similar to those observed at time zero and the static control. After three consecutive uncontrolled freeze and thaw cycles from -80°C to room temperature, all formulations showed pH and osmolality values comparable to those observed at time zero. No pH and osmolality data were collected during six consecutive uncontrolled freeze and thaw cycles from -80°C to room temperature.
[0469] After the addition of 0.02% peroxide and subsequent monitoring for 24 hours, all formulations showed pH and osmolality values similar to those observed at time zero. No pH and osmolality data were collected at the 5 hour time point. After the addition of 0.05% peroxide and subsequent monitoring for 24 hours, all formulations showed pH and osmolality values comparable to those observed at time zero. No pH and osmolality data were collected at the 5 hour time point.
[0470] RP-HPLC and DLS results
[0471] At time zero, all formulations (listed in Table 1) showed low free CPT percentages except the control (P7.4). The phosphate control showed a large increase in free CPT at time zero (+3.37%). All formulations showed particle sizes ranging from 41.0 to 51.7 nm and similar PDIs ranging from 0.293 to 0.438.
[0472] like Fig.11As shown, after 14 days at 2-8°C, formulations S4, C4 and A4 at pH 4 showed relatively small changes in free CPT release compared to that observed at time zero (+0.51% to +0.58%). Formulations W4 and H5 showed slightly higher free CPT release compared to time zero, ranging from +0.73% to +0.93%. The control formulation (P7.4) showed a greater burst of CPT release after 14 days at 2-8°C, an increase of 9.39% compared to time zero. After 14 days at 2-8°C, the particle size and PDI of all low pH formulations did not change significantly compared to time zero, except for formulation S4 at 7 days. The control formulation (P7.4) showed a slight increase in particle size (±9nm) compared to time zero.
[0473] like Fig.12 As shown, after 14 days at 20-25°C, the free CPT release of formulations S4, C4 and A4 at pH 4 increased slightly (+1.60% to +1.76%) compared to that observed at time zero. Formulations W4 and H5 showed slightly higher free CPT releases, ranging from +2.34% to +3.30%, compared to that observed at time zero. The control formulation (P7.4) showed a significant change in CPT release after 14 days at 20-25°C, increasing by 34.7% compared to that observed at time zero.
[0474] like Fig.12 As shown, after 14 days at 20-25°C, the particle size and PDI of the low pH formulations were almost unchanged compared to what was observed at time zero. The citrate-containing formulations showed a slight increase in particle size after 7 and 14 days (+10.3 to +13.9 nm). The control formulation (P7.4) had a significant increase in particle size (+140.1 nm) compared to time zero.
[0475] like Fig.13 As shown, after 14 days at 40°C, the free CPT release of the low pH formulations increased (+3.73% to +4.43%) compared to that observed at time zero, which was a more significant change compared to time zero, but the release was significantly lower than that of the high pH formulations. Formulations W4 and H5 showed slightly higher free CPT release compared to time zero, ranging from +4.16% to +5.23%. The control formulation (P7.4) showed a significant increase in CPT release after 3 days at 40°C compared to time zero (+32.47%). The control formulation was not analyzed at later time points due to the presence of heavy particulate matter.
[0476] Most formulations showed significant particle aggregation after 3 days at 40° C. Although the data indicated particle aggregation (±17.4 nm compared to time zero), the low pH formulation did not have any visible particles after 14 days at 40° C. The control formulation (P7.4) showed significant particle aggregation after 3 days at 40° C. (+1476.3 nm) compared to what was observed at time zero.
[0477] After 3 months at -20°C, there was little significant change in free CPT release for all formulations compared to time zero (+0.17% to +0.24%) and 1 day at 2-8°C (+0.0% to +0.07%).
[0478] After 3 months at -20°C, there were no significant changes in particle size and PDI for all formulations compared to that observed at time zero.
[0479] After 3 months at -80°C, there was little significant change in free CPT release for all formulations compared to time zero (+0.14% to +0.21%) and 1 day at 2-8°C (±0.06%).
[0480] After 3 months at -80°C, there were no significant changes in particle size and PDI for all formulations compared to that observed at time zero.
[0481] like Fig.14 As shown, after stirring at 450 rpm for 24 hours, free CPT release of all formulations except control formulation P7.4 did not change significantly compared to the static control. The control formulation (P7.4) showed a slight increase in free CPT release (+1.56%) compared to the static control.
[0482] After stirring at 450 rpm for 24 hours, all formulations showed no significant change in particle size compared to the static control and no visible particles.
[0483] After 6 consecutive rounds of uncontrolled freezing and thawing from -80°C to room temperature, all formulations showed percentages of free CPT similar to that observed at time zero (+0.10% to +0.39%). There were no significant differences between 3 or 6 consecutive freezing and thawing cycles.
[0484] like Fig.15 As shown, after 6 consecutive rounds of uncontrolled freezing and thawing from -80°C to room temperature, all formulations showed no significant change in particle size compared to that observed at time zero. The high pH control formulation did exhibit gelation after thawing from freezing until the material reached room temperature.
[0485] like Fig.16As shown, 24 hours after the addition of 0.02% peroxide, the CPT release of all low pH formulations was almost unchanged compared to that observed at time zero (+0.28% to +0.32%). The significant difference in CPT release between W4 and H5 (+0.95% vs. +0.53%) suggests that the buffer has a protective effect compared to no buffer. The control formulations at high pH showed a significant increase in the release of free CPT (+16.58%) compared to that observed at time zero. 24 hours after the addition of 0.02% peroxide, the particle size of all formulations was almost unchanged compared to that observed at time zero, except for the control formulation P7.4. The particle size averages confirm that both physical and chemical degradation caused by oxidation are associated with an increase in pH. After the first hour after the addition of peroxide, the high pH control formulation showed obvious visible particle formation.
[0486] like Fig.17 As shown, 24 hours after the addition of 0.05% peroxide, the CPT release of all low pH formulations was almost unchanged compared to that observed at time zero (+0.34% to +0.40%). The significant difference in CPT release between W4 and H5 (+3.05% vs. +1.05% increase) suggests that the buffer has a protective effect compared to no buffer. The control formulations at high pH showed a significant increase in the release of free CPT compared to that observed at time zero (+29.76%). 24 hours after the addition of 0.05% peroxide, the particle size of all formulations was almost unchanged compared to that observed at time zero, except for the control formulation P7.4. The particle size averages confirm that both physical and chemical degradation caused by oxidation are associated with an increase in pH. After the first hour after the addition of peroxide, the high pH control formulation showed obvious visible particle formation and a significant increase in particle size (+282.4nm).
[0487] Step 2 Results
[0488] In the accelerated stability study step 2, the two best performing buffer systems were selected from step 1 and used to evaluate the effects of specific excipients on the performance of the DAN-222 product. Common pharmacopoeial excipients such as sugars, salts, amino acids, and surfactants were screened.
[0489] Visual inspection results
[0490] All formulations were free of visible particles (FFVP) at time zero and up to 1 month at 2-8°C and 7 days at 20-25°C. The control (P7.4) developed visible particles (PP) after 14 days at 20-25°C, while all other formulations remained free of visible particles for up to 1 month. After 7 days at 40°C, all formulations except the control (P7.4) were free of visible particles. The control (P7.4) had visible particles after 1 day at 40°C. All formulations tested were free of visible particles for up to 2 months at -20°C and -80°C.
[0491] All formulations were free of visible particles (FFVP) after 24 hours of stirring at 450 rpm, 6 consecutive cycles of uncontrolled freezing and thawing from -80°C, and exposure to 0.05% peroxide for 24 hours.
[0492] pH and osmotic pressure results
[0493] At time zero, all formulations showed pH values that differed from the target by ±0.38 pH units, and osmotic pressure values that differed from the theoretical buffer osmotic pressure by ±87mOsm / kg. After 1 month at 2-8°C, all formulations showed similar pH values (ranging from ±0.17 pH units) and osmotic pressure values (ranging from ±23mOsm / kg) compared to the values at time zero. After 1 month at 20-25°C, all formulations showed similar pH values (ranging from ±0.19 pH units) and osmotic pressure values (ranging from ±25mOsm / kg) compared to the values observed at time zero. After 7 days at 40°C, all formulations showed a slight decrease in pH compared to time zero. The acetate formulation showed a decrease in the range of ±0.26 pH units, and the histidine formulation showed a decrease in the range of ±1.09 pH units. All formulations showed osmotic pressure values similar to the values observed at time zero, ranging from ±24mOsm / kg.
[0494] After 2 months at -20°C and -80°C, all formulations showed similar pH values (range ± 0.09 pH units) and osmotic pressure values (range ± 19 mOsm / kg) compared to the values observed at time zero. After stirring at 450 rpm for 24 hours, all formulations showed similar pH values (range ± 0.17 pH units) and osmotic pressure values (range ± 24 mOsm / kg) compared to those observed at time zero and under static controls. After 6 consecutive uncontrolled freezing and thawing cycles from -80°C to room temperature, all formulations showed similar pH values (range ± 0.18 pH units) and osmotic pressure values (range ± 13 mOsm / kg) compared to the values observed at time zero.
[0495] Twenty-four hours after the addition of 0.05% peroxide, all formulations showed similar pH values (range ± 0.18 pH units) and osmotic pressure values (range ± 24 mOsm / kg) compared to the values observed at time zero.
[0496] RP-HPLC and DLS results
[0497] At time zero, all formulations except the control (P7.4) exhibited low percentage free CPT values ranging from 0.54% to 0.67%. The phosphate control exhibited a greater amount of free CPT (2.35%) at time zero. All formulations exhibited particle sizes ranging from 54.0 nm to 65.1 nm.
[0498] After 14 days at 2-8°C, all acetate and histidine formulations showed a small change in free CPT compared to time zero (+0.31% to +0.47% vs. +0.43% to 0.62%). After 1 month at 2-8°C, the control (P7.4) showed a greater burst release of CPT (+9.13%) compared to the amount released at time zero.
[0499] like Figures 18A-18B As shown, after 1 month at 2-8°C, the selected low pH formulations tested showed an increase in acetate ( Fig.18A ) and histidine ( Fig.18B ) There was almost no significant change in free CPT in the buffer. After 1 month at 2-8°C, the control (P7.4) showed a larger burst release of CPT (+14.72%) compared to the amount released at time zero. There was no significant change in particle size and PDI for all formulations compared to time zero. Most formulations showed a slight decrease in particle size.
[0500] like Fig.19 As shown, after 4 months at 2-8°C, both A4N and W4N showed an increase in free CPT (+1.96% to +2.09%) and a decrease in particle size (-18.7 nm to -22.6 nm) compared to the values observed at time zero.
[0501] like Figures 20A-20B As shown, after 7 days at 20-25°C, all acetate and water formulations showed an increase in free CPT of +0.86% to +1.14% compared to time zero, while after 1 month at 20-25°C, the selected acetate and water formulations tested showed an increase in free CPT release of +2.54% to +3.18% ( Fig. 20AAfter 7 days at 20-25°C, the histidine formulations showed an increase in free CPT of +1.00% to +1.45% compared to the amount of free CPT at time zero, while after 1 month at 20-25°C, the selected histidine formulations tested showed an increase in free CPT of +2.59% to +3.12% compared to the amount of free CPT at time zero ( Fig. 20B ). The control formulation (P7.4) showed a significant change in the release of CPT after 7 days (+24.71%) and 1 month (+38.14%) at 20-25°C. After 14 days at 20-25°C, the formulations containing acetate, water, and histidine showed a slight to moderate decrease in particle size (-4.2 to -22.8 nm) compared to time zero. Those selected formulations tested after 1 month at 20-25°C continued to show a trend towards smaller particle size (-14.0 to -21.6 nm) compared to time zero. After 14 days at 20-25°C, the control formulation (P7.4) showed little to no change in particle size compared to time zero.
[0502] like Figures 21A-21B As shown, after 7 days at 40°C, all low pH formulations showed a large increase in free CPT release (+4.05% to +5.74%) compared to the amount of free CPT present at time zero. Fig.21A The results of histidine buffer are shown in Fig. 21B After 7 days at 40°C, the control formulation (P7.4) showed a significant change in the release of CPT (+34.78%). After 7 days at 40°C, the formulation containing acetate, water and histidine showed a slight decrease in particle size (-0.2 to -16.9 nm) compared to the size observed at time zero. After 3 days at 40°C, the control formulation (P7.4) showed a significant increase in particle size (+990.3 nm) compared to that observed at time zero, and was not tested at further time points.
[0503] like Fig. 22 As shown, after 2 months at -20°C, all tested formulations showed almost no significant change in the release of free CPT compared to the amount of free CPT present at time zero (+0.03% to +0.09%). The control formulation (P7.4) showed a slight decrease in free CPT (-0.32%) compared to time zero. After 4 months at -20°C, the tested formulations showed a slight increase in the release of free CPT compared to the amount of free CPT present at time zero (+0.27% to 0.44%). After 2 and 4 months at -20°C, there was no significant change in particle size and PDI for all formulations compared to time zero. Most formulations showed a slight decrease in particle size.
[0504] like Fig.23 As shown, after 2 and 4 months at -80°C, all tested formulations showed little significant change in release of free CPT compared to the amount of free CPT present at time zero (+0.01% to +0.08% and +0.11% to 0.15%, respectively). After 2 months, the control formulation (P7.4) showed a slight decrease in free CPT (-0.43%) compared to the amount of free CPT present at time zero. After 2 and 4 months at -80°C, there was no significant change in particle size and PDI for all formulations compared to time zero. Most formulations showed a slight decrease in particle size.
[0505] like Figures 24A-24B As shown in Figure 2, after stirring at 450 rpm for 24 hours, free CPT release for all formulations except the control did not change significantly compared to the amount of free CPT present at time zero. The control formulation (P7.4) showed an increase of +5.11% in free CPT compared to time zero. After stirring at 450 rpm for 24 hours, all formulations showed a slight decrease in particle size (-2.7 nm to -16.3 nm) compared to time zero. The results for the formulations in acetate buffer were Fig.24A Results for preparations in histidine buffer are shown in Fig. 24B Shown in.
[0506] like Figures 25A-25B As shown, after six consecutive cycles of uncontrolled freezing and thawing from -80°C to room temperature, the percentage of free CPT for all formulations except the control was similar to the amount of free CPT present at time zero (+0.14% to +0.28%). The control formulation (P7.4) showed an increase of +2.16% in free CPT compared to time zero. After six consecutive cycles of uncontrolled freezing and thawing from -80°C to room temperature, the particle size of all formulations showed a slight trend of decrease compared to time zero (+2.7 to -20.0 nm). The results for the formulations in acetate buffer were Fig.25A Results for preparations in histidine buffer are shown in Fig.25B Shown in.
[0507] like Figures 26A-26B As shown, twenty-four hours after the addition of 0.05% peroxide, all acetate and water formulations showed little change in CPT release (+0.30% to +0.72%) compared to time zero ( Fig.26A ). The histidine formulation showed a slight increase in CPT release (+0.72% to +1.18%) compared to time zero ( Fig.26B The control formulation at high pH showed a significant increase in the release of free CPT (+47.64%) compared to time zero ( Fig.26BTwenty-four hours after the addition of 0.05% peroxide, the particle size of all formulations except the control showed little change from the size observed at time zero. Five hours after the addition of peroxide, the control formulation (P7.4) showed a significant increase in particle size (+1304.3 nm) ( Fig.26B ).
[0508] Step 3 Results
[0509] In the accelerated stability study step 3, the best performing buffer system / excipient combination from step 2 was selected for robustness checks at pH 4.0, 4.5, and 5.0.
[0510] Visual inspection results
[0511] All formulations had no visible particles (FFVP) at time zero and up to 1 month at 2-8°C and 20-25°C. After 1 day at 40°C, all formulations had no visible particles except the pH 5 formulation. The pH 5 formulation had visible particles (PP).
[0512] After 1 month at -20°C and -80°C, all formulations showed no visible particles.
[0513] After stirring at 450 rpm for 24 hours and six consecutive rounds of uncontrolled freezing and thawing from -80°C, all formulations were free of visible particles.
[0514] pH and osmotic pressure results
[0515] At time zero, all formulations exhibited pH values within ±0.14 pH units of the target, and osmotic pressure values within ±34 mOsm / kg of the theoretical buffer osmotic pressure. After 1 month at 2-8°C, all formulations except W4N showed similar pH values (range ±0.22 pH units) and osmotic pressure values (range ±15 mOsm / kg) compared to the values observed at time zero. W4N exhibited a decrease of 0.54 pH units compared to time zero.
[0516] After 1 month at 20-25°C, all formulations showed similar pH values (range ± 0.24 pH units) and osmotic pressure values (range ± 16 mOsm / kg) compared to the values observed at time zero. After 7 days at 40°C, all formulations showed similar pH values (range ± 0.09 pH units) and osmotic pressure values (range ± 5 mOsm / kg) compared to the values observed at time zero. After 1 month at -20°C and -80°C, all formulations showed similar pH values (range ± 0.12 pH units) and osmotic pressure values (range ± 10 mOsm / kg) compared to the values observed at time zero.
[0517] After stirring at 450 rpm for 24 hours, all formulations showed similar pH values (range ± 0.04 pH units) and osmotic pressure values (range ± 5 mOsm / kg) compared to the values observed at time zero. After 6 consecutive uncontrolled freezing and thawing cycles from -80°C to room temperature, all formulations showed similar pH values (range ± 0.12 pH units) and osmotic pressure values (range ± 10 mOsm / kg) compared to the values observed at time zero.
[0518] RP-HPLC and DLS results
[0519] At time zero, all formulations exhibited low percent free CPT values (ranging from 0.65% to 0.74%) and particle sizes ranging from 42.2 nm to 47.3 nm.
[0520] like Fig. 27 As shown, after 1 month at 2-8°C, all low pH formulations showed a slight increase in free CPT (+0.33% to +0.80%) compared to the amount of free CPT present at time zero. Formulations containing buffer and salt showed lower percentages of free CPT compared to their corresponding pH counterparts containing only buffer (mean -0.12%). In addition, the lower the pH of the formulation, the lower the percentage of free CPT. There were no significant changes in particle size and PDI for all formulations compared to the values observed at time zero.
[0521] like Fig.28 As shown, after 3 months at 2-8°C, all formulations showed an increase in free CPT (+1.34% to +2.23%) compared to the amount of free CPT present at time zero. Formulations containing buffer and salt showed a lower percentage of free CPT (mean -0.28%) compared to their corresponding pH counterparts containing only buffer. In addition, the lower the pH of the formulation, the lower the percentage of free CPT. Particle size and PDI did not change significantly for all formulations compared to the values observed at time zero (-1.0 nm to +6.45 nm).
[0522] like Fig.29As shown, after 7 days at 20-25°C, all formulations showed an increase in free CPT (+0.65% to +1.12%) compared to the amount of free CPT present at time zero. Formulations containing buffer and salt showed lower percentages of free CPT compared to their corresponding pH counterparts containing only buffer (average -0.30%). After 1 month at 20-25°C, all low pH formulations showed greater increases in free CPT (+2.14% to +4.18%) compared to the amount of free CPT present at time zero. Formulations containing buffer and salt showed lower percentages of free CPT compared to their corresponding pH counterparts containing only buffer (average -0.58%). In addition, the lower the pH of the formulation, the lower the percentage of free CPT detected. After 1 month at 20-25°C, there was no significant change in particle size and PDI for all formulations compared to the values observed at time zero (-1.6nm to 4.5nm).
[0523] like Fig.30 As shown, after 7 days at 40°C, all formulations showed a greater increase in free CPT release (+3.06% to +5.00%) compared to the amount of free CPT present at time zero. After 7 days at 40°C, all formulations showed a slight change in particle size (±15.9 nm) compared to time zero.
[0524] like Fig.31 As shown, after 1 month at -20°C, there was no significant change in free CPT release for all formulations compared to the value at time zero (-0.02% to +0.11%), and there was no significant change in particle size (-2.1nm to +9.6nm). After 3 months at -20°C, there was a slight increase in free CPT release in the pH 4.5 and 5.0 formulations compared to the pH 4.0 formulation. Compared to time zero, the percentage of free CPT in the seven different formulations increased from 0% to 0.27%. There was no significant change in particle size among the formulations compared to time zero (-5.6nm to +7.4nm).
[0525] like Fig.32 As shown, after 3 months at -80°C, there was no significant change in free CPT release (+0.05% to +0.15%) and no significant change in particle size (-6.0 nm to 5.8 nm) for all formulations compared to the time zero value.
[0526] like Fig.33As shown, after stirring at 450 rpm for 24 hours, there was little significant change in free CPT release for all formulations compared to the amount of free CPT present at time zero (+0.07% to +0.39%), with higher pH formulations releasing more CPT than lower pH formulations. There was no significant change in particle size for all formulations compared to the size at time zero.
[0527] like Fig.34 As shown, after six consecutive cycles of uncontrolled freezing and thawing from -80°C to room temperature, there was no significant change in free CPT release or particle size change for all formulations compared to the values at time zero.
[0528] Conclusion of Steps 1-3
[0529] In the formulation buffer screening (step 1), the use of a formulation buffer based on a low pH value has obvious benefits on chemical (CPT loss), physical (particle size and PDI) and solution properties. At 2-8°C, the low pH formulation has the lowest CPT loss, about 0.03% per day, while the control (P7.4) has a 20-fold higher CPT loss, about 0.6% per day. Regardless of pH, all formulations did not show significant changes in physical or solution stability. At 20-25°C, the pH 4.0 formulation showed a CPT loss of about 0.03% per day, and the pH 5 formulation showed a CPT loss of about 0.2% per day. The CPT loss of the control (P7.4) was more than 30 times higher, about 3.6% per day. Regardless of pH, all formulations did not show significant changes in physical or solution stability. At 40°C, the low pH formulation showed a higher percentage of CPT loss per day (about 0.6%), and the particle size increased after 3 days. The control (P7.4) exhibited a considerable percentage loss of CPT of approximately 32.0% per day, with rapid formation of visible particles after 1 day. At -20°C and -80°C, all formulations except the control (P7.4) had minimal CPT loss of approximately 0.01% per day. The phosphate control exhibited a CPT loss of approximately 0.04% per day. None of the formulations showed significant changes in physical or solution stability.
[0530] After stirring at 450 rpm for 24 hours, all formulations showed minimal effects on chemical or physical stability. PDI increased slightly after stirring. Freeze / thaw cycles had minimal effects on particle structure and chemical stability in all groups except the control (P7.4), in which gelation was observed for a short period of time after thawing. There were no significant differences in chemical or physical stability between 3 or 6 consecutive freeze / thaw cycles. At low pH, there were no significant changes in physical stability after oxidative stress, and minimal changes in chemical stability. Significant losses in CPT were observed with increasing pH and peroxide levels. The control (P7.4) showed rapid and high physical structural changes after oxidative stress, including visible particle formation.
[0531] The sodium acetate buffer system showed some enhanced benefits compared to other pH 4 systems, reducing chemical and physical degradation, and was therefore selected as the primary buffer system used in Step 2. Histidine was also evaluated as a mid-pH option in Step 2.
[0532] In the formulation excipient screening (step 2), various salts, sugars, amino acids and surfactants were screened in acetate buffer at pH 4.0 and histidine buffer at pH 5.0. At 28°C, the formulations at pH 4.0 and 5.0 had minimal CPT loss of about 0.03% per day and no significant changes in physical or solution stability. There were no significant differences in chemical, physical or solution stability between the excipient groups in the same buffer system. At 20-25°C, the CPT loss was about 0.1% to 0.2% per day at both pH 4.0 and pH 5.0, depending on the excipient. The average particle size decreased with increasing temperature exposure and stabilized at about 7 days. There was no significant change in solution stability at either pH. At 40°C, the daily CPT loss increased to about 0.6%, and the particle size fluctuated after 3 days at both pH values. There were no significant changes in solution properties. At -20°C and -80°C, the pH 4.0 and 5.0 formulations had minimal CPT losses of approximately 0.01% per day and no significant changes in physical or solution stability.
[0533] After stirring at 450 rpm for 24 hours, all formulations except the control (P7.4) showed minimal effect on physical stability, as evidenced by only a slight decrease in particle size. In addition, no significant effect on chemical stability or solution properties was observed by visual inspection. PDI increased slightly in some excipient groups, but it was less obvious in the pH 4.0 formulation. In the pH 4.0 and 5.0 formulations, freeze / thaw cycles showed minimal effect on particle structure and chemical stability. After the addition of peroxide, there was no significant change in the physical stability of all low pH formulations, and there was a slight effect on chemical stability. A greater loss of CPT was seen in the pH 5.0 formulation compared to the pH 4.0 formulation.
[0534] Compared to other excipients, the use of salt as an excipient showed additional benefits in controlling product CQAs. Specifically, it was observed that salt helped to control polydispersity consistently across different stress groups. Sodium chloride was selected to proceed to step 3.
[0535] In the formulation confirmation screening (step 3), acetate formulations with and without NaCl were tested at pH 4.0, 4.5 and 5.0. At 2-8°C, the percentage of CPT loss per day at pH 4.0 to 5.0 was approximately 0.03% to 0.05%. There were no significant changes in physical or solution stability at all pH values for up to 1 month. The W4N formulation showed a decrease of 0.54 pH units after 1 month at 2-8°C compared to time zero, which emphasizes the importance of using a buffer system. At 20-25°C, the percentage of CPT loss per day was approximately 0.1% to 0.2%, depending on the pH and the presence of salt. Compared with the use of buffer alone in the same pH group, the inclusion of salt showed a significant protective effect on CPT loss at all three pH values. No significant changes in physical or solution properties were observed at all pH values with and without salt for up to 1 month. At 40°C, the percentage of CPT loss increased to approximately 0.6% per day at all pH values. Fluctuations in particle size were observed after 3 days, with the average size of the particles generally decreasing and then increasing in size. The inclusion of salt at elevated temperatures may have minimal inhibitory effects on particle size increase. After 1 day, the pH 5.0 formulation showed the presence of visible particles, while the pH 4.0 and 4.5 formulations had no visible particles for up to 1 week. At -20°C and -80°C, all formulations had minimal CPT losses per day of approximately 0.02% to 0.03%, and no significant changes in physical or solution stability.
[0536] Agitation at 450 rpm for 24 hours had minimal effect on chemical (0.1% CPT loss / day) and physical stability. Freeze / thaw cycles had minimal effect on product quality for all formulations regardless of pH or the presence of salt. A slight increase in PDI was observed in some groups and was more pronounced in the group without salt.
[0537] Inclusion of NaCl alone rather than buffer provided significant benefits in most stress groups, and data for pH 4.0 showed improved stability compared to pH 4.5 and 5.0.
[0538] The results of this initial formulation development study resulted in the selection of a target Phase 1 clinical formulation, with a drug substance concentration of 20 mg / mL DAN-222 in 20 mM sodium acetate (equivalent to 6.8 mM anhydrous sodium acetate, 13.2 mM acetic acid), 200 mM sodium chloride, pH 4.3.
[0539] Subsequent formulation development stability studies were conducted with several development batches of DAN-222 material using the proposed clinical formulation and API concentrations. The results of these studies demonstrated that the product is robust and maintains product quality when exposed to a variety of expected conditions during manufacturing and storage. The formulation of this GLP toxicology study batch is identical to the proposed Phase 1 clinical formulation of DAN-222FBDS and drug product. To date, stability trends at the same proposed storage temperature of the Phase 1 clinical drug product (-20±5°C) demonstrate that the critical quality attributes of the product are very stable under this storage condition.
[0540] Example 5 - Properties of DAN-222 formulated bulk drug substance (FBDS)
[0541] This example provides methods and assays for developing and characterizing the properties of a DAN-222 FBDS that can be used to produce a sterile solution of DAN-222 for infusion.
[0542] Properties of DAN-222
[0543] The drug substance DAN-222 consists of chains of 20(S)-camptothecin (CPT) covalently bound to a mucic acid-based polymer carrier via glycyl bonds (MAP-Gly-CPT). During manufacturing, MAP-Gly-CPT is isolated as an amorphous solid. In aqueous solution, the MAP-Gly-CPT polymer-drug conjugate self-assembles into nanoparticles (NPs). The drug substance properties described here refer to the formulated drug substance (FBDS) as designated amorphous MAP-Gly-CPT or DAN-222. Table 6 provides a list of the development batches from which these properties are derived.
[0544]
[0545]
[0546] When purified and isolated by ultrafiltration / diafiltration, the concentrated MAP-Gly-CPT is lyophilized to provide a solid intermediate. The isolated conjugate material is a pale yellow to yellow amorphous low density solid.
[0547] DAN-222FBDS is obtained by dissolving amorphous MAP-Gly-CPT in water for injection adjusted to pH 4.0 and then adding formulation buffer concentrate to achieve the desired buffer concentration (pH 4.3). The solution is concentrated to the desired concentration by ultrafiltration. As formulated, DAN-222FBDS is a clear to slightly opalescent, colorless to pale yellow liquid.
[0548] A series of tests were performed to determine the effect of dissolution of MAP-Gly-CPT in purified water on the pH of the aqueous solution. Samples were tested at ambient temperature using a Thermo Scientific Orion 2Star benchtop pH meter with an Orion 8103BN probe. ND These batches of amorphous MAP-Gly-CPT were dissolved in sterile filtered Dissolution of MAP-Gly-CPT resulted in a small decrease in the pH of the aqueous solution. This may be due to the presence of some free carboxylic acid moieties that are not conjugated to CPT. As formulated, DAN-222FBDS solutions are buffered with a target pH of 4.3 ± 0.3.
[0549] The solubility of DAN-222 in water at ambient temperature was evaluated. Amorphous MAP-Gly-CPT from development batches SKT-874052-2ND-1.2CPT and SKT-874-067-1.2CPT-25G-LYO was sterile filtered. Water Solubility. Solubility was determined by preparing saturated mixtures above the solubility limit in clear glass vials and visually assessing the effect of successive additions of water.
[0550] Because DAN-222 incorporates a hydrophilic polymer backbone, its behavior at high concentrations is different from that of a soluble crystalline material. No significant difference in the solubility of the two batches studied was observed. Starting from 400 mg / mL, the material was not completely dissolved and the mixture was heterogeneous. The solid appeared to absorb the initial aliquot of water and exhibited a homogeneous translucent gel-like state at about 265 mg / mL. Complete dissolution was achieved at about 230 mg / mL, resulting in a clear, yellow, highly viscous solution with little fluidity. Further addition of water resulted in a decrease in viscosity.
[0551] The viscosity of DAN-222FBDS of two different development batches was measured at ambient temperature using a Brookfield DV-II+Pro viscometer with a Brookfield CPA-40Z plate. For two samples, the speed of the plate was set to 50 revolutions per minute (rpm), and the torque percentage was measured. Two batches of SKT-874-069 and SKT-874-073 were prepared in 20mM sodium acetate, 200mM sodium chloride (formulation buffer) at pH 4.3. The results show that viscosity is related to concentration. The viscosity of the prepared solution (target is 20mg / mL) is slightly higher than water (comparable to the viscosity of whole milk), and does not hinder removal from a vial by a syringe.
[0552] Prior to formulation as a drug substance, MAP-Gly-CPT was isolated as an amorphous solid after concentration and lyophilization. This low density solid material was brittle and somewhat spongy and did not clearly exhibit any signs of crystalline structure. X-ray powder diffraction (XRPD) diffraction patterns of MAP-Gly-CPT and its precursors mucin polymer (MAP) and glycylcamptothecin (TFA salt; Gly-CPT) were obtained using a Rigaku SmartLab X-ray diffractometer. Data collection was performed using the instrument in Grabb-Brentano reflection geometry using a line source X-ray beam.
[0553] The XRPD results indicate that the Gly-CPT isolated for the synthesis of DAN-222 is clearly in crystalline form. In contrast, neither MAP nor MAP-Gly-CPT exhibit characteristics of ordered crystalline properties. The diffraction patterns of both compounds are of a broadly diffuse nature, showing little crystalline organization. In the diffraction patterns of MAP and MAP-Gly-CPT, broad peaks at approximately θ19°, 24°, 27°, and 36° suggest the presence of some potential "disordered" crystallinity, but the pattern confirms the overall visual assessment of both materials as amorphous. The XRPD pattern of MAP-Gly-CPT is very similar to that of MAP, which strongly suggests that the structure of the solid is dominated by the properties of MAP and that any tendency for CPT to partially crystallize is suppressed by its binding to MAP.
[0554] DAN-222FBDS Specification Development
[0555] This section provides the justification for the specifications of DAN-222 formulated bulk drug substance (FBDS). Each method and initial specification is based on a combination of process capability demonstrated through process development and the capabilities of compatible, qualified and / or compendial analytical methods.
[0556] The color specification for DAN-222FBDS is colorless to yellow liquid ≤Y3. This specification incorporates the range of colors observed in acceptable batches tested and used during development (including batches used for dose-range finding and IND-enabling GLP toxicology studies); the color of the initial GMP drug substance batch (Batch 21-M007) met this limit. The possibility of a yellow solution is based on the presence of 20(S)-camptothecin (CPT), which is known to be dark yellow in color. In solid form, both amorphous MAP-Gly-CPT and free CPT are yellow and can impart a light yellow tint to the solution. Color intensities greater than the Y3 color standard (e.g., Y2 or Y1) indicate potential degradation.
[0557] The clarity specification for DAN-222FBDS is clear to slightly opalescent liquid ≤ Criteria III. This specification incorporates the range of clarity observed in accepted batches tested and used during development (including batches used for dose range finding and GLP toxicology studies); the clarity of the initial GMP drug substance batch (Batch No. 21-M007) met this limit. DAN-222FBDS is generally clear, but visual assessment may be affected by lighting, viewing conditions, and reflections and refractions from the container.
[0558] DAN-222FBDS was identified using a specific combination of four individual analytical results. This multi-analytical approach was necessary to ensure that DAN-222FBDS, amorphous MAP-Gly-CPT, and free 20(S)-camptothecin (CPT) could be distinguished. The four identity analytical methods used to distinguish DAN-222FBDS, amorphous MAP-Gly-CPT, and free CPT in solution were: (i) identification by ultraviolet-visible spectroscopy (UV-Vis); (ii) appearance; (iii) percent free CPT (expressed as a percentage relative to total CPT) measured by reverse phase high performance liquid chromatography (RP-HPLC); and (iv) total weight percent CPT obtained by RP-HPLC.
[0559] Authentication of DAN-222FBDS samples by UV-Vis Two different wavelength ratios were evaluated to show identity (absorbance at 252nm / 356nm ratio; and absorbance at 295nm / 356nm ratio). These absorbance ratios were found to be unique to CPT-containing compounds. These absorbance ratios and acceptable ranges were established using the developed DAN-222FBDS as a reference standard, thus justifying the specification.
[0560] As previously stated, appearance analysis will differentiate between amorphous MAP-Gly-CPT (solid) samples and liquid MAP-Gly-CTP nanoparticles (DAN-222FBDS) samples. The justification for this specification is demonstrated and is sufficient to further demonstrate the identity of FBDS, which is a liquid compared to the MAP-Gly-CPT amorphous solid.
[0561] Finally, standards for the % free CPT relative to total CPT and total CPT weight % values obtained by RP-HPLC were used to differentiate between liquid samples of CPT and DAN-222FBDS. These tests were also used to demonstrate that the ratio of the amount of CPT present relative to the total drug substance correlated with the expected ratio for DAN-222FBDS. These levels were justified based on the DAN-222FBDS specification limits provided herein.
[0562] Purity was assessed by the % free CPT (relative to total CPT) in the DAN-222FBDS sample. This value was determined by the calculated free and total CPT concentrations in the sample. The "% free CPT relative to total CPT" value provides the clearest indicator of the stability of the drug substance during storage and use. The DAN-222 construct was designed to limit the acute toxicity of CPT by attaching it to a nanoparticle (NP) polymer, thereby controlling the release of this active moiety. The release specification for the % free CPT relative to total CPT in the drug substance was ≤3%. The stability specification for the % free CPT relative to total CPT in the drug substance was ≤5%. These limits are much lower than previous studies using CPT directly administered as a free drug. In two separate 3-week mouse xenograft studies (ER2019-09-1B, ER2019-09-1C), CPT itself was administered and was well tolerated at 3 mg / kg, which has a human equivalent dose of 9 mg CPT / m 2 .
[0563] Additionally, these limits allow for significantly reduced free CPT exposure for DAN-222 compared to the human equivalent dose of CPT tolerated at the proposed clinical dose levels. For example, a potential high-dose cohort for Phase 1 clinical studies could be 16 mg CPT / m 2Under the proposed release specifications, the total free CPT will not exceed 0.48 mg / m 2 , which is well below the tolerated dose. The proposed stability specification of ≤5% free CPT results in a free CPT dose of 0.8 mg / m 2 Each of these free CPT exposures was greater than the 9 mg / m 2 The human tolerance equivalent dose of CPT is more than one order of magnitude lower.
[0564] Evaluation of the ratio of total CPT mass to total drug substance mass (total CPT weight %) provides an indication of the performance and control of the MAP-Gly-CPT synthesis process. This criterion is evaluated for drug substance manufacturing but is not repeated for drug product release because the combined evaluation of % free CPT relative to total CPT, CPT concentration, and % CPT-related substances is sufficient to address drug product quality issues.
[0565] The specification for total CPT weight % is 11-15%. This specification covers the mid-to-high end of the CPT loading range studied during process development. The high end of this range is derived from the theoretical maximum CPT loading of MAP-Gly-CPT, assuming that Gly-CPT is conjugated to every available site on the MAP polymer chain. The lower end of this specification is at CPT loading levels that have been studied in animal models and successfully demonstrated during process development.
[0566] Measuring the total CPT concentration in DAN-222FBDS provides the basis for weight-based dosing of DAN-222 in the clinic. The total CPT concentration determination represents the sum of all CPT species present in the vial, including CPT covalently bound to the nanoparticle polymer backbone; free CPT in solution; and possible trace contributions from unreacted Gly-CPT. The drug substance specification range for total CPT concentration is based on the allowed weight % of total CPT in MAP-Gly-CPT. The specification limits for CPT concentration are derived from the minimum acceptable DAN-222FBDS nanoparticle concentration multiplied by the minimum acceptable weight % total CPT value and the maximum acceptable FBDS nanoparticle concentration multiplied by the maximum acceptable weight % total CPT value. These calculations yield a specification range of 1.7 mg / mL to 3.6 mg / mL. In addition, this target range for CPT concentration is based on the expected dose levels in the Phase 1 clinical study and incorporates the CPT concentration range used in the GLP toxicology study.
[0567] Purity was assessed by integrating up to eight individual impurity peaks in the “total CPT” RP-HPLC profile observed to date in development batches and believed to represent CPT-related impurities but may also include process-related impurities.
[0568] As described above, eight small impurity peaks were detected by UV absorbance that eluted on either side of the unconjugated CPT peak in the “total CPT” RP-HPLC chromatogram (with retention times between approximately 4-8.5 minutes). For the initial Phase 1 study material, these CPT-related substances have not been identified, nor have their response factors been determined. However, these impurities were present in batches used in dose range finding and IND-enabling GLP toxicology studies. The specification requires reporting of any peak with an area greater than 0.05% of the total CPT peak area. Any individual peak area must be ≤ 2% of the total peak area, and the sum of these peak areas must be ≤ 3% of the total peak area. It should be noted that these limits are measured relative to the CPT content, not the entire drug substance. When considering the weight % of total CPT, the individual impurity limits represent approximately 0.3 area % of the DAN-222 drug substance, and the sum of the impurity limits represent approximately 0.45 area % of the DAN-222 drug substance.
[0569] These limits are justified by the presence of these CPT-related substances in the dose-ranging and GLP toxicology DAN-222FBDS batches. In the dose-ranging study, the maximum tolerated dose (MTD) in dogs was determined to be 1.5 mg / kg (human equivalent dose is 30 mg CPT / m 2 In the pivotal GLP toxicology study, the highest non-serious toxic dose (HNSTD) in dogs was determined to be 0.64 mg / kg (human equivalent dose is 12.8 mg CPT / m 2 ). The six-fold safety factor applied to the HNSTD sets the proposed initial clinical dose of DAN-222 at 2 mg CPT / m 2 The sum of CPT-related substances in the dose-range finding and GLP toxicology FBDS batches was 3% and 2%, respectively, resulting in human equivalent doses of 2 These values exceed the CPT-related substance content of the proposed initial dose of the DAN-222 drug product (2 mg CPT / m 2 ).
[0570] Nanoparticle concentrations were determined gravimetrically by drying FBDS samples by lyophilization and correcting for nonvolatile components of the formulation. Based on the planned Phase 1 clinical regimen dose and the target range of CPT loading (total CPT weight %), a strength value of 17-23 mg / mL was selected to provide the desired fill and extractable volumes for the drug product. In-process and stability data indicate that DAN-222FBDS remains stable in formulated solutions at concentrations as low as 5 mg / mL and as high as 40 mg / mL. Concentrations outside this range may be feasible but have not been studied in depth.
[0571] The particle size specification for DAN-222FBDS is 20-80nm. This specification incorporates the range of particle sizes observed in batches tested and used during development. The lower end of the specification was set to ensure that the kidneys and liver will remove a minimal amount of drug substance. The upper end is intended to allow for efficient tumor penetration and tumor cell uptake of the nanoparticles. The nanoparticle sizes for the dose range finding and GLP toxicology batches were 37nm and 31nm, respectively.
[0572] The specification for the polydispersity index (PDI) of DAN-222FBDS is: ≤0.9. This specification incorporates the PDI range observed in batches tested and used during development. The PDIs for dose range finding and GLP toxicology batches were 0.463 and 0.346, respectively.
[0573] The zeta potential is a measure of surface charge. The specification for the zeta potential of DAN-222FBDS is: -5mV to +5mV. This specification incorporates the range of zeta potentials observed in lots tested and used during development. All DAN-222FBDS development lots had a zeta potential close to neutral. The value was typically slightly negative, but occasionally returned a slightly positive charge measurement. The measured zeta potentials for the dose-ranging discovery and GLP toxicology lots were -0.751mV and -0.399mV, respectively.
[0574] The specification for osmotic pressure of DAN-222FBDS is: 336-504mOsm / kg. This osmotic pressure specification is based on the results obtained from repeated measurements of different development batches of DAN-222FBDS (including GLP toxicology batches). This range represents the osmotic pressure of the formulation buffer, because the DAN-222 molecule has little effect on the osmotic pressure results. The specification range proposed is the typical osmotic pressure limit of drug substances and drug products with comparable buffer formulations.
[0575] The pH specification of DAN-222FBDS is: 4.3 ± 0.3. This pH specification was set based on a series of formulation development studies to determine the optimal pH for the stability of DAN-222FBDS. By design, free CPT is slowly released from DAN-222 as pH levels increase. Controlling the pH within the range of pH 4.3 ± 0.3 provides consistent stability for the handling and use of the dosage form and provides reasonable limits for the storage of drug substances and drug products. The proposed specifications are within the usual range for parenteral drug substances and drug products.
[0576] The endotoxin specification (≤6 endotoxin units (EU) / mg CPT) is based on USP <85> Permissible one-hour toxin exposure. The recommended endotoxin limit for parenteral products administered per patient surface area is 100 EU / m, where m is the maximum proposed dose per square meter in one hour. Asserting a higher than expected dose results in a value of 6.25 EU / mg CPT, which is rounded to a CPT of 6 EU / mg in the specification.
[0577] The specifications for bioburden limits for aerobic and anaerobic bacteria and yeasts and molds are based on USP <61> The specified values for each (≤10 colony forming units (CFU) / 10 mL) are set to demonstrate microbiological control of the process and to ensure that the potential microbial load is within the removal capacity of the filtration equipment when the final drug product is sterile filtered immediately prior to vial filling.
[0578] Example 6 - Method for manufacturing DAN-222 formulated bulk drug substance (FBDS)
[0579] The exemplary DAN-222FBDS manufacturing process consists of four major steps: (i) derivatization of camptothecin (CPT) to obtain Gly-CPT (trifluoroacetic acid (TFA) salt); (ii) synthesis of the parent mucin acid polymer (MAP); (iii) covalent attachment of the derivatized camptothecin to the parent polymer to obtain a solid amorphous MAP-Gly-CPT polymer-drug conjugate; and (iv) aqueous formulation of MAP-Gly-CPT to form nanoparticles (NPs).
[0580] Fig.35 A scheme of an exemplary method of manufacturing DAN-222FBDS is provided. Starting materials are indicated in the shaded box at the top of the drawing, and manufacturing steps performed under GMP conditions for a Phase 1 clinical trial drug substance are indicated in text or surrounded by a box 3401.
[0581] Step 1: Derivatization of camptothecin to obtain Gly-CPT
[0582] Fig.36 Derivatization of CPT to synthesize Gly-CPT is shown.
[0583] Gly-CPT is isolated as a TFA salt. All reactions and chemical workups were performed in glassware using equipment and techniques commonly used in synthetic chemistry procedures. The synthesis of Gly-CPT does not require specialized equipment or catalysts. Because both CPT and Gly-CPT are potent compounds, this synthetic process was managed under safe handling procedures consistent with good occupational safety practices.
[0584] Figures 37A-37BA schematic flow chart of the Gly-CPT synthesis process is provided, including control points. Fig.37A Start and Fig.37B Continue. A glass reactor was charged with dichloromethane (DCM) and 3 equivalents of N-(tert-butyloxycarbonyl)-Gly-OH (Boc-Gly) to achieve a Boc-Gly concentration of about 0.06 g Boc-Gly / mL. The solution was stirred for 5-10 minutes, 4-dimethylaminopyridine (DMAP; 2 equivalents) and 20(S)-camptothecin (CPT; 1 equivalent) were added, and the reaction mixture was stirred at 25-30°C for about 10 minutes. The reaction was cooled to 0-2°C, and 3 equivalents of diisopropylcarbodiimide (DIC) were slowly added, maintaining the temperature at 0-2°C. The reaction was warmed to 25-30°C and stirred for about 6 hours.
[0585] The reaction mixture is filtered through a Buchner funnel equipped with a filter cloth to remove any suspended solids, and the filter is washed with DCM (about 0.5x initial DCM volume, represented as V here). The filtrate containing the desired product is transferred to a new glass vessel, and extracted twice with water (each extraction is about 0.5x V). The organic layer is concentrated in vacuo on a rotary evaporator to remove 50-70% of the total starting volume. The distillate is transferred to a new vessel, and methanol (MeOH; about 0.6x V) is added to precipitate the intermediate product. The reaction is cooled to 5-10 ° C, and stirred at 5-10 ° C for about 1 hour. The reaction is filtered through a Buchner funnel equipped with a filter cloth, and washed with MeOH (about 0.2x V). The wet compound is distributed in a new vessel from the filter, isopropyl alcohol (IPA; about 0.5x V) is added, and the reaction is stirred for about 30 minutes. The reaction mixture is filtered through a Buchner funnel lined with a liner. The collected solid was washed with IPA (about 0.2 x V), dispensed from the filter, and dried under vacuum at ambient temperature for at least 4 hours to remove excess solvent. The purified Boc-Gly-CPT intermediate solid was stored at ambient temperature in a low density polyethylene (LDPE) bag contained in a secondary high density polyethylene (HDPE) container.
[0586] The desired intermediate Gly-CPT was obtained by deprotecting Boc-Gly-CPT using trifluoroacetic acid (TFA) as a deprotecting agent. DCM and Boc-Gly-CPT were charged to the reactor to achieve a Boc-Gly concentration of about 0.5 g Boc-Gly-CPT / mL. The reaction was stirred for 5-10 minutes. An equal volume of TFA was added and the reaction was stirred at 25-30°C for about 2 hours.
[0587] The reaction is cooled to 0-5°C, and about 1.5 times the volume of methyl tert-butyl ether (MTBE) is added, and the temperature is maintained at 0-5°C. The reaction is stirred at 0-5°C for about 30 minutes. The resulting suspension is filtered through a lined Buchner funnel under a nitrogen atmosphere, and the filter cake is washed with 2:1 MTBE:DCM mixture (about 2x volume for dissolving Boc-Gly-CPT, represented as V' here), and washed with MTBE (about 2x V'). The step is repeated with a slightly shorter stirring time, and the separated solid is dried under nitrogen for about 1 hour, and vacuum dried at ambient temperature for at least 4 hours to remove excess solvent. The purified glycylcamptothecin (TFA salt; Gly-CPT) solid is stored in a LDPE bag contained in a secondary HDPE container at ambient temperature.
[0588] In the initial manufacturing of Phase I, three batches of Gly-CPT-TFA were manufactured with batch sizes ranging from 145-150 g.
[0589] Step 2: Synthesis of the parent polymer MAP
[0590] Composed of MAM and diSPA-PEG 3500 MAP was prepared by copolymerization Fig.38 All reactions were performed in glassware using equipment and techniques commonly used in synthetic chemistry procedures. The synthesis of MAP does not require specialized equipment or catalysts, but care must be taken to exclude water from the reaction mixture to the extent practicable.
[0591] Fig.39 A schematic flow chart of the MAP synthesis process is provided, including control points. The reactor is charged with 1 equivalent of (succinimidyl propionate) 2PEG 3500 (diSPA-PEG 3500 ) and 1.07 equivalents of mucic acid monomer (MAM). The reactor was purged with argon and dimethyl sulfoxide (DMSO) was added to make diSPAPEG 3500 The concentration reached about 0.17 g diSPA-PEG 3500 / mL. Trifluoroacetic acid (TFA) (1.8 eq.) was added and the reaction was stirred for 10-15 minutes. N,N-diisopropylethylamine (DIPEA) (2.6 eq.) was added and the reaction was stirred at 21-23°C for about 3 hours. These parameters were designed to ensure that the resulting MAP molecular weight was within the target range (50,000-80,000 Da).
[0592] MAP was precipitated with isopropanol (IPA) (approximately 2x the total volume of DMSO). The reaction was cooled to 0±5°C. Approximately 5 volumes of IPA were added and the reaction was stirred at 0±5°C for approximately 50 minutes. The polymer was filtered through a Buchner funnel under an argon atmosphere, washed twice with IPA (approximately 3x the total volume of DMSO per wash), washed twice with ether (approximately 3x the total volume of DMSO per wash), dispensed from the filter into a pyrex drying dish, and vacuum dried at ambient temperature for at least 12 hours to remove excess solvent. The solid was stored at ≤-20°C in a 1000 mL wide-mouth glass bottle with an HDPE-lined cap.
[0593] For Phase I, MAP was manufactured in three batches under GMP conditions with an average isolated yield of about 185 g of copolymer.
[0594] Step 3: Synthesis of MAP-Gly-CPT amorphous polymer-drug conjugate
[0595] The MAP-Gly-CPT amorphous drug substance did not exhibit instability when exposed to typical laboratory lighting conditions. However, CPT is known to be photosensitive, so all manufacturing steps were performed in the presence of CPT with a red filter in place.
[0596] MAP was conjugated with Gly-CPT to synthesize MAP-Gly-CPT. Fig.40 MAP-Gly-CPT is isolated as an amorphous solid; when the amorphous MAP-Gly-CPT is reconstituted in an aqueous medium, nanoparticles (NPs) are formed. All reactions and chemical workups are performed in glassware or polymer disposable bags using equipment and techniques commonly used in synthetic chemistry procedures. The synthesis of amorphous MAP-Gly-CPT does not require special dedicated equipment or catalysts. Since CPT is a potent compound, the management of this synthetic process is carried out under safe handling procedures consistent with good occupational safety practices.
[0597] Figures 41A-41B A schematic flow chart of the synthesis of amorphous MAP-Gly-CPT is provided, including control points. Fig.41A Start and Fig.41B Continue. Charge the reactor with 1 equivalent of MAP and purge with argon. Add dimethyl sulfoxide (DMSO) to achieve a MAP concentration of about 0.01 g MAP / mL. Add glycylcamptothecin (TFA salt; Gly-CPT; 1.2 equivalents) and 2.2 equivalents of (7-azabenzotriazol-1-yloxy)tripyrrolidinephosphonium hexafluorophosphate (PyAOP), and stir the reaction for 5-10 minutes. Add N,N-diisopropylethylamine (DIPEA; 2.5 equivalents), and stir the reaction at 19-25°C for 16-22 hours.
[0598] The reaction was quenched by slowly adding cold water (prepared by water for injection (WFI), about 0.4x total volume of DMSO) of pH 3.0, and the reaction temperature was kept below 30°C. The reactor temperature was set to 10°C, and additional pH 3.0 cold water (about 2.6x total volume of DMSO) was loaded into the reactor and stirred for about 30 minutes. The solution was transferred to a stirred polymer tank system with a polyethylene film tank liner, and another 1x volume of pH 3.0 cold water was added. The total volume of the water added was intended to reduce the concentration of DMSO to about 20%, because the TFF membrane used for further purification is stable at this DMSO concentration. At this point, if immediate purification is not desired, the solution can be stored in a dark refrigerator.
[0599] The solution was purified by ultrafiltration / diafiltration using tangential flow filtration (TFF) technology. The process was performed using a SartoriusFlexAct system equipped with a Sartocon self-contained filter loop assembly equipped with a 10,000Da molecular weight cutoff TFF membrane. Alternatively, the FlexAct system can be operated using a single Sartocon Hydrosart box installed in a conventional TFF membrane rack. The process starts with an ultrafiltration phase, during which the total volume of the product solution is reduced by about half. At this point, water at pH 3.0 is diafiltered for at least eight times the diafiltration volume to significantly reduce the DMSO content and remove low molecular weight water-soluble impurities. When the diafiltration phase is completed, further ultrafiltration is performed to concentrate the solution to about 0.04 g / mL MAP-Gly-CPT. The concentrated solution was frozen and lyophilized for at least 48 hours to obtain a purified MAP-Gly-CPT drug substance intermediate as an amorphous solid. The solid was stored in a wide-mouth glass bottle with an HDPE lined cap at ≤-20°C.
[0600] If a failure occurs in the TFF membrane system that allows the MAP-Gly-CPT drug substance to enter the permeate collection vessel, there is an opportunity to reprocess the permeate. This is accomplished by installing a new TFF membrane unit and returning the product containing the permeate to the FlexAct system to concentrate the solution via ultrafiltration. After concentration is complete, additional diafiltration is performed against pH 3 water prior to concentration and lyophilization.
[0601] For Phase I, MAP-Gly-CPT was prepared in two batches of 250 g MAP each, with an average yield of approximately 250 g conjugate.
[0602] Step 4: Preparation of MAP-Gly-CPTNP solution (DAN-222)
[0603] Aqueous formulation of MAP-Gly-CPT (DAN-222 formulated bulk drug substance (FBDS)) as NP solution Fig.42 Shown in.
[0604] All steps were performed in glassware or polymer disposable bags using equipment and techniques commonly used in synthetic chemistry procedures. The preparation of MAP-Gly-CPT NP solutions does not require special dedicated equipment or catalysts. Since CPT is a potent compound, the preparation process is managed under safe handling procedures consistent with good occupational safety practices.
[0605] Figures 43A-43B A high-level flow chart of the DAN-222FBDS process is provided, including control points. Fig.43A Start and Fig.43B Continue. DAN-222FBDS is formulated in 20 mM acetate, 0.9% sodium chloride buffer (pH 4.3 ± 0.3). To achieve this buffer concentration, a 50 1 tray tank with mixer is charged with WFI and sufficient sodium chloride, sodium acetate, and glacial acetic acid to obtain a 10X concentrate of the desired final buffer.
[0606] The 100L reactor was washed with water and acetone and then heated at 120°C under a positive argon flow to sterilize the vessel. Solid amorphous MAP-Gly-CPT was charged into the reactor. Water for injection (WFI) adjusted to pH 4.0 with H3PO4 was added to bring the MAP-Gly-CPT concentration to approximately 0.005 g / mL MAP Gly-CTP, and the mixture was stirred for at least 12 hours. The MAP-Gly-CPT NP solution was transferred to a tank equipped with a polypropylene tank liner through a pipe equipped with a 0.45 μm filter. The 100L reactor was thoroughly rinsed and the NP solution was returned to the reactor and stirred. The volume of the NP solution in the reactor was measured and the appropriate volume of 10X formulation buffer was calculated and slowly added to the reactor to avoid splashing. The resulting solution was stirred for 2-3 hours and transferred to a HDPE tank equipped with a polypropylene tank liner.
[0607] The calculated concentration of MAP-Gly-CPT in the tank was determined by adjusting the total charge of amorphous MAP-Gly-CPT with the residual solvent value obtained from this material. This calculation provides the target weight of permeate to be removed during the ultrafiltration concentration process. A Sartorius Flex-Act system was used, equipped with a Sartocube ECO tangential flow filtration cassette with a 10,000Da MW cutoff. The solution was concentrated by ultrafiltration until the target weight of the permeate was reached. The retentate was transferred to a 20L Flexboy bag, sampled for process control (MAP-Gly-CPT concentration), and stored at 2-8°C until the analysis was completed. The target concentration range for the DAN-222FBDS was 17-23mg / mL MAP-Gly-CPT. If this range was reached, the solution in the 20L Flexboy bag would be ready for sterile filtration, sampling, and bottling in an FBDS container. If the concentration was too low, the solution was returned for further ultrafiltration, and the measured volume and concentration were used to calculate the additional amount of permeate to be removed. If the concentration is found to be above the specified range, calculate and add the appropriate amount of 1X Formulation Buffer and gently shake the container to blend.
[0608] Transfer DAN-222FBDS to a storage container in a biological safety cabinet (BSC) to improve microbial control. Use a MasterFlex pump and a 0.22 μm Sartopore 2 The sterile tubing set of the filter transfers the solution to a sterile 4L HDPE bottle. After sampling for release, stability and retention purposes, the 4L bottle is filled. Before filling each bottle, two to three 5mL samples are dispensed into sterile Falcon tubes, two of which serve as satellite samples for each bottle. After this sampling, each tared bottle is filled with approximately 3L of solution, capped, tightly sealed and weighed to obtain the net weight of the contents. Label all FBDS containers containing samples.
[0609] Store DAN-222FBDS containers at a controlled temperature of ≤ -70°C, except for samples that require immediate analysis.
[0610] For Phase I, DAN-222FBDS was produced as a single batch with a batch size of 400 g amorphous MAP-Gly-CPT. The resulting formulation provided 17.4 kg (17.4 L) of DAN-222FBDS for further use and 751 mL of DAN-222FBDS as a sample for release, stability, and as a satellite sample for characterization at the drug filling site.
[0611] Example 7 - Improvements in Manufacturing DAN-222 Formulated Bulk Drug Substance (FBDS)
[0612] From initial development to the exemplary method outlined in Example 6, the GMP manufacturing process development of DAN-222 formulated bulk drug substance (FBDS) has progressed and improved. The current process consists of four GMP steps. First, 20(S)-camptothecin (CPT) is derivatized (Gly-CPT) by attaching glycine to the 20 hydroxyl groups of CPT. Second, the parent mucin polymer (MAP) is synthesized by polymerization of comonomer mucin monomer (MAM) and (succinimidyl propionate) 2PEG (diSPA-PEG). In the third step, the derivatized CPT is covalently bound to the parent polymer to obtain a MAP-Gly-CPT amorphous polymer-drug conjugate. Finally, the conjugate is formulated in an aqueous medium to form a nanoparticle (NP) solution.
[0613] After the initial process to produce DAN-222(FBDS) was validated, process development work continued. This ongoing development provided process development, scale-up, and manufacturing of DAN-222FBDS for IND-enabling studies and Phase 1 clinical studies.
[0614] Step 1: Derivatization of Camptothecin to Gly-CPT-Development
[0615] The production of derivatized CPT is a two-step process in which the hydroxyl group of CPT is esterified with a tert-butyloxycarbonyl-protected glycine linker (Boc-Gly), followed by removal of the Boc protecting group and isolation to afford glycine-linked CPT (Gly-CPT) as a trifluoroacetic acid (TFA) salt.
[0616] The initial process for step 1 involves dissolving CPT, Boc-Gly, and 4-dimethylaminopyridine (DMAP) in dichloromethane (DCM). The reaction is initiated by adding diisopropylcarbodiimide (DIC), and the intermediate is isolated by precipitation with methanol (MeOH). To remove the Boc group, the intermediate is stirred with a mixture of trifluoroacetic acid (TFA) and DCM. The Gly-CPT product is isolated by precipitation with methyl tert-butyl ether (MTBE) as a TFA salt. During early development, Gly-CPT was synthesized on a research scale of approximately one gram per synthesis.
[0617] The development process resulted in changes in the synthesis and isolation procedures, primarily related to optimizing solvent volumes and reaction temperatures at the initial GMP scale. Although the quantities of this highly potent intermediate required for initial clinical studies were relatively low, after continued development, including a 10 gram synthesis, it was decided to implement an approximately 15-fold scale-up of the synthesis (150x relative to research scale) for initial GMP production.
[0618] During the development of step 1, several modifications were made to the process to make it more robust, scalable, safe, and / or reduce impurity levels. A summary of these changes is provided in Table 7. These changes mainly involved reaction concentrations and solvent volumes, reaction temperatures, and some additional steps to improve intermediate purity.
[0619]
[0620]
[0621] For the Boc-Gly-CPT synthesis step, the relative ratios of the reactants remained the same, but it was found that the reaction proceeded more smoothly when run under more dilute conditions and at higher reaction temperatures. A new water extraction step was added to improve the removal of process impurities. While DCM was removed to provide a crude solid in earlier syntheses, a vacuum distillation was performed to remove only 95% of the DCM volume, and a significantly lower proportion of methanol was added to allow the final precipitation to be performed at a higher temperature. An additional wash with isopropyl alcohol (IPA) was found to improve separation performance.
[0622] For the deprotection and isolation of Gly-CPT, the same reagent ratios were used as in the previous synthesis. However, in the subsequent precipitation step, a significantly lower volume of methyl tert-butyl ether (MTBE) was used, and the filter cake was subsequently washed with a MTBE:DCM mixture with a lower MTBE:DCM ratio.
[0623] During the development of the release analysis method for the Gly-CPT intermediate, it was found that vacuum drying did not reduce the level of residual MTBE, indicating that the intermediate crystallized in the form of a solvate. 1 H-NMR analysis of a previous synthesis of Gly-CPT used in development determined that significant levels of MTBE were also present in that batch.
[0624] It was also determined that even with the presence of desiccants (magnesium sulfate and sodium sulfate) and azeotropic distillation under mild conditions, residual water could not be completely removed from the final product. In each case, the conditions resulted in degradation of the glycerides. Given that the subsequent conjugation of Gly-CPT to MAP is sensitive to the presence of excess water, future process development for this step will include methods to reduce or eliminate the presence of water in the intermediate product.
[0625] Step 2: Synthesis of the parent polymer MAP - Development
[0626] The parent polymer, i.e., mucic acid polymer (MAP), is produced by the step-growth polymerization of two comonomers, MAM and diSPA-PEG, a linear PEG molecule with a succinimide-activated propionyl ester at each end. The comonomers are dissolved in dimethyl sulfoxide (DMSO), and the reaction is initiated by the addition of N,N-diisopropylethylamine (DIPEA), thereby initiating the amidation of the free amines at each end of the MAM monomer. When the MAP molecular weight (MW) is expected to reach or approach the target, the reaction is quenched with water, and the MAP is separated from the DMSO and water by dialysis and then lyophilized.
[0627] The initial process was aimed at controlling the reaction kinetics and achieving near-stationary polymer MW over time. While conditions for producing MAP can be determined to produce approximately linear growth of MW over time, this strategy requires precise in-process monitoring of MW and reaction quenching. Alternatively, given that polymerization has been shown to follow a known model of stepwise growth of polymers, a strategy to stall the reaction over time was developed based on polymerization theory (modified Carothers equation and Flory-Shulz distribution). This strategy achieves growth stationarity by exploiting the stoichiometric imbalance of the comonomers and slows the reaction as the MAP approaches the target MW. Fig.44 An example polymerization in which the MW of MAP at a late time point is controlled by the stoichiometric ratio of MAM to diSPA-PEG in the reaction mixture is shown.
[0628] like Fig.44 As shown, using the stationary growth strategy, an increase in the MAM:diSPA-PEG ratio leads to polymers with lower MW.
[0629] Based on the above observations, it is desirable that the monomer starting materials be prepared with a high degree of functionalization as specified herein and that the reaction be carried out under anhydrous conditions to maintain the stability of the activated SPA groups on diSPA-PEG in order to prevent early termination of the amidation reaction, thereby allowing the stoichiometric ratio of the comonomers to be well controlled at or near the target.
[0630] During the development of step 2, several modifications were made to the process to make it more robust, scalable, safe, and / or reduce impurity levels. These modifications included: (i) using MAM as its diTFA salt instead of its neutral form; (ii) stoichiometric ratios of MAM, diSPA-PEG, TFA, and DIPEA; and (iii) using dialysis instead of precipitation for purification.
[0631] Early development batches of MAP were made using MAM starting material that was intended to be isolated as the diTFA salt. Subsequently, it was discovered that isolating MAM with a consistent amount of the counterion TFA was difficult. Analysis of the first few MAM development batches showed that the TFA:MAM equivalents varied from batch to batch by as much as ~25% (e.g., 1.5:1 actual value vs. 2:1 target value). Given the sensitivity to the comonomer ratios noted above, this variability could result in significant inaccuracies in the amount of MAM added to the reaction, and thus significant variability in the resulting polymer MW. In order to reduce the potential variability, the decision was made to isolate MAM as a neutral species (lacking the TFA counterion) and allow for more precise addition of TFA as a subsequent reaction step prior to polymerization. Fig.45 The chemical structures of the MAM starting materials are provided for comparison.
[0632] Reactions were performed using isolated MAM as either a diTFA salt or a neutral species (only trace amounts of TFA were isolated) to study the effect of the presence or absence of TFA in the monomer starting material on the reaction behavior. Although the TFA group does not participate in the actual polymerization reaction, it was found that it significantly increases the solubility of the MAM in DMSO and therefore affects the reaction kinetics. Unlike diTFA salts, which are usually soluble in DMSO, the neutral species was found to have the lowest solubility in DMSO. Despite its poor solubility, studies on the polymerization of neutral species with diSPA-PEG have shown that the reaction proceeds without the addition of TFA, although the reaction generally exhibits linear kinetics regardless of the comonomer ratio. In contrast, the polymerization of neutral species with diSPA-PEG is approximately 1-2 eq. Adding TFA to the reaction before initiation with DIPEA results in the expected restoration of smooth behavior.
[0633] Based on the results obtained from preliminary experiments, it was decided to develop reaction conditions with isolated MAM as the neutral species and subsequently add TFA to level out the polymer MW at or near the target.
[0634] During early development work on the new MAM monomer and subsequent addition of TFA, several small-scale (~250 mg diSPA-PEG) screening reactions were performed to identify conditions that would allow MAP polymerization to achieve the desired plateau behavior. Results from two sets (Screen 1 and Screen 2) of many experiments are provided as examples to demonstrate the key learnings that guided the final selection of reaction conditions.
[0635] An initial set of experiments (Screen 1) were performed to investigate the combined effects of different comonomer ratios and TFA and DIPEA equivalents on the reaction kinetics. Fig.46 The reaction conditions investigated in Screen 1 are provided in the lower portion of the table, with italic entries highlighting different conditions. The MW values of MAP using the conditions specified in Screen 1 are also shown in Fig.46 In the upper part.
[0636] like Fig.46 The results shown indicate that a decrease in the amount of DIPEA (approximately 2.5 equivalents) resulted in a decrease in the reaction kinetics. As expected, a decrease in the MAM:diSPA-PEG ratio to 1:1 resulted in an increase in MW. Additionally, it was found that an increase in TFA resulted in a steady improvement in MW. The combined results of the initial screening indicated that the comonomer ratio, equivalents of TFA and DIPEA, and reaction time were sufficient to achieve the targeted MAP polymerization, with Reaction 1-B exhibiting good behavior.
[0637] Based on the above observations, a second set of conditions (Screen 2) was evaluated to further explore the effects of TFA and DIPEA levels on the reaction kinetics at slightly reduced comonomer ratios and to optimize the conditions. Fig.47 The reaction conditions investigated in Screen 2 are provided in the lower portion of the table, with italic entries highlighting different conditions. The MW values for MAP using the conditions specified in Screen 2 are shown in Fig.47 In the upper part.
[0638] like Fig.47 As shown in the results of , it was found that a small decrease in the comonomer ratio resulted in a modest increase in MW. Additionally, an increase in TFA concentration again resulted in an improvement in reaction plateau, while a decrease in DIPEA concentration resulted in a decrease in reaction kinetics. As a result of Screen 2, conditions for a small-scale polymerization were identified (Reaction 2-C) that allowed the MW to plateau and provided MAP with a MW in the target range of 50,000-80,000 Da over a wide time window.
[0639] The MW dependence on comonomer ratio and TFA and DIPEA equivalents was replicated on a 1 g scale, giving similar trends, but a slight decrease in kinetics was observed for all reactions. This behavior may be due to the slightly less stringent anhydrous conditions under which the reactions were performed. Therefore, a modest increase in DIPEA in the scaled-up reactions (2.6 vs. 2.5 equiv.) was evaluated and provided similar kinetics to those observed in the small-scale experiments.
[0640] It was decided to change the purification process from dialysis and lyophilization to precipitation to reduce processing time and eliminate the need for large buffer volumes and long processing times during MAP isolation. During MAP production development, it was observed that large volumes of dialysis media and long drying time periods on the lyophilizer were required to isolate the polymer as a solid. It was anticipated that with scale-up, it would likely be necessary to increase volume requirements, extend processing times, and / or develop a tangential flow filtration (TFF) method.
[0641] To mitigate these process risks, the feasibility of isolating MAP as a solid by precipitation was evaluated to eliminate the need for dialysis and lyophilization during scale-up and save significant process time. Precipitation from DMSO was performed by adding several antisolvents. Of the various solvents evaluated, isopropyl alcohol (IPA) was found to be promising. Precipitation of the polymer by adding IPA directly to the polymerization reaction mixture was also attempted and found to work equally well. MW analysis of the precipitated and dialyzed MAP showed comparable chromatograms and the resulting MW and PDI. Additionally, the precipitated MAP 1 H-NMR analysis showed very low levels of impurities (<0.1 mass %). However, vacuum filtration of precipitated MAP in ambient atmosphere produced a sticky solid material that was difficult to remove from the filter. Filtration under a nitrogen or argon head avoided this behavior and resulted in a fairly dry solid that could be easily transferred from the filter for further drying.
[0642] Based on the above observations, it was decided to continue with the IPA precipitation procedure, including the use of an argon head during filtration, in order to isolate MAP in subsequent scale-up and GMP batches.
[0643] Following process development, scale-up reactions were performed to confirm the optimized reaction conditions and resulting reaction kinetics. As previously mentioned, DIPEA was slightly increased for scale-up relative to the conditions developed during the development batch production. Additionally, the slight to complete plateau at the upper molecular weight limit of MAP (80,000 Da) rather than the midpoint (65,000 Da) provided a wide (several hours) window for quenching and eliminated the risk of falling below the desired MW.
[0644] The scaled-up reaction was performed at 5 g and 50 g using previously identified conditions (1.07:1 MAM:diSPA-PEG, 1.8 eq TFA, 2.6 eq DIPEA). Three development runs were performed on the 5 g scale and allowed to proceed for 5 hours to monitor the long reaction time process. These three repeated runs showed good reproducibility and favorable reaction kinetics and informed that the reaction reached the target quenching in approximately 3.5 hours to achieve the final MAP MW within the target MW range. A 50 g scale reaction was also performed to support GMP manufacturing, where it was quenched within 3.5 hours by adding IPA. As expected, the large-scale reaction proceeded with similar kinetics and resulted in a MAP MW within the target range. In addition, the reaction mixture was directly precipitated by slowly adding IPA to obtain a polymer in the form of a white precipitate, which was successfully separated and dried by filtration under an argon atmosphere to obtain a solid.
[0645] Fig.48MW data for the scaled-up MAP reaction are provided in. GMP manufacturing was performed as described in Example 6 at 165 g (approximately a 3-fold scale-up of 50 g).
[0646] Step 3: Synthesis and development of MAP-Gly-CPT amorphous polymer-drug conjugates
[0647] Production of the polymer-drug conjugate MAP-Gly-CPT involves the reaction of a carboxylic acid on the parent MAP polymer with a derivatized CPT amine to form an amide bond. The initial process utilized EDC / NHS chemistry for this covalent coupling according to the conditions described in Table 8, where the reaction dilutions are indicated in italics.
[0648]
[0649] MAP was dissolved in DMSO, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS), and Gly-CPT were added. The reaction was initiated by adding DIPEA. After the reaction was completed, MAP-Gly-CPT was isolated by dialysis with DMSO and water at pH 3.0, and then lyophilized.
[0650] During the development of step 3, several modifications were made to the process to make it more robust, scalable, safe and / or reduce impurity levels. The first was the use of EDC / NHS with PyAOP-based conjugation. The second was the use of dialysis with TFF purification.
[0651] Early development batches of MAP-Gly-CPT were made using EDC / NHS coupling chemistry, which required a modest (2- to 3-fold) excess of Gly-CPT starting material and reagents to achieve the desired drug loading level. It was found that large volumes of dialysis media and long processing times were required to adequately remove unreacted starting material and other impurities from the product.
[0652] In order to reduce the excess of starting materials and reagents in the reaction, especially the excess of Gly-CPT, the use of the more reactive (7-azabenzotriazol-1-yloxy)tripyrrolidinephosphonium hexafluorophosphate (PyAOP) coupling reagent was evaluated for the preparation of MAP-Gly-CPT. Given its increased reactivity, it is expected that PyAOP will allow for higher coupling efficiencies, thereby reducing the level of Gly-CPT in the reaction relative to the previous EDC / NHS route.
[0653] An initial set of reactions were performed to investigate the coupling efficiency with PyAOP over a range of Gly-CPT equivalents added to the reactions. As expected, near quantitative grafting efficiencies (>80%) were achieved, defined as the efficiency with which Gly-CPT was incorporated into the MAP-Gly-CPT conjugate material under all conditions. In addition to the high coupling efficiencies, the drug loading levels achieved were linear with the Gly-CPT equivalents added to the reactions, indicating that drug loading was significantly controlled during this process step. Table 9 provides the equivalents (eq.) of Gly-CPT as well as the resulting CPT weight % (wt. %) and grafting efficiency % for representative conjugation reactions.
[0654]
[0655] The linear relationship between grafting efficiency and Fig.49 The data of samples AF provided in the table are Fig.49 The results shown match.
[0656] However, later development batches occasionally presented unexpected observations related to the reaction itself and / or NPs from the PyAOP-coupled conjugate material. In one experiment, NPs formed from PyAOP-coupled MAP-Gly-CPT had a diameter larger than the typical diameter (approximately 70 nm) that were also difficult to filter. In another attempt, gel formation was observed during the reaction. It was hypothesized that the cross-linked conjugate material may have been formed by reaction of the MAP polymer amine end groups with activated carboxylic acid groups on other polymer chains, resulting in atypical high molecular weight species (HMWS). Preliminary evaluations appeared to confirm this phenomenon, but the observations have not been explored in detail. Additional modifications to the process were made to enable PyAOP to be used for Gly-CPT conjugation.
[0657] In order to minimize the process risk of HMWS formation, it was decided to target high drug loading levels to minimize the number of unreacted carboxylic acid groups. The reactions were also modified to be performed at increased dilution, which is known to significantly reduce the availability of polymer chain end groups to participate in the reaction. Additional development reactions were performed at increasing dilutions with 1.0, 1.1, and 1.2 equivalents of Gly-CPT at 2.5 and 4 g scales. All reactions performed well under the modified reaction conditions and showed no evidence of HMWS formation. It was concluded that these changes were sufficient to minimize the formation of HMWS.
[0658] Table 10 provides a comparison of the initial and subsequently modified reaction conditions for PyAOP-based conjugations, with reaction dilutions indicated in italics.
[0659]
[0660] Based on the above observations, it was decided to continue with the modified PyAOP-based conjugation procedure in subsequent scale-up and GMP batches to reduce the excess of starting materials and reagents and to reduce the buffer volume and processing time required during conjugate purification.
[0661] The decision to change the purification process from dialysis to ultrafiltration / diafiltration via TFF was based on volume requirements and practicality. Scaled-up versions of dialysis require longer processing times and large volumes of solution and are generally impractical at the scale required for GMP batches. Precipitation was also evaluated with several antisolvents, but no promising antisolvents were initially found. Instead, efforts were focused on developing a TFF process to purify the conjugate. It was determined that polyethersulfone (PESU) TFF membranes were compatible with aqueous solutions containing up to 10% DMSO, so it was decided to dilute the reaction mixture 10-fold with water at pH 3.0 before performing TFF. (Subsequently, it was determined that PESU membranes were resistant to water containing up to 20% DMSO, and the dilution was reduced accordingly for GMP manufacturing.) Several of the 4 g MAP-Gly-CPT batches were subjected to TFF using scaled-down TFF membranes and cartridges comparable to those used in the scaled-up GMP configuration. It was determined that 8-fold diafiltration volume was sufficient to reduce DMSO and impurities to acceptable levels.
[0662] Based on the above observations, it was decided to perform TFF purification in subsequent scale-up and GMP batches to isolate MAP-Gly-CPT.
[0663] After process development, scale-up reactions were performed to confirm the modified reaction conditions and purification methods. Two scale-up reactions were performed at a scale of 25 g using previously determined conditions (1.2 equivalents of Gly-CPT, 2.2 equivalents of PyAOP, 2.5 equivalents of DIPEA, 100 mL of DMSO / g MAP) to support GMP manufacturing. These repeated runs showed good reproducibility and achieved drug loading within the target range for MAP-Gly-CPT. In addition, TFF purification showed performance comparable to the development run, such that after 8 diafiltration volumes of pH 3.0 water, DMSO and impurity levels were sufficiently low. Solid conjugates were successfully isolated by lyophilization.
[0664] GMP manufacturing was performed at 250 g as described in Example 6, with a standard scale-up of 25 g.
[0665] Step 4: Preparation of MAP-Gly-CPTNP solution (DAN-222)
[0666] The preparation of MAP-Gly-CPT NPs requires dissolving the amorphous polymer-drug conjugate in an aqueous medium, whereby the hydrophobicity of CPT promotes the self-assembly of the conjugate into NPs. The process initially developed involved dissolving the MAP-Gly-CPT amorphous material in water at pH 4.0, adding concentrated saline (9% NaCl, pH 4.0), concentrating using a centrifugal ultrafiltration device, and sterile filtering at 0.22 microns.
[0667] During the development of step 4, several modifications were made to the process to make it more robust, scalable, safe, and / or reduce impurity levels, including: (i) concentrated formulation buffer exchange; (ii) use of centrifugal ultrafiltration instead of TFF concentration; and (iii) adjustment of the filtration step.
[0668] Although MAP-Gly-CPT Np exhibited good stability in unbuffered saline solution (0.9% NaCl, pH 4.0), FBDS is sensitive to pH; and a robust drug formulation requires a buffer system to prevent pH drift and degradation during storage. In order to support GLP toxicology studies and subsequent preparations, based on the previously described formulation development work, it was decided to switch from adding concentrated saline to adding concentrated formulation buffer (200mM sodium acetate, 2M NaCl, pH 4.16). The resulting target DP formulation of MAP-Gly-CPT NPs was 20mM sodium acetate, 200mM NaCl, pH 4.3±0.3. After the formulation buffer was changed, no effect on particle properties (e.g., size, zeta potential, filterability) was observed, and FBDS showed sufficient stability in terms of stability during process and use.
[0669] The decision to change the concentration process from centrifugal ultrafiltration to TFF ultrafiltration was based on practicality. Scaled-up versions of centrifugal ultrafiltration require longer processing times and are generally not feasible to perform at the scale required for our GMP batches. Several of the 4 g MAP-Gly-CPT NP batches were subjected to TFF, again using the same membrane and cartridge types as used in the scaled-up GMP configuration. Concentration by TFF produced the target MAP-Gly-CPT concentrations with no effect on particle properties.
[0670] Based on the above observations, it was decided to continue TFF concentration in subsequent development, scale-up, and GMP batches to prepare MAP-Gly-CPT NPs.
[0671] The decision was made to change the filtration process from a single final sterile filtration at the end of FBDS production to an intermediate conditioning filtration step to achieve a seamless and risk-free final sterile filtration. During the development and production of FBDS, it was observed that the final sterile filtration process was often difficult and often required multiple sterile filters to complete the filtration.
[0672] To mitigate this process risk, a 0.45 micron filtration step is used to condition the material and remove some product-related particles after dissolving the MAP-Gly-CPT amorphous material in water at pH 4.0. After subsequent spiking with concentrated formulation buffer and a TFF step to formulate and concentrate the FBDS, a final 0.22 micron sterile filtration can be performed without the risk of extended filtration time. Formulations involving this conditioning filtration step can achieve a relatively simple and rapid final sterile filtration.
[0673] Based on the above observations, it was decided to proceed with the conditioning filtration step in subsequent scale-up and GMP batches to prepare MAP-Gly-CPT NPs.
[0674] Following process development, scale-up formulations were performed to confirm the optimized approach. Using the scaled-up conjugate material described above, two scale-up formulations of MAP-Gly-CPT NPs were performed at a 25 g scale to support GMP manufacturing. Dissolution, formulation, and subsequent concentration by TFF showed comparable performance to the development runs, achieving target levels of formulation components and MAP-Gly-CPT concentrations. In addition, the final sterile filtration was good.
[0675] GMP manufacturing was performed as described above at 400 g (16-fold scale-up of 25 g). This scale-up, slightly above the typical process scale, was assessed as low risk, as the formation of MAP-Gly-CPT NPs has been shown to be consistent and reproducible at various scales.
[0676] Batch 21-M007 is the first batch of DAN-222FBDS manufactured under GMP conditions as Phase I clinical trial material. This batch was manufactured according to the initial manufacturing process described in Example 6. Fig.50 Manufacturing differences between this batch and the batches used in the dose-ranging (Batch SKT-757-077-NPS) and toxicology (Batch SKT-874-031-NPS) studies are summarized.
[0677] The major differences concern the type of monomer and isolation method used for MAP, the coupling agent and purification method used to synthesize MAP-Gly-CPT, and finally the formulation buffer and concentration and filtration methods used for MAP-Gly-CPTNP (DAN-222FBDS). Analytical data from these batches demonstrate that the quality of GMP DAN-222FBDS and DAN-222 drug product is comparable to that used in IND-enabling toxicology studies.
[0678] Example 8 - Sterile Solution of DAN-222 for Infusion and Drug Development
[0679] DAN-222 sterile solution for infusion is supplied as a clear to slightly opalescent, colorless to pale yellow solution. The drug product is stored frozen at -20±5°C and thawed prior to administration.
[0680] The sterile solution of DAN-222 for infusion is delivered in the form of a nanoparticle construct consisting of a hydrophilic polymer backbone conjugated to multiple units of the active moiety 20(S)-camptothecin via a glycyl linker. When dissolved in an aqueous medium, this polymer conjugate spontaneously forms nanoparticles consisting of a hydrophobic active moiety surrounded by a hydrophilic polymer. When administered, 20(S)-camptothecin is slowly released from the nanoparticle construct.
[0681] According to the above formulation screening process, a DAN-222 sterile solution for infusion was selected. The DAN-222 sterile solution for infusion is available in a single strength, wherein the target concentration of DAN-222 is 20±3 mg / mL. At this concentration, the DAN-222 sterile solution for infusion delivers 2.6±0.3 mg / mL of 20(S)-camptothecin active ingredient, and its dosage is based on the active ingredient.
[0682] The composition of the DAN-222 sterile solution for infusion is provided in Table 11.
[0683]
[0684]
[0685] Administration of the sterile solution of DAN-222 for infusion does not require reconstitution and does not provide a reconstitution diluent.
[0686] The physicochemical properties of the DAN-222 drug substance require that it be delivered in the form of a parenteral solution. Therefore, drug development focused on creating a drug product formulation for intravenous infusion. The formulation must meet several criteria: sterility; acceptable stability during drug substance and drug product manufacturing; acceptable stability for long-term storage; and acceptable stability during handling and administration. Since the formation of DAN-222 nanoparticles requires an aqueous solution, formulation design focuses on identifying excipients that can provide both isotonicity and stability within the desired pH range (e.g., buffered pH).
[0687] The use of anhydrous sodium acetate and acetic acid at appropriate concentrations (6.8 mM and 13.2 mM) is critical to controlling the pH of the drug product. These excipients were selected for their ability to buffer the formulation within a pH range that is beneficial to product stability, their ability to maintain a consistent pH over a wide temperature range, and their common use in drug products. These excipients were selected for use based on data obtained in formulation development screening studies of multiple buffer systems, which were described in the previous Examples.
[0688] The combined concentration of this acetate buffer system was 20 mM, a commonly used composition in the pharmaceutical industry. The target pH for the corresponding concentrations of each excipient was 4.3, which provided acceptable stability for the drug as demonstrated in formulation development studies.
[0689] Sodium chloride at 200 mM was used as a tonicity agent in the formulation to prevent the solution from being hypotonic. Infusion of hypotonic solutions can cause pain and safety issues during delivery. Sodium chloride was also chosen as it is a common excipient in the pharmaceutical industry. It was also observed in the formulation screening study that the presence of sodium chloride seemed to provide additional stability to the formulated product.
[0690] During the manufacturing process of the DAN-222 drug substance, trace amounts of phosphoric acid are used for pH adjustment of the nanoparticle solution to provide a low pH environment that is beneficial to the stability of DAN-222 in solution. The concentration of the acetate buffer is designed to give a final pH of 4.3 when added to the slightly more acidic aqueous solution during the final formulation process.
[0691] The DAN-222 drug substance solution is fully compounded into the DAN-222 formulated bulk drug substance (FBDS) at the time of manufacturing. Therefore, the composition of the DAN-222 drug solution in the vial is identical to the composition of the DAN-222FBDS. This drug product manufacturing method is intended to minimize the amount of handling and associated product risks associated with additional compounding or blending activities at the drug product vial filling site. This method also provides a stable formulation for storage and handling of the DAN-222FBDS prior to filling.
[0692] The physicochemical properties of DAN-222 drug substance are the same as those of the drug substance and are discussed in detail in the previous examples. Additional properties are detailed below.
[0693] Compatibility
[0694] The formulation stability studies were conducted in a vial / stopper configuration comparable to that selected for the GMP drug product. There was no evidence of incompatibility or material loss with these surfaces during the development of DAN-222. In addition, these studies provided evidence of the suitability of these vials during frozen long-term storage at -20 ± 5 °C. From a practical standpoint, the use of sterile filled glass vials with rubber stoppers and crimp cap closures is the standard packaging configuration in pharmaceutical manufacturing. Packaging and shipping considerations for liquid-filled vials are well-established and easily configured.
[0695] All polymer components used to manufacture sterile solutions of DAN-222 for infusion are pharmaceutical grade and have been qualified for use in parenteral filling operations.
[0696] The compatibility of development batches representing the DAN-222 drug product was also evaluated by challenging with various clinically administered components. The DAN-222 drug formulation was found to be compatible with various clinically administered components and dose preparation procedures. DAN-222FBDS batch SKT-757-077-NPS (a development batch used for dose range discovery animal studies) was reformulated by dialysis to match the Phase 1 clinical formulation of the drug product. This reformulated drug substance was filled into Type 1 borosilicate glass vials with rubber stoppers to replicate the clinical drug product container closure system. A syringe with a needle was used to remove the drug from the vial for injection into an IV bag.
[0697] The compatibility of the drug products was evaluated using commercially available 100 mL IV bags containing either 0.9% (w / v) saline or 5% (w / w) dextrose. The IV bag materials evaluated were polyvinyl chloride (PVC), polyolefin (PO), and polyethylene-polypropylene (PE-PP). Each diluent and bag material combination used an IV administration device with a 0.22-μm PES (polyethersulfone) in-line filter. According to the clinical protocol, the drug products were added to the IV bags to achieve CPT concentrations of 0.022 mg / mL (low dose) and 0.400 mg / mL (high dose) in the IV bags, thereby covering the planned range of IV clinical dose concentrations that could be observed in the IV bags (0.025-0.36 mg / mL). The high-dose configuration requires the use of more than one vial of drug per IV bag.
[0698] For clinical compatibility testing, the drug product was injected into each test bag using a 25-gauge, 1 / 2-inch needle and a silicone-free syringe. The bags were placed on a laboratory cart and pushed around the laboratory for 0.5 hours to represent the transportation of IV bags from the clinical pharmacy preparation site to the patient for administration. The drug products were sequentially stored in the IV bags under stagnant conditions for 12 hours at ambient room temperature (approximately 22-26°C), which represents the worst-case shelf life. The total amount of time the product was stored in the IV bag prior to simulated infusion was 12.5 hours (0.5 hour shipping simulation, plus 12 hours stagnant storage). The IV bags were protected from light during the entire process.
[0699] Samples were collected with a 25G needle after passing through the IV administration set. In-process sample collection was performed using a syringe through the IV bag port site and discharged through a 25-gauge needle. For informational purposes, IV bag port samples were obtained and analyzed only immediately after: injection of DP into the bag; after a 0.5-hour transport event; and after the subsequent 12 hours, stored in the IV bag before simulated infusion. Samples were analyzed for visual appearance (looking for visible particles), CPT concentration (by comparing the actual CPT concentration with the calculated theoretical CPT concentration to determine possible adsorption to the IV bag and administration set), % free CPT relative to total CPT (purity), sub-visible particles (HIAC), particle size, polydispersity index, pH, and osmotic pressure.
[0700] Results of IV bag administration at low dose (0.022 mg / mL) were Fig.51 , and the results for the high dose (0.400 mg / mL) form are provided in Fig.52 These results demonstrate that the drug product is stable under the conditions tested and recoverable after simulated infusion via the administration device after a 0.5-hour delivery simulation and a 12-hour shelf life. All samples demonstrated acceptable levels of product adsorption, with 90-110% of the theoretical target CPT concentration retained in solution over the course of the study. Based on these results, the compatibility studies support the use of the drug product as specified in the clinical protocol.
[0701] The drug product will be injected into the IV bag using a silicone-free syringe, and an IV administration set with a 0.22 μm filter will be used during the clinical study to match the compatibility study conditions. Acceptable IV bag diluents determined in the study are 0.9% (w / v) saline and 5% (w / w) dextrose. 100 mL IV bags are specified; acceptable IV bag construction materials are PVC, PO, and PE-PP. The maximum allowable drug product storage time for product compatibility in IV bags is 12.5 hours at room temperature.
[0702] Microbial properties
[0703] DAN-222 sterile solution for infusion is provided in Type 1 borosilicate glass vials with chlorobutyl rubber stoppers and aluminum crimp caps. Each vial is single-use and no preservatives are added to the formulation.
[0704] DAN-222 is unstable to high temperature terminal sterilization. The polyethylene glycol component of MAP is likely to undergo free radical degradation if subjected to sterilizing levels of gamma radiation. Therefore, sterile filtration provides microbiological safety of the drug substance and drug product. DAN-222FBDS is passed through a 0.22 μm filter and then transferred to sterile HDPE bottles for storage. Sterility of the drug product is achieved by passing the FBDS through two 0.22 μm sterilizing filters in series before filling the vials under aseptic conditions.
[0705] To ensure continued freedom from microbial contamination, selected container closure systems were subjected to container closure integrity qualification testing (CCIT). The CCIT performed by deterministic vacuum decay analysis was designated as the stabilization time point at the end of the study.
[0706] Example 9 - DAN-222 Dose Escalation Study of Safety and Pharmacology of DAN-222 in Subjects with Metastatic Breast Cancer
[0707] This example provides a protocol for a dose escalation study of the safety and pharmacology of DAN-222 in subjects with metastatic breast cancer using DAN-222. This study investigated the use of DAN-222 in subjects with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC).
[0708] This is an open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of DAN-222 administered intravenously (IV) followed by escalating doses of DAN-222 in combination with niraparib. The clinical program is designed to evaluate DAN-222 as a monotherapy and in combination with PARP inhibitors, which is expected to improve efficacy without significantly increasing toxicity.
[0709] This study is divided into 2 stages. Phase 1 has two parts. Part A analyzes the dose escalation of single agent DAN-222. Part B analyzes the dose escalation of the combination of DAN-222 and niraparib 100mg. Phase 2 involves expanding three separate HER2-negative mBC cohorts: a single agent DAN-222 for subjects with homologous recombination repair deficiency (HRD) positive or HRD-negative tumors, and a cohort for each of the subjects with HRD-positive tumors or HRD-negative tumors. The combination of DAN-222 and niraparib. DAN-222 is administered IV on days 1, 8, 15, and 22 of a 28-day cycle. The niraparib dose is taken orally once a day from day 1 to day 28. For subjects treated with a cycle defined as 4 weeks. Subjects who show acceptable safety and clinical benefit evidence (SD, PR, or CR) continue to receive DAN-222 until objective disease progression or unacceptable toxicity is confirmed. The initial evaluation consisted of MRI / CT at 6-week intervals for the first 6 cycles and then at 8-week intervals after week 24.
[0710] The research program Fig.53 Subjects who demonstrated an acceptable safety profile and evidence of clinical benefit (stable disease [SD], partial response [PR], or complete response [CR]) continued to receive DAN-222 until confirmation of objective disease progression or unacceptable toxicity.
[0711] Dose escalation phase 1
[0712] Phase 1, Part A - The dose escalation phase of the study evaluated the safety, tolerability and PK of DAN-222 as a single agent administered by IV infusion. A classic 3+3 design was used, and subjects were evaluated for DLT. If no dose-limiting safety signal was detected during the 28-day DLT window, the study will continue to higher dose levels.
[0713] Phase 1, Part B - After monotherapy has cleared the DLT safety window at the same dose level or higher, a starting dose of DAN-222 administered IV QW in combination with 100 mg niraparib (e.g., 2 mg / m 2 DAN-222 + 100 mg niraparib only at 2 mg / m 2 Combination dose escalation follows the same dose escalation intervals as single-agent escalation, using a classic 3+3 design, and subjects are evaluated for DLT. Escalation continues to the maximum dose level seen in Part A or until a safety threshold is reached. If no dose-limiting safety signal is detected during the 28-day DLT window, the study will continue to higher dose levels.
[0714] Enrollment into dose escalation cohorts was based on a 3+3 dose escalation design according to the following rules. First, each cohort initially enrolled at least 3 subjects unless the first 2 enrolled subjects experienced a protocol-defined DLT, in which case enrollment into the cohort was terminated. If none of the first 3 DLT-evaluable subjects experienced a DLT, the next cohort was enrolled at the next higher dose level with an increase in the dose interval ≤ 100% of the previous dose. If 1 of the first 3 DLT-evaluable subjects experienced a DLT, the cohort was expanded to 6 subjects. All subjects were evaluated for DLT before any dose escalation decision was made. If a DLT was observed in <17% of the subjects in a given cohort (e.g., a DLT was observed in 1 of 6 DLT-evaluable subjects), enrollment continued into the next dose escalation cohort. The interval between consecutive cohorts increased ≤ 50% of the previous dose level. If a DLT was observed in ≥17% of the subjects in a given cohort, further enrollment at that dose level and dose escalation was stopped and the dose was declared to exceed the MTD. Additional subjects are recruited in the same dose-escalation cohort to further characterize the safety, PK, pharmacodynamics (PD), or efficacy at that dose level.
[0715] The MTD was defined as the highest dose level resulting in DLT < 17% in at least 6 subjects.
[0716] Additional intermediate dose cohorts between two dose levels that were demonstrated not to exceed the MTD were evaluated to further characterize dose-dependent toxicity or pharmacodynamic changes.
[0717] If the dose level that exceeds the MTD is ≥25% higher than the previously tested dose level, an additional dose cohort of at least 6 subjects will be evaluated at the intermediate dose level to determine the MTD.
[0718] Safety information from the intermediate dose-level cohort is used to guide the SRT’s dose-escalation decisions; for example, if the frequency of DLT-defining events observed in the intermediate dose-level cohort is higher than expected based on data from the escalation cohort, the SRT may recommend interrupting or stopping further dose escalation.
[0719] Enrollment in cohorts evaluating intermediate dose levels in either Part A or Part B may occur concurrently with enrollment in dose-escalation cohorts in the other part to determine the MTD. If the MTD is not exceeded at any dose level, the highest dose administered in the study is declared the MAD.
[0720] Dose escalation decisions are made based on the SRT's recommendations and in consultation with the study investigators. Prior to each dose escalation decision, relevant demographic, AE, laboratory, dose administration, and available PK data will be reviewed.
[0721] Dose escalation may be stopped or modified as appropriate by the SRT based on review of real-time safety data and available preliminary PK data. Dose escalation continued until a dose level was reached at which DLTs were observed in ≥17% of subjects in ≥6 subjects.
[0722] Dose interruptions and / or reductions were implemented after cycle 1 in subjects enrolled in phase 1 (dose escalation) and at any time in subjects enrolled in phase 2 (dose expansion) due to any grade toxicity that the subject was deemed unable to tolerate, based on the investigator's judgment.
[0723] Toxicity at each dose was recorded before administration of the next dose and graded according to NCI CTCAE v5.0. All dose reductions were based on the worst previous toxicity and followed the reduction schedule listed in Table 12 below.
[0724]
[0725] In the event of a dose interruption, the next dose follows the subject's original calendar schedule. Cycle timing will not be delayed by treatment interruptions, and tumor assessments will be performed according to this schedule regardless of study drug interruptions. Once the dose of DAN-222 is reduced, any re-escalation should be discussed with the medical monitor.
[0726] For subjects in Phase 1, the dose of DAN-222 may be increased to a higher dose level that was found to be safe during the dose escalation phase after the subject completes 12 weeks of tumor assessments and discussion with the medical monitor.
[0727] Subjects who do not experience a DLT during the DLT observation period are eligible to receive additional cycles of DAN-222 study treatment. Subjects who demonstrate acceptable safety and evidence of clinical benefit (SD, PR, or CR) may continue to receive DAN-222 until objective disease progression or unacceptable toxicity occurs.
[0728] Any treatment delay not due to study treatment may not require discontinuation of study treatment but must be approved by the Medical Supervisor. Dose reductions of DAN-222 may be permitted if it is determined that clinical benefit can be maintained.
[0729] Subjects who complete study treatment without disease progression continue to be monitored, including regularly scheduled tumor assessments, until post-treatment follow-up is discontinued or a different therapy or study is initiated.
[0730] Unless otherwise specified, all adverse events (including DLTs) are reported and graded according to NCI CTCAE v5.0. Dose-limiting toxicities are treated according to clinical practice and monitored through resolution. Adverse events that meet DLT criteria should be reported to the sponsor as soon as possible.
[0731] For the purpose of dose escalation, the DLT assessment period for Phase IA and Part B was defined as the first 28 days of treatment (ie, Cycle 1 Day 1 to Cycle 1 Day 28).
[0732] Dose-limiting toxicity criteria were as follows: (i) any treatment-related Grade 3 or 4 non-hematologic clinical (i.e., non-laboratory) AEs, except fatigue, nausea, vomiting, diarrhea, and electrolyte imbalances, which were manageable with supportive care; (ii) any treatment-related Grade 3 or 4 non-hematologic laboratory abnormalities if: medical intervention was required to treat the subject, or the abnormality resulted in hospitalization, or the abnormality persisted for ≥7 days; (iii) any treatment-related hematologic toxicity, specifically defined as: Grade 4 thrombocytopenia for ≥7 days, or Grade 3 or 4 associated with bleeding or requiring platelet transfusion, Grade 4 neutropenia for ≥7 days, or Grade 3 or 4 associated with infection or febrile neutropenia, or Grade 4 anemia for ≥7 days, or Grade 3 and 4 requiring transfusion.
[0733] Exceptions to DLTs included grade 3 abnormalities in laboratory values that were asymptomatic and considered not clinically significant.
[0734] The following rules will be used to determine whether a subject is available for DLT evaluation. First, subjects who receive study treatment and continue on study through the DLT evaluation window are considered DLT evaluable. Subjects who receive at least 1 dose and have a DLT are evaluable; subjects without DLTs must receive at least 4 doses to be evaluable. Subjects who discontinue study treatment before completing the DLT evaluation window for reasons other than DLT are considered ineligible for dose escalation decisions and MTD determination and will be replaced by another subject at the same dose level. Subjects with pre-existing conditions that affect DLT evaluation during the DLT evaluation window may be replaced at the discretion of the medical supervisor.
[0735] Phase 2
[0736] The RP2D for DAN-222 monotherapy may be selected based on one or more of the following: (i) MAD or MTD (the highest dose level with a DLT rate <17% in at least 6 subjects); (ii) PK and / or PD results; (iii) the occurrence, nature, and severity of toxicities occurring after the DLT assessment period (i.e., the first 28 days of treatment); and (iv) antitumor activity.
[0737] The dose expansion phase of this study is designed to obtain additional safety, tolerability, PK, and preliminary clinical activity data with study treatment at the RP2D dose. The initiation of expansion cohorts is at the discretion of the sponsor. The sponsor, in consultation with the investigators and SRT, continuously evaluates all available safety data from the expansion cohorts to assess the tolerability of the dose levels being studied. At no time will the DAN-222 dose level studied in the expansion phase exceed the highest dose level deemed to be the MTD for a given schedule in the dose escalation phase. In addition, for each expansion cohort, data are continuously reviewed to guide potential early cessation of enrollment in the event of excessive toxicity or death.
[0738] The expansion cohorts further evaluated antitumor activity, safety, and pharmacodynamics. After review of the above and recommendation by the SRT in consultation with the study investigators, recruitment in one or more expansion cohorts was initiated. After the RP2D was defined for single-agent DAN-222 dose escalation, an expansion of 20 subjects was opened for subjects with HER2-negative mBC and with HRD-positive or HRD-negative status. After the RP2D dose of the combination of DAN-222 and niraparib was selected, 2 expansion cohorts of HRD-positive (n=20) and HRD-negative (n=20) subjects were opened.
[0739] Single-agent expansion cohorts can be opened simultaneously with continued dose escalation in the combination group. In this case, the dose of the expansion cohort is adjusted based on the SRT's review of cumulative safety, laboratory and efficacy data. Additional subjects in each cohort can be recruited based on cumulative data, and additional cohorts can be added through protocol amendments. Data from the expansion cohort further supports the RP2D selection for each review by the SRT.
[0740] Study participants
[0741] The study will enroll approximately 96 subjects. The Phase 1 dose-escalation study, Part A, single-agent DAN-222 will include approximately 18 subjects. The Phase 1 dose-escalation study, Part B, combination of DAN-222 and niraparib will include approximately 18 subjects.
[0742] In the expansion phase, the study enrolled as follows: Arm A: single-agent DAN-222 in subjects with HER2-negative mBC and HRD-positive or HRD-negative tumors, n=20; Arm B: combination of DAN-222 with niraparib in subjects with HER2-negative mBC and HRD-positive tumors, n=20; and Arm C: combination of DAN-222 with niraparib in subjects with HER2-negative mBC and HRD-negative tumors, n=20.
[0743] In the dose-escalation phase (Parts A and B), subjects who did not complete the DLT assessment period for reasons other than DLT were considered inevaluable for DLT and were replaced. In the dose-expansion phase, subjects who did not undergo at least one post-baseline radiographic tumor assessment for reasons other than discontinuation of treatment due to toxicity or death due to disease progression were considered inevaluable for efficacy and were replaced.
[0744] Eligibility of subjects
[0745] Subjects must have histologically documented metastatic HER2-negative breast cancer that has progressed after two prior lines of therapy (including adjuvant therapy if progressed within the past 12 months, and aromatase inhibitors will be considered a line of therapy), or for which standard therapy has proven ineffective or intolerant, or is considered inappropriate. HER2 positivity is defined by 3+ staining by standard-of-care fluorescence in situ hybridization (FISH) and / or immunohistochemistry (IHC), according to the American Society of Clinical Oncology / College of American Pathologists (ASCO / CAP) Clinical Practice Guideline Focused Update.
[0746] mBC required at least 2 weeks or 5 half-lives (whichever is longer) from any prior therapy. Therapy included chemotherapy, immunotherapy, and / or radiation therapy. In addition, all reversible toxicities, except alopecia, needed to recover to ≤ Grade 1 at the start of the study.
[0747] Subjects must have measurable disease according to RECIST v1.1. Subjects must be female, 18 years of age or older. Subjects must have an ECOG performance status of ≤2.
[0748] Subjects who have received prior treatment for brain metastases (surgery, whole brain, or stereotactic brain radiation) are permitted, provided that the lesions have been stable for at least 4 weeks and the subject has not taken steroids for at least 7 days before the first dose of study treatment and any neurological symptoms have returned to baseline (without evidence of progression as determined by imaging using the same imaging modality (MRI or CT scan) at each assessment).
[0749] Subjects with brain metastases should not require the use of enzyme-inducing antiepileptic drugs (e.g., carbamazepine, phenytoin, or phenobarbital) within 14 days prior to the first dose of study treatment and during the study. Novel antiepileptic drugs that do not produce enzyme-inducing drug interactions are permitted.
[0750] Subjects were required to have normal organ and bone marrow function, defined as an absolute neutrophil count ≥ 1.5 x 10-1 in the absence of growth factor support within the past 7 days. 9 / L; platelets ≥100 x 10 9 / L; hemoglobin ≥9 g / dL and no blood transfusion in the previous 4 weeks; total bilirubin ≤1.5x upper limit of normal (ULN) (except for Gilbert's Disease); AST(SGOT) / ALT(SGPT) ≤2.5x ULN (≤5x ULN if liver metastases); and creatinine <1.5x ULN or creatinine clearance ≥50 mL / min (calculated using the Cockroft-Gault formula) in subjects with creatinine levels above institutional normal values.
[0751] Subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of study drug, or agree to abstain from activities that could result in pregnancy for 120 days after the last dose of study treatment, starting at the screening visit, or be infertile. Infertility is defined (except for medical reasons): subjects aged 45 years or older who have not had menstruation for >1 year; have been amenorrhea for at least 2 years without hysterectomy and oophorectomy, with follicle stimulating hormone (FSH) values in the postmenopausal range as assessed pre-study (screening); or have undergone hysterectomy, bilateral oophorectomy, or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed by medical record of the actual procedure or by ultrasound. Tubal ligation must be confirmed with medical record of the actual procedure, or the subject must be willing to use 2 appropriate barrier methods throughout the study from the screening visit until 120 days after the last dose of study treatment.
[0752] Phase 2 inclusion additionally requires documentation of DNA repair deficiency status (e.g., BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD54L) verified by plasma testing from a central laboratory or archival tumor tissue or germline testing from any Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory.
[0753] Subject exclusion criteria included: (i) any significant medical condition or laboratory abnormality that would place the subject at unacceptable risk if participation in the study was determined at the discretion of the clinician and not otherwise specified below; and (ii) for the DAN-222 and niraparib combination cohort, the subject had no known sensitivity to FD&C Yellow No. 5 (tartrazine). Subjects were also excluded if they had a history of allergic reaction to irinotecan, topotecan, or govitecan. Excluded subjects also included subjects who were concomitantly administered or received a cytochrome P450 3A4 (CYP3A4) enzyme inducer or inhibitor within 2 weeks prior to the first day of study treatment. Subjects taking medications known to prolong the QT interval or associated with polymorphic ventricular tachycardia were also excluded unless the subject could safely discontinue these medications or switch to comparable medications that did not significantly prolong the QT interval for at least 5 half-lives or 7 days (whichever was longer) before the first dose of DAN-222. Subjects with a history of myelodysplasia or another malignancy known to have progressed or required active treatment within the past 3 years were excluded. Exceptions included non-melanoma skin cancer and carcinoma in situ. Subjects diagnosed with carcinomatous meningitis were also excluded. Excluded subjects also included subjects who were pregnant, breastfeeding, or expected to become pregnant during the expected duration of the study from the start of the screening visit to 120 days after the last dose of study treatment. Therefore, excluded subjects also included subjects who were unable to comply with study procedures or were unwilling to use appropriate birth control. Excluded subjects further included subjects with uncontrolled concurrent illnesses, including but not limited to persistent or active infections, symptomatic congestive heart failure, unstable angina, arrhythmias, or other conditions that limited compliance with study requirements.
[0754] Subjects with a prolonged heart rate-corrected QT interval (QTc) >470 milliseconds at screening were also excluded. If a subject has a prolonged QT interval and the prolongation is considered to be pacemaker-induced as assessed by the investigator (i.e., the subject otherwise has no cardiac abnormalities), the subject may be eligible for the study after discussion with the medical monitor.
[0755] Finally, excluded subjects included those with any serious social, psychological, or medical condition or abnormality on clinical laboratory tests that, in the opinion of the investigator, prevented the subject from safely participating in at least 4 cycles of treatment or that could affect compliance with the protocol or interpretation of the results.
[0756] Estimated study duration and study completion
[0757] The planned study duration is three years. Subject participation will include screening, treatment, and follow-up. Screening may be performed 30 days prior to the first dose of study drug, during which subject eligibility and baseline characteristics are determined. Subjects confirmed to have progressive disease terminate the study at an earlier time point. In subjects with SD, PR, or CR, treatment with DAN-222 continues until unacceptable drug-related toxicity or disease progression. Following treatment, subjects are observed for disease progression and new anticancer therapy, or until withdrawal of consent or end of the study, whichever occurs first. The planned duration of study treatment for individual subjects is approximately 12 months.
[0758] The end of the study was defined as the date of the last subject visit or the date the last data point required for statistical analysis or protocol-defined safety monitoring was received from the last subject, whichever was later.
[0759] DAN-222 and niraparib administration
[0760] DAN-222 was provided by the sponsor. DAN-222 is a polymer-small molecule conjugate NP formulated into a sterile aqueous solution.
[0761] The DAN-222 drug substance and drug product are manufactured in accordance with current good manufacturing practices. The DAN-222 drug product is a sterile, clear to slightly opalescent, colorless to pale yellow, preservative-free liquid intended for IV infusion. DAN-222 is supplied in single-use vials containing 3.1 mL of DAN-222 solution containing 2.6 mg / mL of CPT. The formulation consists of an aqueous solution of 20 mM sodium acetate and 200 mM sodium chloride with the pH adjusted to 4.3. Vials should be stored frozen at -20°C ± 5°C and thawed immediately before use at 2 to 8°C or ambient temperature. Labeling is in accordance with the requirements of applicable regulatory agencies.
[0762] DAN-222 was administered IV once weekly. Each subject's dose of DAN-222 depended on their dose level assignment. Dosage was based on the subject's actual body weight at baseline (Cycle 1 Day 1 or during screening). If a subject's body weight changed >10% during the study, body surface area and drug dose were recalculated. Recalculation of drug dose for each treatment day was also permitted, regardless of the percentage of body weight change, per institutional dosing policy.
[0763] DAN-222 was administered to subjects via IV infusion using an IV bag. Testing showed that DAN-222 was compatible with PVC extension sleeves and non-silicone polypropylene syringes. DAN-222 was administered in a setting with immediate access to trained critical care personnel and facilities equipped to respond to and manage medical emergencies.
[0764] Subjects must drink plenty of water throughout DAN-222 treatment and are encouraged to drink at least 2 liters of water per day. The infusion time of DAN-222 is 1 hour ± 15 minutes. For subjects who experience infusion-related symptoms, the infusion may be slowed or interrupted. For the first infusion, observe the subject for any infusion-related reactions within 90 minutes after the infusion. After each subsequent DAN-222 administration, the dosing duration can be continuously reduced by up to 30 minutes to a minimum infusion time of 30 minutes. In the absence of infusion-related adverse events, the post-administration observation time can also be continuously reduced by up to 30 minutes to a minimum observation period of 30 minutes.
[0765] Subjects receiving within-subject dose escalation or retreatment received the first higher infusion of DAN-222 over a period of at least 1 hour ± 15 minutes.
[0766] Any overdose or misadministration of DAN-222 will be noted on the Study Drug Administration eCRF. Adverse events related to overdose or misadministration of study drug will be recorded on the Adverse Events eCRF.
[0767] Niraparib (2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole 7-carboxamide 4-methylbenzenesulfonate hydrate) (1:1:1) is an orally available, potent, highly selective inhibitor of PARP1 and PARP2. The excipients of niraparib are lactose monohydrate and magnesium stearate.
[0768] Niraparib is supplied in the form of 100 mg capsules and is administered orally once a day (QD) starting on Day 1 of Cycle 1. The daily dose is a single 100 mg capsule. Subjects are instructed to take their dose at the same time each day, preferably in the morning. Subjects must swallow rather than chew the capsule. Niraparib capsules are dispensed to subjects on Day 1 of Cycle 1 and on Day 1 of each 28-day cycle thereafter until the subject stops study treatment.
[0769] Study Drug Administration—Day 1
[0770] Prior to treatment, subjects will need to complete all medical history, physical examinations, and laboratory evaluations. Evaluations will be performed as indicated in the evaluation schedule (Table 13).
[0771] Additionally, measure vital signs approximately 5 minutes (±5 minutes) before and 15 minutes (±5 minutes) after the start of the infusion, and then every 30 minutes (±10 minutes) for the next 2 hours. Thereafter, vital signs may continue to be monitored until the subject's condition is stable and as clinically indicated.
[0772] Following DAN-222 administration on Day 1 of Cycle 1, subjects enrolled in the dose-escalation cohorts will be required to undergo 8 hours of post-infusion clinical monitoring during PK assessments.
[0773] Ongoing Research Treatments
[0774] DAN-222 is administered once a week. Subjects will return to the clinic for safety assessments and to receive DAN-222 infusions. Assessments will be performed as indicated in the Assessment Schedule (Table 13).
[0775] Maintenance therapy
[0776] Subjects who continue to tolerate DAN-222 and do not experience malignancy progression may continue to receive study treatment. Subjects will return to the clinic weekly for safety assessments and to receive DAN-222 infusions.
[0777] End of treatment
[0778] The End of Treatment (EOT) visit must be performed within 28 days of treatment interruption and before initiation of any new anticancer therapy / regimen. All subjects who discontinue study treatment for any reason should undergo the assessments indicated in the Assessment Schedule (Table 13).
[0779] Early Exit
[0780] Regardless of when treatment is completed, all subjects should return to the clinic for an EOT visit evaluation. Adverse events were evaluated until they resolved, returned to baseline, or stabilized, based on the investigator's assessment.
[0781]
[0782]
[0783]
[0784]
[0785] Physical examination, vital signs, and performance status
[0786] A complete physical examination was performed at the Screening Visit. The complete physical examination included assessments of the head, eyes, ears, nose, and throat; as well as cardiovascular, skin, musculoskeletal, respiratory, gastrointestinal, and neurologic systems. At each subsequent physical examination, changes from baseline were recorded. New or worsening abnormalities were recorded as adverse events, if appropriate. Limited physical examinations were performed at other visits to assess changes from baseline abnormalities, any new abnormalities, and to assess patient-reported symptoms. New or worsening abnormalities were recorded as adverse events, if appropriate.
[0787] Vital signs (including blood pressure, heart rate, respiratory rate, and temperature) were monitored and recorded at screening and at the times listed in the assessment schedule (Table 13). In addition to the time points listed in the assessment schedule, vital signs were monitored as clinically indicated, and if there were any new or worsening clinically significant changes since the last examination, these changes were reported on the appropriate eCRF page. Performance status measured by the ECOG scale is intended to quantify the subject's overall health status and ability to perform activities of daily living.
[0788] Heart function
[0789] A baseline 12-lead ECG is performed before the first infusion (ie, Day 1) of every third 4-week cycle. The ECG should be performed before blood is drawn for PK. Prior to recording the ECG, the subject should lie supine and rest for approximately 5 minutes.
[0790] Neurologic examination
[0791] A neurological examination was performed at the screening visit and any abnormalities in the following were recorded: cranial nerves, motor system, reflexes, coordination, sensory system, and neuropsychological findings (e.g., speech, cognition, and mood). Thereafter, a symptom-oriented neurological assessment was performed prior to infusion. Subjects were specifically asked about changes in neurological status since the last examination, as indicated in the assessment schedule (Table 13).
[0792] Nervous system imaging
[0793] During the study screening period, subjects with neurological signs or symptoms underwent a screening brain MRI to exclude central nervous system metastases. If MRI was contraindicated, a brain CT scan was performed instead. If detected during screening, subsequent brain scans were performed at scheduled imaging intervals.
[0794] Disease assessment
[0795] The investigators assessed the subjects' disease response at the times indicated in the assessment schedule. Disease assessment was performed according to RECIST v1.1. As part of the disease assessment, a physical examination included an assessment of the presence and extent of lymphadenopathy, hepatomegaly, and splenomegaly.
[0796] Imaging at baseline
[0797] In order to confirm the eligibility and / or establish a baseline for measurable lesions that meet RECIST v1.1, MRI or CT scans of the chest, abdomen, and pelvis are required during screening, and appropriate imaging is performed on all other disease sites (including brain and bones). If performed within 28 days before the screening visit, and no other anticancer treatment is administered, the MRI or CT performed after the last line of therapy of the subject and before signing the ICF can be used to confirm eligibility. If MRI or CT was performed before the screening visit>28 days, the MRI or CT scan must be repeated to establish a new baseline. MRI or CT should be as close to the screening visit as possible.
[0798] Subjects who are unable to undergo contrast-enhanced MRI or CT scans due to contrast-enhanced allergy or impaired renal function may be evaluated using non-contrast MRI or CT scans.
[0799] All response assessments should preferably use the same radiographic assessment modality as at baseline. Imaging should use the same protocol to ensure consistency across time points (eg, same contrast protocol for MRI or CT).
[0800] After starting study drug treatment
[0801] The first study imaging assessment was performed at 6 weeks (42 ± 7 days) from the date of the first dose of study treatment; if disease progression was equivocal, confirmatory images were required < 4 weeks later. Tumor imaging was subsequently performed every 6 weeks (42 ± 7 days) if there was an SD or better response, or more frequently if disease progression was suspected if clinically indicated. After the 6-month radiographic assessment, subjects were imaged every 8 weeks (56 ± 7 days). Imaging should not be delayed due to delays in cycle initiation or prolonged intervals between combination treatment cycles. The same modality (i.e., CT or MRI) should be used for a given subject throughout the study.
[0802] Subjects with a CR or PR will have repeat tumor imaging assessment at the next scheduled scan (i.e., 6 weeks later) to confirm their response.
[0803] Clinical laboratory analysis
[0804] Screening and other laboratory assessments were performed according to the assessment schedule. Investigators had the option of repeating any abnormal test once to rule out laboratory or sample collection errors. The assessments listed in Table 16 were performed at the local laboratory at the time points indicated in the assessment schedule (Table 13).
[0805]
[0806] Research laboratory analysis
[0807] Blood is analyzed to evaluate PK and PD markers for DAN-222. In general, testing and analysis of samples follows the evaluation schedule. However, in cases where sample material is limited, sample allocation for specific tests may be modified.
[0808] Clinical biospecimens (e.g., serum) are sent from clinical sites to a central laboratory for sample processing, warehousing, and distribution to specialized laboratories or Dantari, Inc. All samples, and any derivatives of these samples, can be stored for up to 5 years to address exploratory scientific questions related to the treatment or disease being studied.
[0809] Several specialized laboratories are available for specific analyses.
[0810] Pharmacokinetic Assessment (Plasma)
[0811] DAN-222 in plasma was assessed using liquid chromatography with mass spectrometry detection (LC-MS-MS) specific for DAN-222.
[0812] Phase 1 (dose escalation): Pharmacokinetic evaluation (plasma)
[0813] Plasma samples will be obtained for PK analysis at the following time points: On Day 1 of Cycle 1, samples will be drawn prior to dosing and at 30 minutes, 2, 4, 6, 8, 24, 48, 96, and 120 hours after the end of the infusion. PK samples obtained prior to dosing, 30 minutes, 2 hours will be obtained ±5 minutes from the end of the scheduled infusion. PK samples obtained 4+ hours will be obtained ±15 minutes after the end of the infusion. On Day 1 of Cycle 2, samples will be drawn prior to dosing and at 30 minutes (±5 minutes) and 4 hours (±15 minutes) after the end of the infusion. On Day 1 of Cycle 3+, samples will be drawn prior to dosing and at 30 minutes (±5 minutes) after the end of the infusion. In addition, PK samples will be obtained 4 hours (±15 minutes) after the end of the infusion in Cycle 3 and every 3 cycles thereafter.
[0814] PK samples were collected at any time during the visit, following treatment interruption or premature termination. Additional PK samples may be collected if severe toxicity or inconsistent drug exposure occurs.
[0815] Post-dose PK samples are drawn from a location different from the site where the study drug was administered. For example, if the study drug is administered through a vein in the arm, the post-dose PK sample is drawn from a vein in the contralateral arm.
[0816] Phase 2 (dose expansion): Pharmacokinetic evaluation (plasma)
[0817] Plasma samples were obtained for PK analysis at the following time points: samples were drawn on Day 1 of Cycle 1 before dosing, 0.5 hours (±5 minutes), and 4 hours (±15 minutes) after the end of the infusion. Samples were drawn on Day 1 of Cycle 2 before dosing and 0.5 hours (±5 minutes) after the end of the infusion. Samples were drawn on Day 1 of Cycle 2 before dosing and 0.5 hours (±5 minutes) after the end of the infusion in Cycle 3 and every three cycles thereafter before dosing, 0.5 minutes (±5 minutes), and 4 hours (±15 minutes) after the end of the infusion.
[0818] PK samples were collected during visits after treatment interruption or premature discontinuation. Additional PK samples may be collected if severe toxicity or inconsistent drug exposure occurs.
[0819] Post-dose PK samples are drawn from a location different from the site where the study drug was administered. For example, if the study drug is administered through a vein in the arm, the post-dose PK sample is drawn from a vein in the contralateral arm.
[0820] Pharmacodynamic evaluation (plasma)
[0821] The primary central laboratory assessment consisted of circulating tumor count (CTC) measurement.
[0822] Statistical considerations
[0823] This was an open-label clinical study, and descriptive statistics were generally used to analyze the data. The data were tabulated and analyzed with respect to subject recruitment and disposition, demographics and baseline characteristics, previous and concomitant medications, efficacy, and safety measures.
[0824] Sample size considerations
[0825] Approximately 18 to 36 subjects will be enrolled in the study during the dose escalation phase (Phase 1), and approximately 60 subjects will be enrolled in the study during the dose expansion phase (Phase 2). The overall sample size for this study is estimated to be between 18 and 96 subjects.
[0826] In the dose escalation part of the study, a standard 3+3 dose escalation design was divided into two parts. Part A was used to explore the MTD of DAN-222 as a single agent, and Part B was used to explore the MTD of DNA-222 in combination with niraparib. Each part had a maximum of 5 pre-planned dose cohort levels, with an estimated total of 18 DLT-evaluable subjects per part. Subjects who were not evaluable for DLT were replaced.
[0827] The sample size of 20 evaluable subjects in each Phase 2 group (Group A, Group B, and Group C) was based on practical considerations and clinical judgment to obtain adequate information about the overall study objectives, including the characterization of the safety, initial clinical efficacy, and PK data of DAN-222 in the selected population as a monotherapy or in combination with niraparib. For example, if there are 4 responders in the group consisting of 20 evaluable subjects (i.e., an ORR of 20%), the 95% accurate CI for the ORR is (5.7%, 43.7%); similarly, if the ORR is 45% (9 responders in 20 evaluable subjects), the 95% accurate CI is (23.1%, 68.5%).
[0828] Statistical methods
[0829] Unless otherwise indicated, data are summarized by phase and dose level (Phase 1) or cohort (Phase 2) as appropriate, and all data for all subjects are presented. Data from each phase are also presented as a whole. Data may also be pooled to support additional summary analyses described elsewhere in this article.
[0830] Descriptive summaries of categorical variables include counts and percentages. Continuous variables were summarized using standard summary statistics (N, mean, standard deviation, median, minimum, and maximum). Median values and the 25th and 75th percentiles (where assessable) were presented for survival data. Where appropriate, 95% CI around a point was presented.
[0831] Pharmacodynamic analysis
[0832] All subjects in the FAS were assessed for reduction in circulating tumor cells at 4 weeks compared with the baseline visit.
[0833] Pharmacokinetic analysis
[0834] The PK analysis set (PKAS) included all subjects in the FAS who had PK blood samples collected during the study and for whom DAN-222 concentrations were measurable. For subjects with sufficient data, the following PK parameters were estimated from individual concentration-time curves using non-compartmental analysis methods: total exposure (AUC 0-last );C max ; C min (trough concentration) and time to lowest observed plasma concentration; if data permit, CL, V, and t 1 / 2 ; and PK parameters without CPT.
[0835] If sufficient data were available, parameters were calculated using data after the first and fifth doses. Additional analyses could be performed if deemed useful and appropriate.
[0836] Summary statistics for pharmacokinetic parameters are presented by dose group and may include mean, standard deviation, geometric mean and standard deviation, median, 25th to 75th percentiles, minimum, and maximum values. All concentrations below the detection or quantification limit or missing data are marked in the concentration data list. Concentrations below the detection limit are considered zero in the summary statistics.
[0837] Efficacy analysis
[0838] Investigators performed response assessments according to RECIST v1.1. Efficacy summaries were based on the EAS unless otherwise stated. Selected summaries may also be presented for the FAS and PPAS.
[0839] Objective response rate
[0840] ORR was defined as the proportion of subjects with a best overall response (BOR) of either a complete response (CR) or a partial response (PR) according to RECIST v1.1. The proportion of subjects with an ORR in the EAS was reported descriptively, along with 95% CIs based on the Clopper-Pearson exact method. Overall response was summarized at each visit; BOR was also summarized. Secondary analyses of ORR and BOR could be repeated in the FAS and PPAS.
[0841] Additional secondary efficacy endpoints
[0842] PFS: Progression-free survival is defined as the time from the first dose of study drug to the first documented progressive disease (according to RECIST v1.1) or death from any cause. Subjects who do not experience progressive disease and are alive will be censored at the last evaluable tumor assessment. Subjects who do not experience progressive disease and start new anticancer therapy will be censored at the last evaluable tumor assessment on or before the start of new anticancer therapy. For any additional analyses performed in the FAS, subjects without evaluable post-baseline tumor assessments will be censored when receiving the first study drug. Subjects lost to follow-up for progressive disease assessment will be censored at the last evaluable tumor assessment. Analysis of PFS will be based on the KaplanMeier method.
[0843] DCR: Disease control rate was defined as the percentage of subjects with a BOR of CR, PR, or SD. The analysis of DCR was performed in the same manner as ORR.
[0844] CBR: Clinical benefit rate was defined as the percentage of subjects with a BOR of CR, PR, or documented SD for a continuous period of at least 6 months. The analysis of CBR was performed in the same manner as ORR.
[0845] DOR: Duration of response included subjects with an objective disease response (PR or CR) and was defined as the time from the first tumor assessment supporting the subject's objective disease response to progressive disease or death from any cause. Subjects who did not experience progressive disease or death at the time of analysis were censored using the same rules as for PFS. Analysis of DOR was performed using the Kaplan-Meier method.
[0846] Homologous recombination repair defect analysis
[0847] Special attention is paid to subgroups of subjects who may have different potential DNA repair pathway defects (HR, nucleotide excision repair or mismatch repair deficiency) and different drug responses. In some cases, due to practical or sample quality reasons, it may be decided to stop biomarker sample collection, or not to perform or stop blood or tumor analysis. In this case, the number of samples may not be sufficient for complete data analysis, so FAS lists and summarizes the available data. In addition, exploratory efficacy analysis can also be performed based on subgroups identified using HRD and / or other biomarkers.
[0848] Security Analysis
[0849] All safety analyses were performed in FAS. Adverse events were coded according to the current version of MedDRA. The severity of adverse events was graded according to the US NCI CTCAE, v5.0.
[0850] TEAE: Treatment-emergent adverse events were defined as any adverse event (or exacerbation of a pre-existing condition) occurring after the first dose of study drug through 30 days after the last dose of study drug. Events included TEAEs, adverse events leading to dose reduction / interruption, adverse events related to study drug, serious adverse events, adverse events leading to study drug discontinuation, and fatal adverse events, summarized by system organ class and preferred term for each treatment group. A summary of adverse events of NCI CTCAE grade 3 or higher was provided, as well as the most common adverse events (by preferred term) and adverse events related to study treatment.
[0851] For phase 1, the incidence of DLTs was summarized. For phases 1 and 2, the incidence of infusion-related reactions was also summarized. Values and changes from baseline in clinical laboratory results were summarized by follow-up. Clinical laboratory values were graded according to the NCICTCAE for applicable tests. Changes in toxicity grade from baseline grade were summarized. Changes in ECOG performance status from baseline were also summarized. Vital signs, ECG, and concomitant medication data were summarized.
[0852] Managing Adverse Events
[0853] In subjects enrolled at any time during Phase I (dose escalation) and Phase 2 (dose expansion), dose interruptions and modifications may be implemented after Cycle 1 at the discretion of the investigator. The dose interruption and reduction instructions provided in this section are intended as recommended guidelines to allow continued treatment of subjects without signs or symptoms of progression while ensuring the safety of the subject. In addition to these guidelines, more conservative drug interruptions or dose reductions may be allowed at the discretion of the treating investigator to manage adverse events when deemed to be in the best interest of the subject and to ensure the safety of the subject.
[0854] Subjects who discontinued niraparib treatment due to intolerance were allowed to remain in the study and continue to receive DAN-222 treatment at the investigator's discretion.
[0855] After Cycle 1, all study medications may be temporarily withheld for up to 28 consecutive days if a subject experiences toxicity related to study treatment and requires withholding study treatment. Subjects who miss >28 consecutive days of scheduled study treatment will cease participation in the study.
[0856] DAN-222 treatment must be interrupted for any treatment-related non-hematologic CTCAE Grade 3 or 4 event. Once resolved to ≤ Grade 1, subjects may restart treatment with DAN-222 at a reduced dose level (Table 17) unless prevention is deemed feasible. Dose interruption / modification criteria for DAN-222 hematologic toxicity will be based on blood cell counts and guidance in Table 17 below. Granulocyte colony-stimulating factor (G-CSF) is permitted if clinically indicated, per current ASCO guidelines. Reasons for study drug interruption, reduction, or discontinuation should be recorded in the eCRF.
[0857]
[0858]
[0859]
[0860]
[0861] Study screening
[0862] Subjects who fully consented to participate in this study underwent a screening assessment within 28 days (4 weeks) prior to administration of the first infusion of DAN-222 (unless otherwise specified). The screening period began on the date the subject signed the IRB / IEC approved Informed Consent Form (ICF). Informed consent must be obtained prior to completing any non-standard of care study specific procedures.
[0863] All subjects who meet the eligibility criteria and are recruited into the study are scheduled for study treatment Day 1. If at any time prior to recruitment, a subject does not meet the eligibility criteria, the subject should be designated as a screen failure and the reason for the screen failure should also be recorded.
[0864] The initial screening evaluation consisted of obtaining informed consent; assessing eligibility according to the inclusion / exclusion criteria; obtaining a medical history, including the disease diagnosis and previous treatments for malignancy (chemotherapy, radiation, and surgery) and any history of toxicity related to previous treatments and allergies; obtaining an ECOG performance status assessment; a complete physical examination; and recording all adverse events and serious adverse events related to the protocol-specified procedures and concomitant medications taken at the time.
[0865] Incorporated by Reference
[0866] Other documents, such as patents, patent applications, patent publications, magazines, books, papers, and web content, have been referenced and cited throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes.
[0867] Equivalent
[0868] Various modifications of the invention and many additional embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the entire content of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, illustrations, and guidance that can be adapted to practice the invention in its various embodiments and its equivalents.
Claims
1. A method for producing a preparation of a compound of formula (I): wherein n is a number in the range of 20 to 200; and where m is a number in the range of 5 to 200, The method comprises: (i) derivatizing camptothecin (CPT) to obtain Gly-CPT in the form of a trifluoroacetic acid (TFA) salt; (ii) Synthesis of matrix mucoid acid polymer (MAP); (iii) covalently linking the Gly-CPT to the parent MAP to obtain a solid amorphous MAP-Gly-CPT; and (iv) preparing an aqueous formulation of the amorphous MAP-Gly-CPT, thereby producing an aqueous formulation of nanoparticles comprising the compound of formula (I).
2. The method of claim 1, wherein step (i) comprises: dissolving CPT, N-(tert-butyloxycarbonyl)Gly-OH (Boc-Gly), and 4-dimethylaminopyridine (DMAP) in dichloromethane (DCM) to form a reaction mixture; and Diisopropylcarbodiimide (DIC) was added to the reaction mixture, resulting in a solution including the Boc-Gly-CPT intermediate.
3. The method of claim 2, wherein the step (i) further comprises removing 90% to 99% of the DCM from the solution comprising the Boc-Gly-CPT intermediate.
4. The process of claim 3, wherein the DCM is removed by vacuum distillation.
5. The method of claim 3, wherein the step (i) further comprises precipitating the Boc-Gly-CPT intermediate using methanol.
6. The method of claim 5, wherein the step (i) further comprises washing the precipitated Boc-Gly-CPT intermediate with isopropyl alcohol (IPA).
7. The method of claim 6, wherein the step (i) further comprises treating the Boc-Gly-CPT intermediate with DCM containing TFA to obtain Gly-CPT.
8. The method of claim 1, wherein step (ii) comprises: Charge (succinimidyl propionate) 2PEG into the reactor 3500 (diSPA-PEG 3500 ) and a neutral substance of mucin acid monomer (MAM) of formula (II): adding dimethyl sulfoxide (DMSO) to the reactor; Initiating the reaction by adding TFA to the reactor; and To the reaction was added DIPEA, Thereby the maternal MAP is obtained.
9. The method of claim 8, wherein the comonomer ratio of DIPEA:MAM used in step (ii) is at least about 2.
5.
10. The method of claim 9, wherein the comonomer ratio is at least 2.
6.
11. The method of claim 8, wherein step (ii) further comprises precipitating the parent MAP from the DMSO by adding at least one antisolvent.
12. The method of claim 11, wherein the at least one antisolvent is IPA.
13. The method of claim 11, wherein the precipitation step is followed by a filtration step under an inert atmosphere.
14. The method of claim 1, wherein step (iii) comprises: Add the parent MAP and DMSO into the reaction vessel; adding the Gly-CPT (TFA salt) and 7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP) to the reaction vessel; and DIPEA was added to the reaction vessel, resulting in a solution including MAP-Gly-CPT.
15. The method of claim 14, wherein step (iii) further comprises purifying amorphous MAP-Gly-CPT from the solution using tangential flow filtration (TFF).
16. The method of claim 15, wherein the solution is diluted with water at pH 3 prior to the tangential flow filtration, and wherein the tangential flow filtration uses a polyethersulfone (PESU) TFF filter.
17. The method of claim 1, wherein step (iv) comprises: adding water having a pH of about pH 4 to the amorphous MAP-Gly-CPT to produce a nanoparticle (NP) solution; and Formulation buffer was added to the NP solution.
18. The method of claim 17, wherein the formulation buffer comprises sodium acetate.
19. The method of claim 18, wherein the formulation buffer comprises NaCl and has a pH of about pH 4.
16.
20. The method of claim 18, wherein after the step of adding water having a pH of about pH 4, the NP solution is filtered.
21. The method of claim 20, wherein after the step of adding the formulation buffer to the NP solution, the NP solution is concentrated by ultrafiltration.
22. A formulation comprising nanoparticles comprising a mucin acid polymer (MAP) camptothecin (CPT) conjugate compound of formula (I): wherein n is a number in the range of 20 to 200; and where m is a number in the range of 5 to 200, The preparation is formulated as an aqueous preparation.
23. The formulation of claim 22, wherein n is a number in the range of about 75 to 85.
24. The formulation of claim 23, wherein m is a number in the range of about 12 to 20.
25. The formulation of claim 24, wherein the compound of formula (I) has a molecular weight of about 75,000 Da.
26. The formulation of claim 25, wherein the nanoparticles of the formulation comprise, on average, two chains comprising the compound of formula (I), and wherein the average molecular weight of the nanoparticles is about 150,000 Da.
27. The formulation of claim 26, wherein the nanoparticles of the formulation have an average particle size of about 20 nm to 80 nm.
28. The formulation of claim 27, wherein the nanoparticles have an average particle size of about 30 to 40 nm.
29. The formulation of claim 28, wherein the formulation has a nanoparticle concentration of about 17-23 mg / mL.
30. The formulation of claim 24, wherein the formulation has a total CPT concentration of 1.7 to 3.6 mg / mL.
31. The formulation of claim 30, wherein the formulation has a total CPT concentration of about 2.6 mg / mL.
32. The formulation of claim 31, wherein the formulation comprises the compound of formula (I) at a concentration of about 20 mg / mL.
33. The formulation of claim 24, wherein the pH of the formulation is between pH 4 and pH 5.
34. The formulation of claim 33, wherein the pH of the formulation is between pH 4 and pH 4.
6.
35. The formulation of claim 34, wherein the pH of the formulation is about 4.
3.
36. The formulation of claim 35, wherein the formulation further comprises at least one buffer selected from the group consisting of sodium succinate, sodium citrate, sodium acetate, phosphoric acid, histidine-HCl, and sodium phosphate.
37. The formulation of claim 36, wherein the at least one buffer is a sodium acetate buffer.
38. The formulation of claim 37, wherein the formulation further comprises at least one tonicity modifier selected from the group consisting of KCl, NaCl, proline, arginine-HCl, sucrose, and glycine.
39. The formulation of claim 38, wherein the at least one tonicity modifier is NaCl.
40. The formulation of claim 39, wherein the formulation comprises about 20 mg / mL of the compound of formula (I).
41. The formulation of claim 40, wherein the formulation comprises about 20 mM sodium acetate, about 200 mM NaCl, and a pH of 4.3 ± 0.
3.
42. A method for treating cancer in a subject, the method comprising providing to a subject having cancer at least one dose of a composition comprising a compound of formula (I): wherein n is a number in the range of 20 to 200; and Wherein m is a number in the range of 5 to 200.
43. The method of claim 42, wherein: n is a number in the range of about 75 to 85; m is a number in the range of about 12 to 20; and The pH of the composition is between pH 4 and pH 4.
6.
44. The method of claim 43, wherein the composition is provided in the form of a solution for infusion.
45. The method of claim 44, wherein the composition comprises 2 mg / mL to 3 mg / mL of camptothecin (CPT).
46. The method of claim 42, wherein the dosage of the composition comprises 2 mg / m 2 Up to 16 mg / m 2 The compound of formula (I).
47. The method of claim 42, wherein the dosage of the composition comprises about 2 mg / m 2 , about 4mg / m 2 , about 6mg / m 2 , about 8mg / m 2 , about 10mg / m 2 , about 12mg / m 2 , about 14mg / m 2 or about 20 mg / m 2 The compound of formula (I).
48. The method of claim 42, wherein multiple doses are provided to the subject during a treatment cycle.
49. The method of claim 48, wherein the plurality of doses are provided as weekly doses.
50. The method of claim 49, wherein each dose comprises 2 mg / m 2 Up to 16 mg / m 2 The compound of formula (I).
51. The method of claim 42, wherein the method further comprises providing at least one dose of a poly (ADP-ribose) polymerase (PARP) inhibitor.
52. The method of claim 51, wherein the PARP inhibitor is selected from olaparib, rucaparib, niraparib, and talazoparib.
53. The method of claim 52, wherein the PARP inhibitor is niraparib.
54. The method of claim 53, wherein the dosage of the composition comprising the compound of formula (I) comprises 2 mg / m 2 Up to 16 mg / m 2 The compound of formula (I).
55. The method of claim 54, wherein multiple doses of the composition comprising the compound of Formula (I) are provided to the subject during a treatment cycle.
56. The method of claim 55, wherein the multiple doses of the composition are provided as weekly doses.
57. The method of claim 56, wherein the subject is provided with a dose of niraparib daily during the treatment cycle.
58. The method of claim 57, wherein each dose of niraparib is a 100 mg dose.
59. The method of claim 42, wherein the cancer is one or more of breast cancer, ovarian cancer, brain cancer, lung cancer, testicular cancer, head cancer, neck cancer, esophageal cancer, central nervous system cancer, peripheral nervous system cancer, bladder cancer, stomach cancer, pancreatic cancer, liver cancer, oral mucosal cancer, anal cancer, kidney cancer, bladder cancer, urothelial cancer, prostate cancer, endometrial cancer, uterine cancer, or fallopian tube cancer; or is colorectal cancer, mesothelioma, melanoma, myeloma, leukemia, lymphoma, or Kaposi's sarcoma.
60. The method of claim 59, wherein the cancer is breast cancer.
61. The method of claim 60, wherein the breast cancer is homologous recombination repair deficiency (HRD) positive or HRD negative breast cancer.
62. The method of claim 42, wherein the cancer is brain metastasis of breast cancer.
Citation Information
Patent Citations
Methods and compositions for synthesis of therapeutic nanoparticles
US20210170049A1
